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Abstract 
Despite the numerous interventions employed in the past few decades, malaria remains one of 
the most lethal diseases affecting millions of people worldwide. This is partly due to the 
emergence of resistance to the current parasite-targeted antimalarials. In contrast, erythrocytic 
genetic mutations have been conferring malaria protection in humans for thousands of years 
without losing their effectiveness. This presents a new therapeutic approach to mimic these 
genetic mutations to treat malaria, known as host-directed therapy (HDT), which requires 
further understanding of host-parasite interactions to identify potential HDT drug targets.  
One such HDT target is the erythrocytic cytoskeleton, which parasites rely on for their survival. 
Ankyrin-1 (Ank-1) is one of erythrocytic cytoskeleton proteins, which has been associated with 
hereditary spherocytosis (HS) in humans. This thesis investigates the roles of Ank-1 in malaria 
infections using mouse models and blood from HS patients. Mice with Ank-1 mutations were 
found to exhibit phenotypes similar to human HS patients and are protected against malaria via 
multiple mechanisms, suggesting that Ank-1 plays a complex role in malaria infections. These 
mechanisms are heavily influenced by the nature of Ank-1 mutations, which is further confirmed 
in human HS erythrocytes. This thesis also explores the possibility of using the ankyrin-spectrin 
interaction as a HDT target. Results show that the disruption of this interaction has little effect 
on the health of the mice, while conferring significant resistance towards malaria, thus enabling 
the use of high throughput screening (HTS) for drug discovery.  
To summarise, this thesis highlights the complex interactions between the erythrocyte 
cytoskeleton and malarial parasites, as well as providing insights into the heterogeneous 
protective role of Ank-1 in mediating malaria resistance. It also raises the possibility of using 
erythrocytic cytoskeletal proteins as HDT drug targets, which could potentially yield novel 
therapies for malaria in the future.  
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1.1 Introduction to Malaria 
Malaria remains one of the most lethal diseases in the world, with more than 200 million cases 
and approximately 400,000 deaths each year 1, with the majority of the victims being young 
children and pregnant women. Although the number of cases has decreased considerably with 
improvements in socio-economic status, the introduction of bednets and insecticides, as well as 
artemisinin combination therapies 2-4, malaria still poses a major threat to people in developing 
countries and areas with limited access to healthcare 5. This is due to several factors which 
significantly impede the eradication of malaria from these countries, such as the development 
of drug resistant malarial parasites, insecticide-resistant mosquito vectors and the low 
socioeconomic status of these countries.  
Malaria is caused by a parasitic protozoa, Plasmodium, of which there are currently five major 
species of Plasmodium that infect people – Plasmodium falciparum, P. vivax, P. ovale, P. 
malariae and P. knowlesi. P. falciparum is endemic to many countries and is responsible for the 
majority of the deaths associated with malaria; whereas P. vivax is also widespread but has 
lower mortality. Transmission of Plasmodium is dependent on Anopheles mosquitoes, and is 
therefore limited to areas where Anopheles thrive 6. This includes tropical and sub-tropical 
regions in Africa, South-east Asia, South America and the Middle East 7. Malaria incidence usually 
increases during wet seasons, where humidity and temperature are ideal for the mosquitoes. 
 
1.1.1 Parasite lifecycle and pathogenesis 
As illustrated in Figure 1.1, the Plasmodium lifecycle involves two hosts – the Anopheles 
mosquitoes and humans. The sexual stage occurs in the mosquitoes, where sporozoites 
accumulated in the salivary glands ready to be injected into the human host during blood meals. 
Following injection, the sporozoites travel to the liver where they infect the hepatocytes 8 and  
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the host remains asymptomatic. After 6-8 days, the parasites differentiate into thousands of 
merozoites 9. These merozoites then invade red blood cells (RBCs) and begin another round of 
asexual replication. The intra-erythrocytic parasites are classified into three different growth 
stages, starting with the ring stage, then trophozoite stage and finally the schizont stage, which 
is followed by egress of new merozoites to invade more RBCs. After 10-12 days 10, some parasites 
will instead differentiate into sexual gametocytes and be ingested by the mosquitoes, 
completing the lifecycle. Blood stage parasites are responsible for the clinical symptoms 
associated with malaria, including but not limited to fever, severe anaemia, cerebral malaria, 
coma and even death 11. The presentation of these symptoms greatly dependent on the gender, 
age and genetics of the host, as well as the parasite species 12. It is important that these 
characteristics are considered as we develop effective tactics to combat malaria.  
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Figure 1.1: The asexual lifecycle of Plasmodium falciparum. 1) The sporozoites are first injected 
by Anopheles mosquito during a blood meal, which then travel to the liver and infect 
hepatocytes. 2) After few cycles of asexual replication, the merozoites emerge from liver and 
start invading erythrocytes. 3) During the blood stage, the parasites mature from ring, to 
trophozoite and finally replicate into schizonts before egress. The newly released merozoites 
invade more erythrocytes and the cycle continues again. 4) After 10-12days, merozoites are able 
to differentiate into male or female gametocytes. 5) These gametocytes are then taken up into 
mosquito during blood meal and the sexual cycle occurs in the mosquito.  
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1.1.2 Malaria preventative strategies 
1.1.2.1 Vector control 
As the Plasmodium requires insect hosts for their survival, many malaria preventative strategies 
often target the mosquito vectors to control the spread of malaria. One such intervention is the 
long lasting insecticide-treated bednets (ITN), which have been a major contributor to the 
decline of malaria cases since their introduction in the 2000s 13.  The financial support from the 
World Health Organisation (WHO) in the implementation of ITNs has accounted for an 
approximately 50% reduction in parasite prevalence over 15 years in sub-Saharan Africa 14. 
Indoor residual spraying (IRS) of insecticides also contributes towards reduction of malarial 
incidence, although not as much as ITNs 14. Despite this success, there have been some concerns 
about the emergence of insecticide-resistant mosquitoes as the current interventions rely 
heavily on one class of insecticides – the pyrethroids 15. Also, the effectiveness of these 
approaches appeared to vary with mosquito species, as it was observed that ITNs were not as 
effective when employed in Southeast Asia, likely due to these mosquitoes having blood meals 
during early evening, when ITNs were not in use 16,17.  
 
1.1.2.2 Malaria vaccine 
Apart from vector control, there has been a lot of effort invested in the development of a 
potential vaccine for malaria in the past few decades, especially against the most lethal 
Plasmodium parasite species, P. falciparum, which is the main focus of this section. Although 
several vaccine candidates were developed, such as SPf66 and SE36 18-21, only one is 
commercially available.  This is partly due to the fact that Plasmodium often have a high genetic 
mutation rate, making them genetically diverse, and hence, difficult to target. Coupled with the 
lack of cross-species protection, vaccine development for Plasmodium has been very challenging. 
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RTS, S is currently the most advanced malaria vaccine candidate available. It targets the parasite 
circumsporozoite surface protein (CSP), one of the important proteins involved in the invasion 
of sporozoites into the hepatocytes 22. In the phase 3 of the clinical trial, however, it was 
reported that it only reduced about 30% of malaria cases 23.  The vaccine also did not provide 
long lasting protection, with only modest protection after 18 months, and required booster 
injections 24. Others have suggested using radiation-attenuated sporozoites to achieve malarial 
immunity 25, which was shown to have excellent protection, although the feasibility of this 
approach is questionable as it is greatly dependent on the dosage of radiation and on vaccine 
delivery methods 26-28. From these examples, it is apparent that the development of a malaria 
vaccines requires substantial amount of time and resources, which is unlikely to alleviate the 
malaria burden in the near future. As a result, it is reasonable to consider alternative approaches 
to combat malaria more effectively. 
 
1.1.3 Current treatments and antimalarial resistance 
In addition to various preventative measures, malaria treatment also plays a crucial role in the 
control of this disease. Indeed, treatments for malaria can be found as early as 200BC in China, 
indicative of the long  treatment history between humans and Plasmodium 29. Since then, a lot 
of treatments for malaria have been developed, particularly in the last century, with the majority 
of them falling into one of four classes: quinoline derivatives, anti-folates, artemisinin 
derivatives and antimicrobials, each with different mechanisms of action, although most target 
the erythrocytic parasite stage. However, all antimalarials face the issue of drug resistant 
parasites (reviewed in 30).  This is attributed to the limited number of drug classes which all the 
current antimalarials are derived from and the widespread use of antimalarial treatment 
without proper controls 31.  Therefore, the WHO recommends malaria treatments in regions 
with reported drug resistance to  combine at least two drug classes, one of which must be an 
7 
 
artemisinin derivative, and the other one usually consist of a slow-acting antimalarial drug of 
another class 32. Although drug resistance is a worldwide socio-economic burden, drug 
resistance in Plasmodium allows us to understand the complex genetics and biology of 
Plasmodium parasites, which will be useful for future drug design and development, hopefully 
leading to the discovery of new classes of antimalarials. Examples from each of the current 
classes of antimalarial drugs and their mechanisms of action are discussed below. 
 
1.1.3.1 Quinoline derivatives 
Quinoline derivatives in malaria treatment include chloroquine, mefloquine, quinine, 
primaquine and lumefantrine. Starting from the 1940s, chloroquine was used extensively to 
treat malaria as a monotherapy 33. Resistance was reported by the end of 1950s in both 
Colombia and the Cambodia-Thailand border 34. It then spread to Africa in the 1970s, and now 
it is no longer effective as a monotherapy for treating erythrocytic stage malaria 34,35. During the 
development of the intra-erythrocytic parasite, haemoglobin is the major food source for the 
parasites, the digestion of which produces toxic free haem as a by-product. Under native 
conditions, parasites are able to detoxify the free haem into inert haemozoin crystals 36. 
Chloroquine acts by inhibiting the haem detoxification process following haemoglobin digestion 
37,38. It is thought that chloroquine binds to the haematin µ-dimer and adsorbs to the haemozoin 
crystal, resulting in interruption to the detoxification process 39,40. Chloroquine-resistant 
parasites, however, were found to have less accumulation of chloroquine in their food vacuole 
41. Further investigation revealed two important transporter proteins that are responsible for 
the resistance, P. falciparum chloroquine resistance transporter (PfCRT) and P. falciparum 
multidrug resistance transporter 1 (PfMDR1) 42,43. PfCRT was thought to be responsible for the 
efflux of chloroquine out of the digestive vacuoles (DV), with more than 15 candidate mutations 
described 35,44,45.  The predominant PfCRT mutation is lysine to threonine at amino acid residue 
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76 (K76T), suggesting that it might be responsible for chloroquine resistance 45. PfMDR1, a 
member of ATP-binding cassette protein, was proposed to be involved in the import of 
chloroquine and other antimalarials 46-48. This is supported by a knockdown study where down-
regulation of PfMDR1 showed decreased sensitivity to chloroquine 43. Further studies have 
revealed five PfMDR1 mutations (N86Y, Y184F, S1034C, N1042D, and D1246Y) to be associated 
with increased resistance to chloroquine, possibly by reducing its influx to the DV 49.  
 
1.1.3.2 Folate metabolism inhibitors 
Anti-folate drugs such as sulfonamides, pyrimethamine, proguanil, and dapsone, have become 
a predominant treatment in countries with widespread chloroquine resistance 50. They are often 
used in combinations or with drugs from other classes, including sulfadoxine-pyrimethamine (SP) 
or atovaquone-proguanil. The main function of the folate pathway is to produce folate co-
factors which are used for DNA and amino acid synthesis 51. In particular, pyrimethamine 
competitively inhibits dihydrofolate reductase (PfDHFR), whereas sulfadoxine targets 
dihydropteroate synthase (PfDHPS). Resistance to SP emerged at the end of the 1980s 52, first in 
Southeast Asia before rapidly spreading to Africa 53, rendering the drug ineffective to treat 
malaria 54,55. Four PfDHFR point mutations have been described to be associated with 
pyrimethamine resistance – N51I, C59R, S108N and I164L 56,57, all of which decrease the binding 
affinity with pyrimethamine 58. Similarly, amino acid change such as 437G, 581G and 613S in 
PfDHPS gene are associated with resistance to sulfadoxine 56. 
 
1.1.3.3 Antibiotics 
Antibiotics such as doxycycline and clindamycin are a class of drugs which inhibit protein 
synthesis of microorganisms. They are occasionally used in combination therapy to treat malaria. 
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Both are slow-acting drugs, which have longer-lasting protective effects. As a result, they are 
usually used in complement with other fast-acting antimalarials such as chloroquine or quinine, 
especially in areas with suspected chloroquine resistance 59. Doxycycline (as reviewed in 60), in 
particular, was initially thought to inhibit mitochondrial protein synthesis of Plasmodium 61,62, 
but more recent studies seemed to suggest that the apicoplasts are the drug target 63,64.  
Doxycycline is active against both erythrocytic and pre-erythrocytic stage of Plasmodium 
falciparum 65,66. As such, it is proposed that doxycycline be used as an adjuvant in prophylactics 
for malaria, as well as a slow-acting schizontocidal drug 67.  Resistance to doxycycline is not well 
established, although a study inferred P. falciparum tetQ GTPase (PfTetQ), to be associated with 
doxycycline resistance based on previous work on other organisms 68,69. 
 
1.1.3.4 Artemisinin derivatives 
Artemisinin and its derivatives have become the first line of treatment for malaria infections 
since the emergence of multidrug resistant Plasmodium falciparum in Southeast Asia. It was first 
purified in the 1970s and started to be widely used in the 1980s 70. It is a fast acting drug with 
short half-life, and as such, it is often paired with slower acting drugs, which are known as 
artemisinin combination therapies (ACTs) 32. Although it was observed that artemisinin affects 
all stages of the parasites 71-73, the exact mechanisms of action still remains unknown. It was 
initially thought to cause oxidative stress by producing reactive oxygen species (ROS) when 
activated by either haem iron or non-haem iron during haemoglobin breakdown 74,75. However, 
the fact that ring-stage Plasmodium falciparum parasite and Toxoplasma gondii, which produce 
little to none haemozoin, are also susceptible to artemisinin seem to contradict the theory 72,76. 
It has also been suggested that artemisinin might also prevent the formation of haemozoin 77,78, 
though this was not observed in vivo 79.  More recently, it was proposed that artemisinin targets 
parasite ATPase PfATP6, based on its structural similarities with thapsigargin, an ATPase 
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inhibitor 80,81, again, contradicting findings have also been reported 82. While the mechanism of 
action for artemisinin is still largely unknown, the rapid ability of Plasmodium species to develop 
resistance and overcome these drug pressures is well established, with clinical resistance to 
artemisinin being observed in Southeast Asia 83,84 since the early 2000s. Kelch13 gene was 
believed to be responsible for this resistance 85,86. PfKelch13 is involved in ubiquitination and 
oxidative stress adaptation in Plasmodium. Artemisinin-resistant parasites with PfKelch13 
mutations are thought have reduced proteolysis of phosphatidylinositol-3-kinase (PfPI3K), 
leading to the accumulation of PfPI3K 87. It is thought that increased PI3P-dependent signalling, 
as the result of elevated PfPI3K, mediates artemisinin resistance 87. Another proposed 
mechanism involves the up-regulation of unfolded protein response pathways, which is thought 
to alleviate the protein damage caused by artemisinin 88, although further studies are required 
to support this hypothesis.  
 
1.1.4 Summary 
With the rapid emergence of parasite resistance to the current drugs and limited progress in 
vaccine development, new antimalarials are urgently needed. However, careful considerations 
must be taken in order to minimise drug resistance - which requires better understanding of 
parasite biology as well as host environments. In fact, natural resistance to malaria in endemic 
regions have existed for thousands of years 89, suggesting the importance of the host genetic 
background in determining malaria susceptibility. Therefore, studying host genetic and host-
parasite interactions would prove to be beneficial for developing theoretically resistance-proof 
therapies in the future.  
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1.2 Host Genetic Resistance to Malaria 
Host genetics plays a significant role in determining malaria susceptibility.  For instance, many 
RBC-related mutations were found to be associated with malaria resistance 90-93. This is 
evidenced by the higher-than-usual allele frequency of these RBC mutations in malaria endemic 
areas (reviewed in 94). This phenomenon was first described and proposed by Haldane, 
suggesting that mutations which might otherwise be deleterious actually provide selective 
advantages against malaria 95. Since then, many mutations have been characterised, ranging 
from mutations in RBC membrane proteins, haemoglobin, enzymes and the immune system. 
Some of these mutations are examined below.  
 
1.2.1 Haemoglobin polymorphisms 
Haemoglobin is the most abundant protein in erythrocytes. It usually exists as a heterodimer 
comprise of two α-globin and two β-globin subunits, and allows the transportation of oxygen 
and carbon dioxide through the blood. Haemoglobin polymorphisms have long been associated 
with malaria resistance, including haemoglobin (Hb) S, E and C, which have abnormal β-globins, 
and α- and β-thalassaemia, which affect the amount of α- and β-globin produced.  
The haemoglobin polymorphism, HbS, is associated with sickle cell disease in homozygous 
individuals 96 and is also one of the well-known polymorphisms to influence malaria 
susceptibility 97,98. It is prominent in Middle East populations, as well as sub-Saharan African 
populations, where the frequency of HbS allele was predicted to be up to 18% in certain regions 
97. Its prevalence is largely influenced by the protection it confers against malaria and the 
morbidity associated with sickle cell disease. It is caused by a glutamic acid to valine substitution 
at position 6 of the β-globin chain, resulting in unstable haemoglobin, which polymerises under 
a low oxygen environment. HbS heterozygosity was shown to have a 10-fold reduced malaria 
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risk 99, and increased protection towards cerebral malaria and severe malaria 100. HbS 
homozygosity, however, is usually associated with higher mortality and morbidity.  On the other 
hand, the HbC allele is far less common than the HbS allele, and it is usually found in parts of 
West Africa. It is caused by a glutamic acid to lysine substitution at position 6 in β-globin gene. 
Unlike HbS, HbC homozygosity only causes mild haemolytic anaemia, and provides significant 
protection against malaria, with up to 90% for homozygotes, and 30% for heterozygotes 101-105. 
HbE allele is widely distributed in Southeast Asia and neighbouring regions, with up to 60% allele 
frequency in certain areas 106,107. It is caused by a glutamic acid to lysine substitution at position 
26 of β-globin chain. It is thought to effect the expression of β-globin gene by creating an 
alternative splice site, which decreases the production of functional β-globin, thus resulting in 
β-thalassaemia-like symptoms. However, only homozygotes present a mild haemolytic anaemia, 
whereas heterozygotes are asymptomatic. It is shown to confer resistance against malaria in 
several studies 108,109, although increased susceptibility was also implicated as patients with HbE 
beta thalassemia appeared to have more severe clinical symptoms from malaria infection 110. 
Thalassaemias are defined as the loss or reduction in haemoglobin production, typically via 
deletion or inactivation of the gene. Both α- and β-thalassaemia are found throughout Southeast 
Asia, Africa and the Middle East 111. The symptoms of the disorder can range from asymptomatic 
to severe anaemia, depending on the number of affected alleles. Also, it is not uncommon for 
α-thalassaemia to be co-inherited with β-thalassaemia, which further complicates the clinical 
diagnosis. Nevertheless, both thalassaemias are associated with malaria resistance 112-114.  
 
1.2.2 Enzyme-related polymorphisms 
Defects in certain enzymes involved in RBC maintenance, or Plasmodium development, have 
been shown to provide increased resistance towards malaria. One notable polymorphism is the 
X-linked glucose-6-phosphate dehydrogenase (G6PD) deficiency (reviewed in 115,116). It is 
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involved in maintaining the oxidative stress environment of RBCs. Increased prevalence of G6PD 
deficiency is found in all malaria endemic regions, including Africa, Southeast Asia and South 
America 117-120. However, it is unclear if the protection only affects hemizygous and homozygous 
individuals 121-123.  
Pyruvate kinase (PK) deficiency is another well-known enzymopathies affecting susceptibility to 
malaria. It is found worldwide, but with slight increased prevalence in African populations 124,125. 
It is a crucial enzyme involved in ATP production. This observation is further supported by in 
vitro and in vivo studies, which show significant malaria resistance in both tissue cultured and 
mouse models 126-128.  
 
1.2.3 Immune-related polymorphisms  
In addition to erythrocytes, malaria applies a large selective pressure on the human immune 
system. One particular aspect is the major histocompatibility complex (MHC) proteins which are 
encoded by the human leukocyte antigen (HLA) gene complex. High MHC polymorphic rate in 
African population compared to other populations suggests the possible selection by various 
environmental pathogens including malaria 129-131.  Many studies have indicated that certain 
variants of HLA can either confer resistance or susceptibility towards severe malaria or cerebral 
malaria 132-135. However, the exact roles of these HLA polymorphisms are still elusive. In addition, 
cytokines including TNF-alpha 136-138, IFN-gamma139,140 and interleukins (specifically IL-1141,142, IL-
4143 and IL-10 144) have been implicated to play various roles during malaria infection. 
Several studies have indicated that another polymorphisms, complement receptor 1 (CR1), is 
associated with malaria resistance in endemic areas (reviewed in 145,146). CR1 is a membrane-
bound glycoprotein involved in the activation of the complement of the immune system. These 
polymorphisms often cause reduction in CR1 levels and it is thought to confer malaria protection 
147,148. Further studies have revealed that erythrocyte CR1 is involved in merozoite invasion and 
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cytoadherence 148,149, therefore it is likely individuals with CR1 polymorphisms are protected 
from cerebral malaria which improves their survival. 
One further immune-related polymorphism which has been sown to influence susceptibility to 
malaria is a range of polymorphisms in nitric oxide genes. Nitic oxide is a free radical that 
mediate host resistance during various infections, and is produced by three different nitric oxide 
synthases (NOS) 150. One of the NOS, NOS-2 gene, along with increased NO, have been associated 
with increased resistance against malaria 151-153. Specifically, individuals with certain 
polymorphisms in the promoter region of NOS2 were reported to have less severe malaria 154-
156. 
 
1.2.4 Erythrocyte membrane-associated protein polymorphisms 
During malaria infections, Plasmodium requires specific interactions with erythrocyte surface 
receptors and cytoskeletal proteins for invasion, protein export and egress. As a result, 
mutations affecting these proteins are often associated with increased resistance to malaria. 
Several polymorphisms are described as below. 
One of the most notable RBC surface proteins involved in malaria infections is the Duffy antigen 
receptor for chemokine (DARC), which is a chemokine receptor involved in inflammatory 
regulation, and is required for effective P. vivax invasion into RBCs 157. Duffy negativity, the 
absence of Duffy antigen receptor on RBC surface, is common in African populations and in parts 
of Papua New Guinea 158-160. Studies have repeatedly suggested that co-evolution between Duffy 
negative African populations and Plasmodium species has resulted in a lack of P. vivax 
distribution across Africa 91,158,161, as well as resistance to P. knowlesi in other populations 162-164. 
However, this hypothesis was recently challenged due to reports of P. vivax infections in Duffy-
negative individuals in Madagascar 165-168. It is thought that P. vivax are subjected to large 
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selective pressure to be able utilise cryptic pathways to invade RBCs in this Madagascan 
population 166,169,170.  
Another polymorphism that has also been associated with malaria susceptibility is ABO blood 
antigens. These blood groups were thought to emerge during co-evolution with Plasmodium 
millions of years ago, suggesting selective advantage offered by group O allele 171,172. Although 
several studies have indicated that individuals with non-O blood group have higher risk of severe 
malaria, they appear to not have accounted for other confounding factors 173-175.  
Glycophorins (GYP) are another major glycoprotein family found on the RBC membrane which 
facilitates RBCs circulating with less resistance by providing a hydrophilic surface. 
Polymorphisms such as Glycophorin B-null and Gerbich (Glycophorin C) negativity were found 
at high frequency in certain malaria endemic regions 176,177, although contradicting findings 
regarding their roles in malaria have been reported 178-180. Recent studies have also revealed 
basigin to be involved in facilitating erythrocyte invasion. Erythrocytes lacking basigin were 
found to be significantly resistant to merozoite invasion in vitro 181. Although several 
polymorphisms have been described for basigin, no association has been implied between 
basigin polymorphisms and malaria protection at the population level 181.  
Southeast Asian ovalocytosis (SAO), as the name implies, is a hereditary condition found 
exclusively in Southeast Asia 182, and certain parts of Papua New Guinea, with up to 35% 
prevalence 183. It is commonly caused by mutations in the transmembrane protein band 3 on the 
RBC surface. This results in more rigid and elliptical shaped RBCs 184. It has been reported to 
protect against cerebral form of P. falciparum and more importantly, P. vivax, which is more 
common in these regions 185-187.   
Hereditary spherocytosis (HS) and elliptocytosis (HE) are disorders caused by disruptions to the 
RBC cytoskeletal structure vertically and horizontally, respectively. Both disorders have been 
hypothesised to confer resistance towards malaria, demonstrated though in vitro and in vivo 
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studies with mouse models 188-193. HE has increased prevalence in African populations, with 0.6 
to 3% incidence 188,194,195, while on the other hand, HS appeared to be more common in Northern 
European populations 196-198, with only rare cases have been reported in other populations 199,200. 
HS is typically caused by mutations in ankyrin-1, spectrins, band 3 or protein 4.2, with the 
majority of cases arising from ankyrin-1 mutations 201. HS patients often exhibit deficiency in 
ankyrin and spectrin and, less commonly, band 3 202,203. One particular study examined the RBCs 
from HS patients and found that they significantly impaired the growth of parasites 191. This is 
consistent with various mouse models carrying ankyrin-1 mutations, including (nb/nb), Ank-
1MRI23420 and Ank-11674 mice. All of these mutations exhibit HS-like phenotypes and were found 
to be significantly resistant to murine malarial parasites, P. chabaudi infection 189,190,204. When 
compiled, it is evident that HS confers protection against malaria despite the lack of evidence 
from population studies. 
  
1.2.5 Summary 
 From the studies reviewed above, there is no doubt that host genetics play a significant role in 
malaria infections.  These genetic polymorphisms that arise as humans and Plasmodium co-
evolve are likely to reveal crucial weaknesses in parasites that can be exploited for future 
therapeutics. However, many mechanisms behind these polymorphisms are not well-
established. As a result, it would be of great interest to the malaria community to investigate 
how these polymorphisms contribute towards malaria resistance, as we combat the issue of 
antimalarial drug resistance.                          
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1.3 Effects of Genetic Polymorphisms on Host-parasite Interactions 
It is well-established that certain genetic polymorphisms confer protection against malaria, 
although their exact roles are not always clear. Understanding how these polymorphisms give 
rise to malaria resistance would not only provide useful insight on host-parasite interactions, 
but also reveal new drug targets. Since these drug targets are not under the influence of parasite 
genetics, they are consequently thought to be resilient to development of drug resistance. This 
is the basis of host-directed therapy, and its major strength. 
During the blood stage of malaria infection, parasites undergo several distinct phases of 
development – from RBC invasion to egress. During each phase, merozoites interact with 
different host proteins in order to thrive. As a result, genetic polymorphisms of these proteins 
are thought to impair parasite development, as summarised in Table 1.1. This review will focus 
on the protective effects of these genetic polymorphisms in various aspects of blood-stage 
malaria. 
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Table 1.1: Resistance mechanisms of common RBC genetic polymorphisms 
 
  
Genetic 
Polymorphisms 
Possible mechanisms of resistance 
Reference Erythrocyte 
invasion 
Intra-
erythrocytic 
growth 
Cytoadherence 
ability 
Susceptibility 
to 
phagocytosis 
Haemoglobin S Reduced Reduced Reduced Increased 205-209 
Haemoglobin C Normal Reduced Reduced Unknown 209-212 
Haemoglobin E Reduced Reduced Unknown Increased 109,213 
α- and β-
thalassaemia 
Reduced Reduced Reduced Increased 114,205,214-
217 
Glucose-6-
Phosphate 
Dehydrogenase 
(G6PD) 
Deficiency 
Normal Reduced Unknown Increased 218-221 
Pyruvate Kinase 
(PK) Deficiency 
Reduced Normal Unknown Increased 128,222 
Complement 
Receptor 1 (CR1) 
polymorphisms 
Reduced Unknown Reduced Unknown 148,149,223,22
4 
Duffy negativity Reduced 
(P. vivax) 
Normal Unknown Unknown 91,225,226 
O blood group Normal Normal Reduced Unknown 172,227 
Glycophorin A 
(GYPA) 
deficiency 
Reduced Unknown Unknown Unknown 228,229 
Glycophorin B 
(GYPB) deficiency 
Reduced Unknown Unknown Unknown 179,230 
Glycophorin C 
(GYPC) deficiency 
Reduced Unknown Unknown Unknown 178,231 
Southeast Asian 
Ovalocytosis 
(SAO) 
Reduced Normal Reduced Unknown 186,232 
Hereditary 
elliptocytosis 
(HE) 
Reduced or 
Normal 
Reduced Unknown Unknown 191-193 
Hereditary 
spherocytosis 
(HS) 
Reduced or 
Normal 
Reduced or 
Normal 
Unknown Unknown 189-191,204 
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1.3.1 Merozoite invasion 
Blood stage of malaria infection begins with the invasion of merozoites into RBCs, which has 
been extensively studied. Merozoites are propelled into the bloodstream following their egress 
from RBCs or in vesicles known as merosomes, to allow safe passage into the bloodstream 233,234. 
The merozoites first reversibly attach at any location on the RBC membrane, followed by the 
reorientation of merozoites to align their apical end towards the RBCs 235. This allows specific 
receptors to interact and bind to various RBC receptors. Additional proteins are then released 
from the apical organelle to modify RBC cytoskeleton in preparation for invasion 236. Tight 
junctions are formed between the RBC and the merozoite and are powered by actin-myosin 
motor to move from the anterior to posterior end of merozoite while surrounding the it with 
RBC membrane, thus forming parasitophorous vacuole 237. The RBC membrane is then resealed 
and returned to normal in 10 minutes 238. This process is illustrated as below (Figure 1.2). 
 
Figure 1.2: The erythrocyte invasion process by a merozoite. 1) Merozoite first binds reversibly 
onto erythrocyte surface. 2) Merozoite then reorients to align its apical end with erythrocyte 
surface, and binding with various host ligands occurs. Parasite proteins are secreted to remodel 
erythrocyte cytoskeleton. 3) Tight junctions are formed and merozoite is propelled into the 
erythrocyte through actin-myosin motor. 4) Resealing of erythrocyte membrane occurs to give 
rise to parasitophorous vacuole. The erythrocyte plasma membrane then returns to normal. 
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The RBC invasion process has been an area of interest due to the direct exposure of parasite 
antigens to the host immune system as well as its dependence on host RBC receptors and 
cytoskeleton. Over the past decades, several RBC receptors have been implicated to facilitate 
the invasion process, and mutations in these receptors are often associated with malaria 
resistance. 
Perhaps one of the most prominent examples of such receptors is the Duffy antigen receptor 
for chemokine (DARC) on the erythrocyte surface. As previously mentioned, Duffy negativity has 
been thought to be responsible for eradication of Plasmodium vivax from the majority of Africa 
158. The inhibition of erythrocyte invasion was further supported by in vitro studies where 
antibodies raised against Plasmodium vivax Duffy binding protein (PvDBP) prevents the invasion 
of P. vivax into Duffy-positive erythrocytes 91,225. It is well-established that PvDBP binds to DARC 
irreversibly during erythrocyte invasion 226. Further studies revealed that the binding motif is 
localised to 170 amino acids in domain II of PvDBP 239,240, which made it one of the promising 
targets for vaccine development 241.  
On the other hand, two families of Plasmodium falciparum proteins have been discovered to be 
involved in the apical interaction with erythrocytes: the Duffy or erythrocyte binding-like (DBL 
or EBL) proteins and the reticulocyte binding-like (RBL) proteins 242. Both families were thought 
to have redundant roles during merozoite invasion, as seen in a knockout study showing no 
significant invasion impairment when several invasion proteins were disrupted 243-246. EBL 
proteins are involved in the sialic acid-dependent invasion pathway, which recognise and bind 
specifically to erythrocyte receptors containing sialic acid residues. Furthermore, studies in 
murine malaria models such as Plasmodium yoelii, revealed that EBL proteins might determine 
the parasite’s preference for erythrocyte type 247, emphasising the importance of understanding 
interactions with host proteins. Several EBL proteins and their binding partners have previously 
been identified: erythrocyte-binding antigen 175 (EBA-175) binds to Glycophorin A 248,249; EBL-1 
binds to Glycophorin B 179; and EBA-140 (or BAEBL) binds to Glycophorin C 178. Deficiency in 
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Glycophorin A was reported to have reduced P. falciparum erythrocyte invasion 228, whilst 
antibodies against EBL-1 and EBA-140 were found to inhibit interaction with Glycophorin B and 
C respectively 178,230,231, and they were thought to be the basis behind the increased resistance 
to malaria in population with Glycophorin B-null and Gerbich (Glycophorin C) negativity. 
Examples of RBL protein family members include P. falciparum reticulocyte-binding homolog 4 
(PfRh4) and PfRh5, which are involved in sialic acid-independent invasion pathways. PfRh4 was 
found to interact with CR1 during erythrocyte invasion, and treatment with antibodies and 
soluble CR1 inhibits the merozoite-RBC binding 149,223,250. Recently, it was discovered that PfRh5 
interacts with CD147 or basigin on the erythrocyte surface during invasion 181,251. The 
correlations of basigin polymorphisms with malaria protection in human populations are still 
unclear, despite the fact that some of these polymorphisms were found to have reduced binding 
with PfRh5 in vitro. Nevertheless, with the characterisation of the blocking epitope, PfRh5 was 
considered to be a candidate for vaccine development, whereas basigin might be a druggable 
target for host-oriented therapy for malaria 252,253.  Other RBC receptors such as CD55 have 
recently been proposed to be essential for merozoite invasion, based on genetic screening 254, 
although its implications in human populations remain to be investigated 255. 
Modification of the erythrocyte cytoskeleton is also essential in establishing a successful 
merozoite invasion. As a result, polymorphisms in various cytoskeletal proteins have been 
associated with increased resistance towards merozoite invasion. One of the major component 
of RBC cytoskeleton, the protein band 3, is necessary for merozoite invasion into RBC. Band 3 
mutations have been shown to give rise to Southeast Asian Ovalocytosis (SAO), which is thought 
to impair the invasion of P. falciparum and P. knowlesi merozoites into RBCs 256-258. While the 
mechanisms remain elusive, some researchers have suggested that reduced deformability of 
erythrocytes to be the primary mechanism behind this resistance 259,260. However, band 3 could 
also be involved in the primary contact of the merozoites with RBCs, forming a complex with 
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merozoite surface proteins-1 (MSP-1) and Glycophorin A 261. This might suggest a more complex 
mechanism apart from RBC deformability. 
Invasion inhibition has also been reported for other cytoskeletal proteins. Hereditary 
elliptocytosis (HE), a genetic disorder caused by mutations in a single, or multiple, RBC 
cytoskeletal proteins including alpha-spectrin, beta-spectrin and protein 4.1, was thought to 
confer malaria resistance 192,193. Although HE is more commonly reported in malaria endemic 
countries 188, the mechanisms behind its resistance are not well-defined. Some in vitro studies 
reported increased resistance to invasion 192,193, while others reported no differences 191. It is 
possible that contradicting results might be due to the heterogeneity of the manifestation of HE, 
where different causative mutations would give rise to different phenotypes, which 
consequently affect malaria susceptibility, a phenomenon known as allelic heterogeneity. 
Other genetic disorders such as pyruvate kinase deficiency (PKD) were also reported to affect 
erythrocyte invasion, with RBCs from PKD patients being more resistant to merozoite invasion 
128,222, possibly due to ATP depletion 127. Similarly, several haemoglobin variants including HbAE, 
beta-thalassemia/HbE and alpha-thalassemia have been shown to experience less erythrocyte 
invasion in vitro 109. Despite the evidence, the exact mechanisms behind these polymorphisms 
have not yet been dissected.  
 
1.3.2 Parasite intra-erythrocytic growth and egress 
In order to grow and replicate following erythrocyte invasion, parasites remodel the 
erythrocytes to better suit their requirements. They export proteins for nutrient acquisition, 
immune evasion and for egress from the erythrocyte, as well as importing host proteins for food 
and to carry out certain enzymatic reactions. These processes heavily rely on the RBC 
environments in order to provide the necessary conditions for optimal parasite growth. 
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Therefore, disruptions to any of these pathways are likely to give rise to impaired parasite 
growth.  
The primary food source of intra-erythrocytic parasites is thought to be the haemoglobin. 
Numerous studies have discovered an acidic vacuole in parasites responsible for haemoglobin 
degradation, and detoxification of the toxic haem into haemozoin crystals 262,263. The parasites 
also employ new permeation pathway (NPP) to import other nutrients including amino acids, 
carbohydrates and various ions 264,265. Parasite protein export is facilitated by the Plasmodium 
translocon of exported proteins (PTEX), which is essential for growth in blood stage 266,267. PTEX 
is responsible for exportation of proteins containing PEXEL-motif as well as several PEXEL-
negative exported proteins (PNEPs) into the RBC cytosol 268-270. Further protein trafficking is 
mediated by a Golgi-like membranous structure known as the Maurer’s cleft which interacts 
with cytoskeletal actin and plays a crucial role in remodelling the RBCs by transferring 
membrane-associated proteins to the RBC surface. One of which is Plasmodium falciparum 
erythrocyte membrane protein 1 (PfEMP1), which involved in immune evasion by mediating 
cytoadherence to the endothelium 209,271,272. In addition, parasites are also known to utilise host 
proteins for their survival. Host kinases – specifically MEK-1 and PAK-1, have been proposed to 
be used by the blood-stage parasites 273. Other examples include haem synthesis enzymes such 
as delta-aminolevulinate dehydratase (ALAD) 274 and ferrochelatase 275, as well as enzymes 
involved in anti-oxidation – superoxide dismutase 276 and peroxiredoxin 2 277.  
During the egress of merozoites from the RBCs, the parasites have to modify RBC cytoskeletons 
in order to destabilise the erythrocyte membrane. This involves the loss of adaptor proteins such 
as adducin and tropomycin, as well as phosphorylation of Band 3 to weaken the cytoskeletal 
network 278,279. Further degradation of the cytoskeletal structure is mediated through the 
parasite cysteine protease falcipain-2 and the aspartic protease plasmepsin II 280-282. 
Chandramohanadas, et al. 283 have also proposed that host erythrocyte-derived calpain-1 is 
hijacked during egress, and the absence of this protein prevented egress. 
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Many genetic polymorphisms affecting RBCs have been associated with intra-erythrocytic 
parasite growth inhibition, such as those that give rise to abnormal haemoglobin. HbAS was 
reported to impair P. falciparum growth due to RBC sickling under low oxygen conditions 206,207. 
LaMonte, et al. 284, on the other hand, proposed that growth inhibition is due to the translocation 
of sickle erythrocyte miRNAs to the parasites, impairing ribosome functions and thus protein 
translation machinery. Abnormal parasite growth was also observed in HbCC erythrocytes, 
where a high percentage of the parasites die as they mature 211,285. Both HbS and HbC were also 
thought to impair host cell remodelling, possibly as a result of high oxidative stress from 
abnormal haemoglobin, which is thought to impair the polymerisation of actin filament, thereby 
weaken the interaction of Maurer’s cleft and RBC cytoskeleton 209. Presence of free-haem and 
oxidised haemoglobin can also damage and destabilise the actin filament, which is unfavourable 
for the maturing parasites208,286. In addition, alpha- and HbE/beta-thalassemia were also 
reported to retard parasite growth in vitro 214,217,287, though the exact mechanisms were not clear. 
Vernes and colleagues proposed that HbE impair parasite growth under high oxygen conditions 
suggesting oxidative stress-related mechanisms 213. However, these hypotheses were 
challenged when normal parasite development was often observed in these cells in vitro and in 
field studies 110,207,288,289. 
G6PD deficiency has also been associated with reduced parasite growth 218,290,291, despite 
numerous contradictory findings 219. Although the exact mechanisms are still being investigated, 
two possible explanations have been proposed. First, as with the haemoglobinopathies, parasite 
deaths occur due to high oxidative damage in both the host cells and the parasites as the result 
of low glutathione levels 292,293. Another possibility is that parasites are unable to acquire 
sufficient ribose derivatives for nucleic acid synthesis due to the low glutathione level 294.  
Reduced intra-erythrocytic growth is also reported in erythrocytes with abnormal cytoskeletal 
structure. Both Schulman, et al. 191 and Chishti, et al. 192 have reported a reduction in parasite 
growth in erythrocytes deficient in the RBC cytoskeletal proteins ankyrin and spectrins. A more 
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recent study on mice with Ank-1 mutation has also reported an increased number of apoptotic 
parasites in erythrocytes, in agreement with the previous findings 189.  
Indeed, blood stage Plasmodium have been found to interact with erythrocytic ANK-1 during 
RBC remodelling. One of the exported proteins, knob-associated histidine-rich protein (KAHRP), 
has been found to interact strongly with ANK-1 295,296, and is required for the formation of knob-
like structure on infected RBC surface 297, as well as facilitating proper presentation of PfEMP1 
298. Parasite acyl-CoA synthetases, PfACS1 and PfACS3, have also been reported to bind to ANK-
1 299. These enzymes are involved in converting fatty acids scavenged from the extracellular 
matrix into CoA derivatives for further lipid biogenesis 300, and their interactions with ANK-1 are 
thought to facilitate their functions. ANK-1 was also proposed to be one of the target proteins 
for cleavage by falcipain-2 during parasite egress 282. Further research has shown that inhibition 
of ANK-1 cleavage impaired the development of late-stage parasites 301. It is possible that ANK-
1 mutations might cause parasite deaths through impairment to RBC remodelling, parasite 
growth, or egress, which could be explored through further studies. 
 
1.3.3 Splenic filtration and parasite cytoadherence 
Another challenge blood-stage Plasmodium parasites have to overcome is the constant threat 
of being removed from blood circulation, either by splenic filtration or the host immune system. 
The spleen is an important organ responsible for removing old and damaged RBCs, inducing the 
adaptive immune system and recycling  iron 302. In the context of malaria, the spleen is 
responsible for three functions: First, the spleen traps the less deformable parasitised 
erythrocytes thus removing them from circulation 303; second, development of the immune 
response through phagocytosis 304; and third, it acts as a secondary erythropoietic and 
haematopoietic organ during infections 305. However, parasites have evolved behaviours and 
pathways to avoid detection. One such process to evade detection is cytoadherence, a process 
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where parasites adhere to the endothelium, against the blood flow, which is observed 
specifically in P. falciparum. This provides a safe haven for the late-stage parasites, which would 
have reduced RBC deformability 306, to escape splenic clearance and avoid recognition by 
complements and antibodies 307. Cytoadherence of the parasites often lead to the formation of 
“rosettes”, where clusters of infected and uninfected RBCs aggregate together mediated by 
parasite proteins of the parasitised erythrocyte surface, as shown in Figure 1.3. This causes 
obstruction to the blood flow and often manifests as cerebral malaria. 
 
Figure 1.3: Various mechanisms of parasite cytoadherence. 1) Mature stage infected RBC (iRBC) 
express PfEMP1, which binds to various endothelial receptors, including CD36, ICAM-1 and EPCR. 
2) Aggregation of infected and uninfected RBC, known as rosetting, occurs through binding of 
PfEMP1 with CR1 and A/B antigen on RBC surface. 3) Platelets can also mediate clumping of 
iRBCs through binding of PfEMP1 with platelet CD36. 
 
Cytoadherence of the parasites depends on two important factors: the presence of parasite 
antigens on the surface of iRBCs, and the presence of host receptors on other host cells. Similar 
to other parasite processes, host genetics is a major determinant to the outcome during this 
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process. As mentioned earlier, previous studies have discovered that polymorphisms in CR1 
effect malaria pathogenesis 148,308. PfEMP1 on the surface of parasitised RBCs has been shown 
to bind with CR1 on other uninfected RBCs, leading to the formation of rosettes 309,310. Reduced 
CR1 levels have been implicated in reducing rosette formation, both in field studies and in vitro 
148,224. Soluble CR1 reduces rosette formation, further supporting the interaction 309. 
Furthermore, polymorphisms that affect PfEMP1 binding site, such as S1 (a-), were found in 
higher frequency in malaria endemic regions 311, and individuals with this phenotype were found 
to have reduced rosette formations and less likely to have cerebral malaria 148, thus providing a 
survival advantage 312. Similar explanation was also proposed for SAO patients, as evidenced 
from the protection it confers against cerebral malaria 186,232. Reduced rosetting was also 
proposed for individuals with O blood group 313, since it is thought that non-O blood groups have 
trisaccharides which act as receptors for rosetting 227. Rosettes formed with O blood group more 
easily disrupted 227, which might contribute to malaria protection.  
Receptors on other host cells such as CD36 and ICAM-1 (CD54) are also implicated in mediating 
cytoadherence. CD36 is a host cell receptor found on endothelial cells, platelets, erythroblasts 
and macrophages, and it plays a role in a wide range of cellular processes, including lipid 
metabolism, angiogenesis and promoting inflammation 314,315. In the context of malaria 
pathogenesis, PfEMP1 associates with endothelial CD36, leading to sequestration of parasitised 
erythrocytes from the circulation to evade detection by the spleen 302,316. PfEMP1 also binds to 
CD36 on platelets, leading to platelet-mediated clumping and promoting cytoadhesion by acting 
as a bridge between the endothelium and iRBCs 317,318. Similarly, ICAM-1 is also found on 
endothelial cells and has also been implicated to bind to PfEMP1 319, and is often thought to 
enhance the adhesion of iRBCs to endothelium, acting synergistically with CD36 320,321.  Despite 
evidence from field isolates and in vitro studies, associations between CD36 and ICAM-1 
polymorphisms and protection towards severe malaria have been unclear. Many studies failed 
to report an increased malaria protection in populations with CD36 and ICAM-1 variants 322-326, 
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even though some studies seem to suggest otherwise 327-330. It is possible that confounding 
factors might be responsible for the severity of malaria, and thus makes these association 
studies challenging 331. More recently, endothelial protein C receptor (EPCR) was discovered to 
have a role in cerebral malaria pathogenesis 332. Brain endothelium EPCR is thought to bind to 
PfEMP1, activating coagulation and promoting obstruction, which leads to cerebral malaria 
333,334. However, contradictory findings regarding associations of EPCR polymorphisms and 
severe malaria risk have also been reported 335-337. 
A proper presentation of various parasite proteins on erythrocyte surface is also crucial for 
parasite survival. As such, disruptions to the parasite’s ability to remodel and export proteins 
may also contribute towards easier detection of iRBCs. Indeed, impaired cytoadherence was 
reported in infected erythrocytes with certain haemoglobin variants, including HbS, HbC and 
alpha-thalassaemia 210,212,215,338. HbC and HbS erythrocytes were shown to have slower export 
and reduced amount of parasite proteins to host cell cytoplasm, Maurer’s cleft and erythrocyte 
membrane 339, suggesting impairment to host cell remodelling 209. This also resulted in abnormal 
expression of PfEMP1 on iRBC surface, which explained the reduced cytoadherence and 
rosetting 212,288. Similar mechanism was also proposed for alpha-thalassaemic erythrocytes 212. 
 
1.3.4 RBC senescence and parasite detection 
In addition to splenic filtration, erythrocytes also have their own senescence indicators, which 
signal the clearance of these erythrocytes from circulation (as shown in Figure 1.4), which poses 
a challenge for the parasites. One of these mechanisms is through erythrocyte apoptotic 
pathways, also known as eryptosis. Rise in intracellular calcium levels has been implicated as a 
stimulator for eryptosis, likely due to oxidative damage and cell shrinkage as the erythrocytes 
age 340. It also eventually leads to membrane scrambling which exposes phosphatidylserine (PS) 
extracellularly, and it has been linked with increased RBC clearance 341. It is believed that 
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exposed PS is recognised by various receptors on macrophages, thus facilitates phagocytosis of 
the erythrocytes 342-344. 
Another RBC clearance mechanism, which is non-eryptotic, involves oxidative damage to 
haemoglobin which produces hemichromes, a product of haemoglobin denaturation 345. 
Hemichromes are known to interact with various cytoskeletal proteins, including band 3, 
ankyrin-1, protein 4.1 and glycophorins 346, causing them to cross-link and aggregate 347,348. This 
aggregation is further facilitated by the phosphorylation of band 3 proteins, which reduces their 
binding affinity for ankyrin-1, making them more mobile to traverse across membrane 349. 
Aggregated band 3 has been shown to have increased affinity for naturally occurring 
autoantibodies IgG and complement C3, making the erythrocytes more likely to be 
phagocytosed by macrophages 350,351. Another erythrocyte membrane protein, CD47, has also 
been implicated in mediating phagocytosis. It has long been believed that presence of CD47 on 
the erythrocyte surface inhibits phagocytosis through interaction with SIRP-alpha on 
macrophages 352,353. The absence or gradual loss of CD47 has also been shown to accelerate RBC 
clearance in mice 354,355, although some studies have reported otherwise 356. Upon further 
investigation, it was discovered that oxidative damage induces CD47 conformational changes, 
which alters its interaction with SIRP-alpha, switching from inhibitory to activating signal and 
enabling phagocytosis during malaria infections 357. 
Interestingly, parasites have developed several strategies to avoid being phagocytosed. As the 
parasites grow inside the erythrocytes, they develop new permeation pathways (NPP) to dispose 
of wastes and obtain nutrients from extracellular space, which causes oxidative damage and 
makes erythrocytes more permeable to calcium, a stimulator of eryptosis 358. However, parasites 
counter this by sequestering intracellular calcium in their organelles to possibly delay eryptosis 
359. Even if membrane scrambling and PS exposure eventually occurs, parasites have been shown 
to utilise PS to mediate cytoadhesion to endothelium through thrombospondin and CD36 
receptors 360,361, thus evading splenic clearance altogether.   
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Figure 1.4: Various mechanisms of infected RBC detection. 1) Infected RBC have increased 
permeability to calcium, which leads to calcium-mediated scrambling of PS, thus exposing PS on 
RBC surface. Exposed PS is recognised by various PS receptors on the macrophage and facilitates 
phagocytosis. Parasites counteract by sequestering intracellular calcium to keep RBC calcium 
level low. 2) Oxidative damage to haemoglobin produces hemichromes, which bind to RBC 
cytoskeletal proteins and phosphorylate band 3, increasing its mobility. Aggregation of band 3 
eventually occurs and allows the binding of autoantibodies IgG and complement C3, leading to 
phagocytosis. 3) CD47 undergoes conformational change due to oxidative damage from aging, 
which activates signals for phagocytosis. However, parasites preferentially invade CD47-rich 
young RBC to avoid this. 4) Direct immune recognition of parasite antigens can activate host 
immune systems, although high antigenic variation prevents effective recognition.  
 
Another strategy parasites employ to avoid clearance is by invading erythrocytes selectively. 
Recent studies revealed that some parasite species preferentially invade young RBCs which are 
rich in CD47 362.  Infected erythrocytes from mice lacking in CD47 are more likely to be 
phagocytosed, suggesting an evolutionary adaptation to invade CD47 rich RBCs to evade 
phagocytosis 362. In addition, direct immune recognition of parasite proteins has also been 
challenging due to the high genetic variation of PfEMP1, which is encoded by var genes. 
Parasites contain around 60 var genes but each parasite only express one gene at a time, making 
antibody-mediated clearance difficult 363,364.  
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With the long co-evolutionary history with malaria, certain genetic polymorphisms in humans 
have been implicated to promote parasite detection and clearance. Both G6PD deficiency and 
pyruvate kinase deficiency are associated with increased phagocytosis of infected RBCs 128,220,221. 
It is currently thought that these deficiencies cause high oxidative stress, causing accelerating 
aging, which in turns promote PS exposure 216. Increased phagocytosis is also observed for 
infected thalassaemic and sickle cells 205, and several mechanisms have been hypothesised. 
These include increased PS exposure due to translocase impairment and scramblase activation 
365,366 and increased permeability to certain cations, making RBCs more likely to undergo 
eryptosis 367. Increased oxidation of haemoglobin in these haemoglobinopathies also promotes 
the formation of hemichromes, enhancing the aggregation of band 3 348.  As a result, these cells 
also exhibit increased binding of naturally occurring antibodies 205,368, indicating possible 
phagocytosis-mediated parasite clearance. 
 
1.3.5 Summary 
As evidenced in this section of the review, Plasmodium parasites have developed strategies to 
exploit various host pathways and processes to their own benefit, including immune evasion 
and host cell remodelling, as the result of co-evolution with humans. On the flip side, genetic 
polymorphisms in humans such as the ones that were described above, have proven effective 
at impairing parasite lifecycle. This constant struggle between host and parasites is a perfect 
example of “The Red Queen hypothesis”, where both species have to constantly evolve and 
adapt to gain an upper hand in survival. This also demonstrates the importance of host genetics 
in understanding various parasite processes, as many of these mechanisms would still be unclear 
if not for these genetic polymorphisms. 
This section not only summarises resistance mechanisms of various genetic polymorphisms, but 
also highlights the complex interactions between hosts and parasites. This is demonstrated by 
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the fact that mutations in a single gene often affect various processes of parasite lifecycle, giving 
rise to multiple mechanisms of protection, such as mutations affecting RBC cytoskeletons, 
haemoglobins and surface receptors. These examples provide a basis for the development of a 
new host-directed therapy for malaria, which will be discussed in the following section.  
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1.4 Host-directed Therapies 
As discussed in the previous sections, it is evident that Plasmodium parasites are highly reliant 
on the host cell microenvironment for their survival. As such it presents an attractive 
opportunity for drug interventions to combat malaria. In the past, many antimalarial drugs have 
been designed to target parasite proteins and processes, rather than the host. With the 
inevitable emergence of parasite resistance against these antimalarials, it might be more 
reasonable to turn our attention to the opportunities presented by targeting the host. Such 
approaches of targeting host proteins and processes are known as “host-directed therapies” 
(HDT), which have become a popular approach to treat diseases in the past few years 369. Since 
it only relies on the host proteins, it is often regarded as a theoretically resistance-proof 
approach to treat infections. This section of the review will discuss and examine examples of 
HDT in various infections, and explore the possibility of applying HDT for malaria.  
 
1.4.1 Advantages and disadvantages of HDT 
HDT provide some distinctive advantages over the conventional pathogen-directed treatments. 
Pathogen-directed approaches, although offer more specificity towards pathogens as the result 
of evolutionary divergence, often face the development of drug resistance. This is especially 
ineffective in the case of multidrug resistant pathogens, such as Acinetobacter 370, tuberculosis 
371 and malaria 372. One explanation for this is that the pathogen-directed drugs impose selective 
pressure and therefore subjected to changes in pathogen genetics, where mutations in drug 
targets are likely to cause resistance to the treatments. On the other hand, HDT target the host 
proteins, which is outside of parasite genetic control. The pathogens would not have control 
over the availability of various host resources to the pathogens. It is also unlikely for the 
pathogens to develop a parallel but independent pathways through mutations alone. As the 
result, HDT are thought to be more resilient to drug resistance, thus providing a possible way 
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out of the never-ending cycle of drug development. However, one major weakness of HDT is the 
potential side effects related with targeting the host. It is possible that inhibiting host proteins 
would affect normal functions of these proteins, which might be deleterious to the host. As an 
example, imatinib, a tyrosine kinase inhibitor, has been shown to be a potential treatment for 
vaccinia virus or microbes that rely on host tyrosine kinase 373. However, it is also associated 
with skin toxicity, oedema, and potentially cardiac toxicity 374,375. As the result, it is important to 
have full understanding on the mechanisms of action and the safety of these drugs. Nevertheless, 
with proper drug delivery and administration, HDT can still be an invaluable tool to combat 
multidrug resistant pathogens 376. 
 
1.4.2 Applications of HDT 
With a better understanding of host-pathogen interactions, increasingly more research has been 
aimed at discovering host-directed treatments. HDT typically involves utilising agents such as 
repurposed drugs, antibodies, recombinant proteins and cellular therapies to improve host 
defences against pathogen, either by augmenting host immune responses, or by preventing the 
hijacking of host factors by pathogens 369. Development of HDT has been applied to wide range 
of infections and their diseases, including Mycobacterium tuberculosis (tuberculosis) 377, HIV 378, 
Dengue virus 379, Ebola virus 380 and Leishmania protozoans (Leishmaniasis) 381. A few of these 
are discussed below. 
1.4.2.1 Tuberculosis 
HDT development for tuberculosis is a trending area of research in recent years. Studies have 
shown that elevated levels of interleukin-1 (IL-1) are able to inhibit excessive type 1 interferon 
production, preventing eicosanoid imbalance and thus pathogenesis 382. Immunotherapy 
treatment with drugs to increase prostaglandin E2 have been shown to reduce mortality in 
infected mice 382. Similarly, another potential HDT for tuberculosis involves the use of a 
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glucocorticoid receptor inhibitor, Prednisone, to increase the expression of inducible nitric oxide 
synthase (iNOS) and inducible cyclooxygenase (COX-2) 383, which improves patient survival 384. 
Studies have also shown the potential of using Metformin as an adjuvant for antituberculosis 
treatment. The mechanism of killing Mycobacterium tuberculosis by Metformin adjuvants is 
thought to be via induction of oxidative damage to the bacteria, and improved T-cell responses 
385,386.  
1.4.2.2 Ebola virus 
Ebola virus has received substantial attention in treatment development due to the recent 
outbreaks and subsequent high mortality 387. Recent HDT in development for Ebola virus include 
using repurposed drugs such as Irbesartan and Atorvastatin, to improve tissue repair and reduce 
pro-inflammatory responses that occur during infection 388. These are currently in the early 
phase of clinical trials for improving survival of patients 389. It is also possible to use a 
recombinant inhibitor, rNAPc2, to reduce blood coagulation and the release of pro-
inflammatory cytokines, which has been shown to work in rhesus monkeys 390. 
   
1.4.3 Discovery of ANK-1 as a candidate HDT target for malaria 
Currently, little research has been done on the application of HDT for malaria. It is possible to 
develop HDT that mimic the protective effect of various genetic polymorphisms, since they are 
generally well-characterised and effective at conferring resistance. However, most of them are 
associated with deleterious effects to the host, prompting the need to discover novel, safe, HDT 
targets for malaria.  
Previously, an N-ethyl-N-nitrosourea (ENU) mutagenesis study performed in our lab has 
discovered ankyrin-1 (ANK-1) to be a potential HDT target for malaria, as described by Greth, et 
al. 189.   Ankyrin-1 is a 210kDa protein and a major component in RBC cytoskeletal structure. It is 
36 
 
made up of 3 large domains: the amino terminal ankyrin repeats, the middle spectrin-binding 
domain, and the regulatory domain towards the carboxyl terminus. It has 3 major binding 
partners: band 3, protein 4.2, and beta-spectrin 391-393, thus functioning as a vertical connector 
between the RBC membrane and the cytoskeleton structure, as shown in Figure 1.5. Mutations 
in ANK-1 in humans are often associated with hereditary spherocytosis (HS), a genetic disorder 
that results in reduced RBC volume and increased osmotic fragility. Symptoms can range from 
asymptomatic to severe haemolytic anaemia depending on the nature and position of mutations 
195,394.  
Greth, et al. 189 described an ENU-induced Ank-1 mutation, MRI23420, which gives rise to a HS-
like phenotype, with reduced RBC volume, elevated RBC count but normal total haemoglobin 
levels. When challenged with a mouse malarial parasite, P. chabaudi, heterozygous mice showed 
significant resistance compared to wild-type, which was consistent with other previously 
described mice carrying Ank-1 mutations – namely the Ank-1(nb/nb) and Ank-11674 mice. In terms 
of resistance mechanisms, both Ank-1(MRI23420/+) and Ank-1(nb/nb) were thought to impair parasite 
intra-erythrocytic growth 189,204, whereas the mechanisms are unclear for Ank-11674 mice 190. For 
(nb/nb) mice, the authors proposed spectrin deficiency to be the cause of reduced parasite 
growth 204. However, Ank-1(MRI23420/+) and Ank-11674 heterozygotes have normal levels of spectrins 
and yet they were significantly resistant to P. chabaudi. This conflicting evidence suggests that 
ANK-1 might mediate resistance through multiple mechanisms. Therefore, a more detailed 
study is required to elucidate the exact roles ANK-1 has during malaria infection. 
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Figure 1.5: Schematic diagram of RBC cytoskeletal structure showing major cytoskeletal 
proteins of ankyrin complex. Ankyrin is responsible for connecting the spectrin networks to the 
RBC membrane via binding with protein 4.2 and band 3 on the RBC membrane. The N-terminal 
ankyrin repeats (D2-D4) are involved in ankyrin-band 3-protein 4.2 binding, whereas Zu5 domain 
binds to repeat 14-15 of β-spectrin. 
 
Several in vitro studies have also recently revealed the binding site of ankyrin-1 and β-spectrin 
391,395,396. It appears to be localised to the Zu5 domain of ANK-1 and repeat 14 and 15 of β-
spectrin 396,397. Mutagenesis studies have indicated several crucial residues that facilitate 
ankyrin-spectrin binding on beta-spectrin, such as D1781, E1784, T1788 and Y1866 of β-spectrin 
398. Given that mutations in ankyrin-1 or spectrins often result in RBC abnormalities, it is likely 
that mutations in these residues might also give rise to similar phenotypes as HS patients. This 
raises the possibility to further investigate this interaction in the context of malaria using a 
reverse genetics approach in an in vivo setting. 
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1.4.4 Hypotheses of this study 
In order to elucidate the exact roles ANK-1 has during malaria infection, several mouse strains 
carrying various ENU-induced Ank-1 mutations were examined in this study, namely Ank-
1(MRI61689), Ank-1(MRI95845) and Ank-1(MRI96570). These mice were identified by significantly lower RBC 
volume, similar to Ank-1(MRI23420). Their response to malaria infection, as well as their 
mechanisms of resistance were further explored. We hypothesise that the location of the 
mutations will give rise to different degrees of malaria resistance, and possibly through different 
mechanisms. 
Another aspect of this study is to determine if ANK-1 is a suitable HDT target. This was done by 
examining another strain of mouse, TAR3.5, which was generated through CRISPR/Cas9 
technique to carry a mutation, D1781R, on the ankyrin binding site of β-spectrin. We 
hypothesised that the ankyrin-spectrin interaction would be disrupted in the mice, similar to the 
in vitro studies, and consequently conferring resistance to malaria. The RBC phenotypic 
characteristics of these mice and their response to malaria infections were investigated in this 
study. This would not only give us insight into the host-parasite interactions, but also raise the 
possibility of disrupting this interaction pharmacologically as the first step towards HDT 
development for malaria. High throughput drug screening (HTS) could then be used to identify 
drug candidates that disrupt the binding of recombinant proteins in vitro, which is explored in 
this study. 
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1.5 Project Aims 
The goals of this project were to investigate the roles ankyrin plays in malaria infections through 
the use of mouse models with various Ank-1 mutations, as well as to determine if ANK-1 is a 
suitable candidate for HDT development for malaria. This is achieved through the following 
specific aims: 
1. Characterise and compare the phenotypes of mice carrying Ank-1MRI61689, Ank-1MRI95845 
or Ank-1MRI96570. 
2. Examine their response towards malaria infection and determine the underlying 
mechanisms of their resistance. 
3. Determine if ANK-1 is a suitable HDT target by characterising TAR3.5 mice and 
developing an in vitro binding assay for HTS to look for drug candidates for disrupting 
ankyrin-spectrin binding. 
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CHAPTER 2 
MATERIALS AND METHODS 
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2.1 Mouse Husbandry and Maintenance 
2.1.1 ENU mutagenesis screen and ethics statement 
SJL/J or B6.BKS (D)-Leprdb/J male mice (G0) were injected with 150 mg/kg and 100 mg/kg of N-
ethyl-N-nitrosourea (ENU) (Sigma-Aldrich, St Louis, MO), respectively, at seven weeks old and 
crossed to females from the isogenic background to produce the first generation progeny (G1). 
The seven-week-old G1 progeny were bled and analysed on an Advia 120 Automated 
Haematology Analyser (Siemens, Berlin, Germany) to identify abnormal red blood cell 
parameters. The G1 MRI61689, MRI95845, MRI96570 mice were identified due to their 
significantly low mean red cell volume (MCV) – three standard deviation lower than other G1s. 
These mice were crossed again with mice from the isogenic background to generate G2 progeny 
and to assess the heritability and the dominance mode of inheritance. Mice that exhibited low 
MCV (<48 fl) were subjected to whole exome sequencing to identify the causative mutations. 
Mutant mice were identified via haematological analysis, osmotic fragility test or Amplifuor SNP 
genotyping assay, which is carried out by the Australian Phenomics Facility (APF). The mice were 
maintained according to the NHMRC code of practice for experimentation using laboratory 
animals and all experiments were carried out under the ethics agreements ARA2012/019 and 
A2014/54 and the NLRD 15.03.  
 
2.1.2 CRISPR/Cas9 system to introduce D1781R mutation in TAR3.5 mouse strain 
The CRISPR/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR-
associated 9) system was used to introduce D1781R mutation in SJL/J mice to generate TAR3.5 
mouse strain, and was conducted by Dr Gaetan Burgio and Ms. Emmaline Brown. Briefly, guide 
RNA (gRNA) was first designed as indicated below and cloned into a Px461 plasmid containing a 
Cas9-D10 as described in published protocol 399.  
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ACCATCGCTGAGTGGAAGGATGGACTCAATGACATGTGGGCGGACCTGCTGGAGCTCATTGACACCCG
CATGCAGCTGCTGGCTGCCTCCTACGACCTGCACCGCTATTTCTACACAGGC 
The highlighted section indicates the gRNA sequence, with the underlined nucleotide being the 
targeted mutation site. 
 
Embryo donor SJL/J mice were first injected intraperitoneally with 5 IU Pregnant Mare Serum 
Gonadotrophin, followed by 5 IU of Human Chorionic Gonadotrophin 48 hours later to induced 
superovulation. They were then immediately placed with fertile a stud male and embryos were 
collected 12 hours post-conception. 5 ng/µl of cloned Px461 plasmid as above and 25 ng/µl of 
150 bp single stranded oligonucleotides containing the nucleotide to be integrated (Integrated 
Device Technology, San Jose, California) were co-injected into the pronucleus of the fertilised 
zygotes, followed by transferring into pseudo-pregnant females. The newborn pups were 
genotyped by Sanger sequencing using primers listed in Section 2.3.2 and the mice positive for 
the mutation were bred for the maintenance of TAR3.5 mouse strain.  
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2.2 Phenotypic Characterisation of Mice  
2.2.1 Complete blood count analysis 
Peripheral blood was collected from at least seven week old uninfected mice via mandibular 
puncture or retro-orbital bleeding with EDTA lined-CAPIJECT® Micro Collection Tubes (Terumo 
Medical Corporation, NJ). Blood samples were analysed using an ADVIA® 2120 haematology 
system (Siemens, Berlin, Germany) on CBC/DIFF settings and species Mouse C57BL/6. 
 
2.2.2 Osmotic fragility measurement 
To assess the susceptibility of the RBC membrane to osmotic stress, whole mouse blood was 
diluted 100-fold with hypotonic mouse tonicity phosphate buffered saline (MT-PBS) containing 
0 to 10 g/L of sodium chloride, and incubated for at least 10 minutes at room temperature. The 
cells were centrifuged at 800 g for 3 minutes, and the supernatant, which contains free 
haemoglobin, was measured at 540 nm to assess the degree of haemolysis. The absorbance 
values were expressed as percentage of haemolysis, with haemolysis at 0 g/L sodium considered 
as 100% lysis. 
 
2.2.3 Scanning electron microscopy 
Fresh blood was fixed overnight at 4°C, in 3% EM-grade glutaraldehyde (Sigma-Aldrich, St Louis, 
MO) immediately upon collection. The samples were washed with MT-PBS 3 times, 10 minutes 
soak each. The cells were then adhered to the coverslips with 0.1% polyethylenimine (PEI) for 
10 minutes, before washing off with MT-PBS. The cells were then dried serially using 30%, 50%, 
70%, 80%, 90%, 100%, 100% ethanol, each with a 10 minutes soak. The cells were then soaked 
in 1:1 ethanol: hexamethyldisilazane solution for 10 minutes, followed by 2 washes with 100% 
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hexamethyldisilazane (Sigma-Aldrich, St Louis, MO), each 10 minutes. The coverslips were then 
air-dried overnight and coated with gold and examined under JEOL JSM-6480LV scanning 
electron microscope, with the assistance from the staff in the Microscopy Unit of Macquarie 
University, Sydney. 
 
2.2.4 RBC lifetime assay 
Each uninfected mouse was injected with 1 mg of EZ-link® Sulfo-NHS- LC Biotin (Biotin) (Thermo 
Scientific, Waltham, MA) in MT-PBS intravenously. 2 µl of blood was collected on day 1, 7, 14, 
21 and 28 from the day of injection. Samples were stained and analysed using a flow cytometer 
(details described in method 2.4.5). The proportion of Biotin-labelled mature RBCs on day 1 was 
considered as the “starting point” of 100% of labelled cells. For subsequent timepoints, the 
remaining number of biotin-labelled RBCs were expressed as a percentage of the starting 
number as the indication of RBC turnover rate. 
For infected mice (according to method 2.4.1), 1 mg of Biotin was injected intravenously as soon 
as parasitaemia was detectable on flow cytometry (approximately 0.05-0.3%). Samples were 
collected daily and analysed as above. In addition, the production of reticulocytes 
(reticulocytosis), parasite load and relative levels of anaemia were also tracked.  
 
2.2.5 RBC deformability assays 
2.2.5.1 Ektacytometry 
10-15 µl of uninfected RBCs were first resuspended in 500 µl of pre-warmed 
polyvinylpyrrolidone (PVP) solution at a viscosity of 30 mPa/second at 37 °C until needed. 
Samples were analyzed according to the manufacturer’s instructions with a RheoScan 
Ektacytometer (Rheo Meditech, Seoul, South Korea) and the elongation index measured across 
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a range of pressures from 0-20 Pa. Each sample was measured three times to account for 
technical variabilities. The values were normalized against the wild-type samples. 
 
2.2.5.2 In vitro splenic retention assay 
Another method used to indicate RBC deformability is through an in vitro splenic retention assay, 
modified from the method as described by Deplaine, et al. 400. The unstained cell solution was 
first prepared by diluting 100 µl wild-type whole blood with mouse-tonicity Ringer’s complete 
solution (MTRC). Separately, 50 µl of whole blood was first labelled with 0.1 µg of either 
hydroxysulfosuccinimide Atto 633, Atto 565 or Atto 495 (Sigma-Aldrich, US) on ice for 45 
minutes. They were then washed two times with MTRC and resuspended in 500 µl of MTRC. 
Each sample mixture was prepared by adding 40 µl of each labelled blood and made up to  
200 µl with MTRC, followed by adding 500 µl of the unstained cell solution, making up to 700 µl 
in total. Replicates of samples were also prepared with different combination of labelled RBCs 
to account for dye effects. 
The bead layers were prepared by mixing 1 g of each 5-15 µm and 15-25 µm beads, and 
resuspending these in 4 ml of MTRC. 500 µl of the well-mixed bead mixture was added into a  
1 ml filter pipette tip with a trimmed tip. More beads mixture was added to the tip if necessary 
to make up an approximately 2 mm thickness of bead layer in the tip. The tip was filled with 
MTRC to the brim of the tip. 
These prepared tips were first briefly flushed with MTRC before injecting 500 µl of the sample 
mixture into the system, followed by flushing the tip with at least 6 ml of MTRC. The leftover 
sample mixtures were kept as the “pre-filtered” samples. The flow through from the tips were 
centrifuged and resuspended in 500 µl of MTRC, as the “post-filtered” samples. They were then 
analysed on BD LSRFortessa flow cytometer (BD Biosciences, Franklin Lakes, NJ) to determine 
the proportion of each labelled blood pre- and post-filtration (as described in Section 2.4.5). The 
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percentage of retention is calculated by dividing the difference in labelled blood population pre-
and post-filtration by the pre-filtered population to obtain the percentage retained. They were 
then normalized to the unlabeled population. 
 
2.2.6 Fluorescence Recovery after Photobleaching (FRAP) analysis 
To determine the mobility of Band 3 on the erythrocyte membrane, 15 µl of uninfected whole 
blood was washed once with PBS and subsequently stained with 0.2 mg/ml of Eosin-5-maleimide 
(EMA) (Biotium, Hayward, CA) in pH8.0 PBS (from a pre-made EMA stock of 50 mg/ml in DMF or 
DMSO). Cells were stained for 1 hour on ice, followed by washing with PBS at least twice until 
the supernatant was clear. Cells were then incubated at room temperature for 6 minutes with 
approximately 7000 U/ml of Streptolysin-O (Sigma-Aldrich, St Louis, MO) which was pre-
activated with 100 mM DTT for 15 minutes at room temperature. Cells were then washed twice 
with PBS and spread on a glass slide. They were then covered with cover slips and pressed 
upside-down to remove excess liquid and sealed. The samples were then examined on Leica SP5 
confocal microscope (Leica Microsystems, Wetzlar, Germany) with the help of Dr Matthew 
Dixon using the settings below: 
FRAP settings on SP5:  
- 80% Argon laser power 
- 10% opened shutter except during bleaching 
- Pinhole fully opened (600 microns) 
- 128x128 pixels during FRAP 
- 2 line averages 
- Zoom factor: 5 
- 1µm diameter circular bleach area 
- 3 pre-bleached images each at 0.6 seconds interval 
- 1 bleach image at 0.6 seconds with 100% opened shutter 
- 2 post-bleached images with 0.6 seconds interval 
- 10 post-bleached images with 30 seconds interval 
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2.2.7 Band 3 solubility assay 
To determine the proportion of un-bound band 3 in the RBC membrane, 100 µl of mouse whole 
blood was lysed with ice-cold 5mM phosphate buffer (ph7.4) with cOmplete Protease Inhibitor 
Cocktail Tablets (protease inhibitor) (Roche, Basel, Switzerland), and centrifuged at 20,000 g for 
20 minutes followed by removal of the supernatant. The pellet (RBC ghosts) was further washed 
with the 5 mM phosphate buffer until the supernatant became clear. 20 µl of RBC ghost was 
then dissolved in the same volume of phosphate buffer containing 3% v/v Triton-X100 and 
incubated on ice for 20 minutes, followed by centrifugation at 20,000 g at 4oC. The supernatant 
containing soluble band 3 was isolated from the pellet, which contained the insoluble band 3. 
The pellet was resuspended in phosphate buffer with 3% v/v Triton-X100 and centrifuged again 
at 20,000 g at 4oC. The supernatant was discarded, and the pellet was resuspended in 10 µl of 
phosphate buffer. Both soluble and insoluble band 3 were denatured at 95oC, and loaded onto 
SDS-PAGE. Western blotting was then carried out and analysed as described in section 2.3.3. 
 
2.2.8 Ex vivo haemolysis and phosphatidylserine (PS) exposure assays 
The susceptibility of RBCs to haemolysis was assessed by first incubating whole mouse blood at 
room temperature for up to 72 hours, with timepoints at 0, 3, 6, 12, 24, 48 and 72 hours of 
incubation. For each timepoint, 2 µl of whole blood was resuspended in 200 µl of MT-PBS and 
centrifuged at 800 g for 3 minutes. 100 µl of the supernatant was taken and the absorbance at 
540 nm was measured as an indicator of haemolysis. The percentage of haemolysis was 
calculated from the absorbance value, with haemolysis in pure water considered as 100% lysis 
and baseline haemolysis at 0 hour.  
The PS exposure was measured by incubating 1.5 µl of the whole blood in 100 µl of Annexin V 
binding buffer containing 5 µl of Annexin V- Fluorescein isothiocyanate (FITC) for 30 minutes at 
49 
 
room temperature. 400 µl of Annexin V binding buffer was further added into the samples 
before analysing on BD LSRFortessa (BD Biosciences, Franklin Lakes, NJ) as described in Section 
2.4.5. 
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2.3 Molecular Biology Techniques 
2.3.1 Whole exome sequencing  
DNA from two G2 mice carrying the abnormal red blood cell parameters (MCV <48fl) were 
extracted with Qiagen DNeasy blood and tissue kit (Qiagen, Venlo, Netherlands) for exome 
sequencing as previous described 401.  Briefly, at least 10 µg of DNA was prepared for exome 
enrichment with Agilent Sure select kit paired-end genomic library from Illumina (San Diego, CA), 
followed by high throughput sequencing using a HiSeq 2000 platform. The bioinformatics 
analysis was conducted by Dr Denis Bauer according to the variant filtering method previously 
described by Bauer, et al. 402. Briefly, to avoid the variant loss due to algorithm bias, four variant 
calling pipelines were created from the raw sequencing data. The sequencing reads were 
mapped using BWA 403 V0.61 or BOWTIE2 404 onto the mouse genome (mm9/NCBI37), followed 
by variant calling using SAMTOOLS 405 V0.1.19 or GATK UnifiedGenotyper 406. All resulting 
variants were first annotated using GATK and variants from Sanger’s The Mouse Genomes 
Project, followed by filtering using python scripts to retain true (identified in more than one 
pipeline) and exclusive variants. Private variants that were shared between the two mutants but 
not with other mice from isogenic background or previously described ENU mutants were 
functionally annotated using ANNOVAR 407. Private non-synonymous exonic and intronic 
variants within 20 bp from the exon spicing sites were retained as potential candidate ENU 
mutations. 
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2.3.2 Genotyping 
For routine genotyping of experimental mice, DNA was extracted from mouse tails using Qiagen 
DNeasy blood and tissue kit. Purified DNA was amplified through PCR using primers listed below. 
Either GoTaq® DNA polymerase or AmpliTaq® DNA Polymerase were used for all PCR reactions, 
which was conducted using following conditions: 
Temperature (°C) Time (m:ss) Number of cycles 
95 1:00 1 
95 0:30 
35 57 0:30 
72 0:40 
72 5:00 1 
 
The PCR products were examined using agarose gel electrophoresis for quality control, followed 
by purification using either Wizard® SV Gel and PCR Clean-Up System (Promega, Madison, WI) 
or treatment with ExoSap digestion, where 0.025 µl Exonuclease I (New England Biolabs, Ipswich, 
MA), 0.25 µl of shrimp alkaline phosphatase (New England Biolabs, Ipswich, MA) and 9.725 µl 
water was added and incubated at 37°C for 30 minutes. Purified PCR products were then sent 
for Sanger sequencing by Australian Genome Research Facility (AGRF, WEHI, Melbourne) or to 
Biomolecular Resource Facility (BRF, ANU, Canberra). Logarithm of odds (LOD) score was 
calculated based on the number of mice that segregated with the candidate mutations. 
Primers for MRI61689 mutation: 
Amplicon Forward Reverse 
Acp5 CAGAAGGATGCCTTTGGGTA ACCAGCGCTTGGAGATCTTA 
Kcnk1 GGGCCTTTTCCTCCTTACAGA CAGGAAACGGTGACAAATCC 
Epas1 GGAAGCCAGAACTTCGATGA GTAGTGTTCCCTGGGGTGT 
Picalm TCACTGAATGTAATTGGGATATCAT CACCCTCTCTTCACTTTTGTG 
Socs6 CCGCTTTGTTATCCGTCAGT TGGCAGCAAAGACTTCAATG 
Ank-1 TCCCTGGCTTAAAGTTGGTG CTCTCCCTTAGCTGCATTCC 
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Primers for MRI95845 mutation: 
Amplicon Forward Reverse 
Snai2 CATCTGCAGACCCACTCTGA TGGTTGGTAAGCACATGAGAA 
Tbc1d23 CACCCCCTTTTTGGTTTCTT ACGTGCACATCGACTAACCA 
Pnpla6 AGGCTGAGGAAGTGTGCCTA AACTAGCTGGGCTTTGGTCA 
Zglp1 CTGGCCTTTGACTTCTGACC CCTCACAAGGTGGCTGTTTC 
Ank-1 CTCCAAGTGAGAGGGTTTGC GATGGCACACAGTCAGACCA 
 
Primers for MRI96570 mutation: 
Amplicon Forward Reverse 
Fat4 CGCATCCCTTCATACAACCT ACACCCCACTCACGTAGCTC 
Rhcg TGAGGAATGAGGGAGAAAGG CCAATATGGCAGCCCTCTAA 
Plxnb3 TACCCGATCAATCCAGAAGG TTCTGAATGTGCAGGGTCAC 
Ank-1 TGTGCAGGCATTTCTACATGA ACTCTCTGGGTAGACCCCGT 
 
Primers for TAR3.5 mouse strain: 
Forward: 5’- GTGACAACCTGGCAAAGTGA-3’ 
Reverse: 5’-ACACCAACACTGGGAGAAGG-3’ 
 
2.3.3 RNA extraction, cDNA synthesis, qPCR and cDNA sequencing 
RNA was isolated from embryonic livers of E14 embryos using Qiagen RNeasy kit (Qiagen, Venlo, 
Netherlands), followed by cDNA synthesis using Transcriptor High Fidelity cDNA Synthesis Kit 
(Roche, Basel, Switzerland). Quantitative PCR was carried out on ViiA™ 7 Real-Time PCR System 
(Thermo Scientific, Waltham, MA). The ΔΔCT method was used to determine the cDNA levels of 
Ank-1 and the housekeeping gene β-actin and expressed as a fold-change of the mutants to the 
wild-type. The primers used for Ank-1 gene spanned exon 2 to 4:  
Ank-1-F: 5’-TAACCAGAACGGGTTGAACG-3’;  
Ank-1-R: 5’-TGTTCCCCTTCTTGGTTGTC-3’  
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β-Actin-F: 5’- TTCTTTGCAGCTCCTTCGTTGCCG-3’;  
β-Actin-R: 5’- TGGATGCGTACGTACATGGCTGGG-3’ 
 
To characterise the effect of the MRI61689 mutation, cDNA was amplified through PCR using 
two primers set were design as shown below: Primer set 1 was designed to amplify the wild-
type Ank-1 transcript, whereas primer set 2 was designed to only amplify the predicted mutant 
transcript with the 11 bp insertion. Amplified PCR products were analysed using agarose gel 
electrophoresis and each band was purified and sequenced as described previously. 
Primer set 1: Forward: ATGCAGAGTCGGTACAAGGC; Reverse: CCGTTCGAGCTGACCTCATT 
Primer set 2: Forward: CCTGGGGAACAAGTTTCTTT; Reverse: GTGCAAGGGGCTGTATCCTA 
 
2.3.4 SDS-PAGE, Coomassie staining, Western and proteomic analysis 
RBC ghosts (prepared as described in Section 2.2.7) or whole blood lysates were denatured in 
SDS-PAGE loading buffer (0.0625M Tris pH 6.8, 2% SDS, 10% glycerol, 0.1 M DTT, 0.01% 
bromophenol blue) at 95°C for 5 minutes before loading onto a Mini-PROTEAN® TGX™ Precast 
Gels (Bio-Rad, Hercules, CA). The gels were then either stained with Coomassie blue solution 
(45% v/v methanol, 7% v/v acetic acid, 0.25% w/v Brilliant Blue G) overnight or transferred to a 
nitrocellulose membrane.  
For proteomic analysis of Ank-1(MRI95845/MRI95845) and wild-type erythrocytes, each lane of 
Coomassie-stained gel was cut into pieces and destained and washed with 50% v/v acetonitrile 
/ 50 mM ammonium bicarbonate at 37oC for 15 minutes four times. The pieces were then dried 
and sent to Australian Proteome Analysis Facility (APAF) for protein alkylation and reduction, 
trypsin digestion and analysis on a mass spectrometer.   
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Western blotting was carried out using these primary antibodies: anti-alpha 1 spectrin (clone 
17C7) at 1:1000 dilution, anti-beta 1 spectrin (clone 4C3) at 1:1000 dilution (Abcam, Cambridge, 
UK), anti-N-terminal Ank-1 “p89” (1:1000 dilution), anti-Band 3 (1:5000 dilution) and anti-
protein 4.2 (1:4000 dilution) (kind gifts from Connie Birkenmeier, Jackson Laboratory, US). 
Housekeeping gene GAPDH or β-actin were detected either using anti-GAPDH (clone 6C5) at 
1:1000 dilution (Merck Millipore, Darmstadt, Germany), or anti- β-actin (ab8227) (Abcam, 
Cambridge, UK) at 1:1000 dilution, respectively. Each primary antibody was detected with the 
appropriate horseradish peroxidase (HRP)-conjugated secondary antibody at 1:5000 dilution 
from 1 mg/ml stocks. The blots were visualised using ImageQuant LAS 4000 (GE Healthcare Life 
Sciences, Arlington Heights, IL), and quantified using ImageJ software 408.  
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2.4 Malaria Infection-related Techniques 
2.4.1 Malaria infection 
250 µl of thawed P. chabaudi adami DS infected blood was injected into the intraperitoneal 
cavity of a C57BL/6 donor mouse. When the donor mouse reached 1-10% parasite load 
(parasitaemia), the mouse was euthanised and blood was collected through cardiac puncture. 
The parasitised blood was diluted in Krebs’ buffered saline with 0.2% glucose as described 
previously 409.  Each experimental mouse was infected with either 1x104 (low dose) or 1x107 
(high dose) parasites intraperitoneally. Each mouse was then monitored daily until they started 
exhibiting symptoms, in which they were monitored four times daily according to the 
parameters described below. Each parameter was scored 0 to 3 according to the severity of the 
symptoms, where a score of 3 in any parameters denotes immediate euthanisation of mice. The 
parasitaemia of these mice were monitored either using light microscopy or flow cytometry. 
Parameters to monitor Score (0-3)  
Coat 
1 – Rough coat 
2 – Unkempt coat, thin body, wounds present 
3 – Discoloured, skin discharge 
Activity 
1 – Isolated, abnormal posture 
2 – Huddled/inactive OR overactive 
3 – Declining or seizuring 
Movement 
1 – Slightly uncoordinated/ abnormal 
2 – Uncoordinated, walking on toes, reluctant to move 
3 – Staggering, paralysis, limb dragging 
Eating/drinking 
1 – Increased/decreased for 24 hrs 
2 – Increased/decreased for 48 hrs 
3 – Increased/decreased >48 hours. Obese* 
Dehydration 
1 – Skin less elastic 
2 – Skin tents 
3 – Skin tents, eyes sunken 
Blood in faeces/urine 
1 – Moist faeces 
2 – Diarrhoea or dry faeces, abnormal urine (volume/colour) 
3 – Uncontrolled diarrhoea, blood in faeces. Nil urine or 
incontinent 
Body weight 
1 – Reduced growth 
2 – Weight loss >15% 
3 – Weight loss >10% over short period or >20% over time 
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2.4.2 Light microscopy 
Blood was collected from mouse tail and smeared onto a glass slide to make a thin blood film. 
The slides were then briefly fixed in methanol for one minute and air-dried before being stained 
in a 10% Giemsa solution (Sigma-Aldrich, St Louis, MO) at pH 7.4 for 10 minutes. The slides were 
examined under a light microscope with the 100x objective with immersion oil, and at least 300 
RBCs were counted. Infected RBCs were counted as a proportion to total RBCs, and expressed 
as percentage parasitaemia. 
 
2.4.3 Terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) staining 
3µl of infected blood containing 1-10% parasitaemia were collected during trophozoite stage 
and fixed in 1 in 4 diluted BD CytofixTM Fixation Buffer (BD Biosciences, Franklin Lakes, NJ) at 4oC 
for at least 24 hours until they were needed. Each sample was then washed twice with MT-PBS, 
and adhered to a glass slide pre-coated with 0.1% polyethylenimine (PEI) for 10 minutes at room 
temperature. The excess cells were washed off with the wash solution from APO-BrdU TUNEL 
assay kit (Thermo Scientific, Waltham, MA) and incubated overnight at room temperature with 
TUNEL labelling solution (1 mM Cobalt Chloride, 25 mM Tris-HCl pH 6.6, 200 mM sodium 
cacodylate, 0.25 mg/ml BSA, 60uM BrdUTP, 15 U Terminal transferase). The slides were washed 
three times with rinse buffer from APO-BrdU TUNEL assay kit, followed by staining with 50 µg/ml 
of anti-BrdU-Biotin antibody (Novus Biologicals, Littleton, CO) in MT-PBT (MT-PBS, 0.5% BSA, 
0.05% Triton X-100) for 1 hour. The slides were then washed three times with MT-PBT, followed 
by probing with 2 µg/ml Alexa Fluor® 594 conjugated streptavidin (Thermo Scientific, Waltham, 
MA). Next, they were washed three times with MT-PBS and mounted with SlowFade® Gold 
antifade reagent with DAPI (Thermo Scientific, Waltham, MA) and sealed. When the slides were 
dried, they were examined using Axioplan 2 fluorescence light microscope (Carl Zeiss, 
Oberkochen, Germany) between 60x to 100x magnification. At least 100 DAPI-positive cells were 
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counted, and each was graded as either positive or negative for TUNEL staining, as an indication 
of DNA fragmentation. 
 
2.4.4 In vivo erythrocyte tracking (IVET) assay 
The IVET assay was carried out as previously described by Lelliott, et al. 410. Briefly, 1.5 to 2 ml 
of whole blood was collected from multiple wild-type and mutant mice via cardiac puncture. 
The bloods were then stained with either 10 µg/ml of Atto 633 or 125 µg/ml of EZ-Link™ Sulfo-
NHS-LC-Biotin (Biotin) (Thermo Scientific, Waltham, MA) for 45 minutes at room temperature, 
followed by washing three times with MT-PBS. The labelled blood was then mixed in two 
different dye combinations to correct for any dye effects. 1x109 erythrocytes were injected 
intravenously into infected wild-type mice at 1-5% parasitaemia during schizogony stage, usually 
8-10 days post-infection with 1x104 parasites. Blood samples were collected at 30 minutes, 3 
hours, 12 hours, 20 hours and 36 hours after injection. The ratio of infected labelled erythrocytes 
was determined using flow cytometry, as an indication of the relative susceptibility of RBC to 
malaria infections. The proportion of labelled blood populations was also tracked over time to 
determine the clearance of these RBCs from the circulation. 
 
2.4.5 Flow cytometric analysis of blood samples 
For RBC lifetime assays, 2 µl of whole blood samples were stained with 2 μg/ml streptavidin-PE-
Cy7, 1 μg/ml anti-CD71-allophycocyanin (APC) (clone R17217), 1 μg/ml anti-CD45–APC eFluor 
780 (clone 30-F11) (eBioscience, San Diego, CA), 4 µM Hoechst 33342 (Sigma-Aldrich, St Louis, 
MO) and 12 µM JC-1 (Thermo Scientific, Waltham, MA) in MTRC. The samples were washed once 
with MTRC and further stained with 2 μg/ml streptavidin-PE-Cy7 to capture all biotin-labelled 
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cells. Immediately prior to analysing on flow cytometer, 5 µl of 123count eBeads (eBioscience, 
San Diego, CA) was added to determine the relative anaemic levels. 
For both malaria infections and IVET assay, 2 µl of whole blood samples was stained with 2 μg/ml 
streptavidin-PE-Cy7 (only for experiments with biotinylated erythrocytes), 1 μg/ml anti-CD45–
allophycocyanin (APC)–eFluor 780 (clone 30-F11), 1 μg/ml anti-CD71 (TFR1)–PerCP–eFluor 710 
(clone R17217) (eBioscience, San Diego, CA), 4 µM Hoechst 33342 (Sigma-Aldrich, St Louis, MO) 
and 12 µM JC-1 (Thermo Scientific, Waltham, MA) in MTRC.  
All samples analysed through flow cytometry were performed on BD LSRFortessa (BD 
Biosciences, Franklin Lakes, NJ), where 100,000 to 2,000,000 events were collected and 
visualized on FACSDivaTM and FlowJo software. The RBCs and leukocytes were first selected on 
forward scatter and side scatter channels (FSC/SSC) signals, followed by gating of single cells 
based on FSC area to height ratio. RBCs were further isolated by gating on CD71 negative and 
CD45 negative population, followed by gating on Atto-labelled and Biotin-labelled erythrocytes 
on appropriate channels (APC for Atto-633, PE for Atto-565 and PE-Cy7 for Biotin). The 
parasitaemia of each labelled erythrocyte population was determined by gating on Hoechst 
33342 positive and JC-1 positive population.  
 
 
  
59 
 
2.5 In vitro P. falciparum Culture Techniques 
2.5.1 Maintenance of in vitro P. falciparum cultures 
3D7 strain P. falciparum cultures (a gift from R. Anders, La Trobe University, Melbourne, 
Australia) were maintained in isolated type O+ RBC from the Australian Red Cross under 1% O2 
and 3% CO2 in Complete Culture Media (CCM) at 370C. Parasitaemia levels were monitored using 
light microscopy every two days and sub-cultured when necessary, usually above 5% 
parasitaemia. The cultures were maintained up to fifteen passages before being replaced with 
a new frozen stock. 
 
2.5.2 Isolation of late stage erythrocytic P. falciparum 
70% Percoll® was first prepared by diluting 100% Percoll® (Sigma-Aldrich, St Louis, MO) with 10x 
RPMI and Red Cell Wash/Sorbitol (13.3% Sorbitol, 10 mM sodium phosphate, 160 mM NaCl, pH 
7.4). Pelleted P. falciparum culture was layered gently on top of the Percoll® solution and 
centrifuged at 3500 rpm (2850 g) for 10 minutes without brakes. The top layer containing late 
stage P. falciparum was collected and washed twice with CCM wash (CCM without serum and 
Albumax®), and a small RBC smear was made. These cells were examined under light microscopy 
to determine the proportion of mature trophozoites. 
 
2.5.3 P. falciparum in vitro invasion and growth assay 
Blood from patients with hereditary spherocytosis was obtained from the Royal North Shore 
hospital by Dr David Rabbolini with informed consent (HREC 2014/715). The buffy coats were 
first removed via centrifugation and kept for DNA isolation and genome sequencing using 
Qiagen DNeasy blood and tissue kit (Qiagen, Venlo, Netherlands) according to the 
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manufacturer’s instructions. The RBCs were collected and washed twice with CCM wash. 
Previously purified late stage P. falciparum was added to the control or patient’s blood to give 
approximately 1% parasitaemia and diluted to 2.5% haematocrit with CCM, followed by 
distributing into a 24-well plate, 1ml in each well with four replicates. Blood smears were 
collected from each well every 6-24 hours for three days. The parasitaemia and parasite 
developmental stages were determined under light microscopy where at least 1,000 RBCs were 
counted. Alternatively, the samples were fixed with a 1 in 4 dilution of BD CytofixTM Fixation 
Buffer (BD Biosciences, Franklin Lakes, NJ) in PBS, and analysed using flow cytometry (Section 
2.4.5).  
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2.6 In vitro Expression of Recombinant Proteins 
2.6.1 Plasmid design and cloning 
Plasmids with inserts containing the cDNA for the human ANK-1 protein residue 866-1068 (ANK-
1 Zu5) and fragment containing the cDNA for the human β-spectrin protein residue 1517-1905 
(SPTB-1315) and β-spectrin protein residue 1517-1905 with D1781R mutation (SPTB-D1781R), 
were purchased from Thermo Scientific. These fragments were amplified using PCR with primers 
that introduced new restriction sites for cloning into a GST-tag expression plasmid (pGEX-6P-3) 
(GE Healthcare Life Sciences, Arlington Heights, IL) as described below, and illustrated in Figure 
2.1:  
 
ANK-1 Zu5: BamHI and Xhol restriction sites 
Forward: 5’-CTGATTGGATCCATGCCTGAGACAGTGGTGA-3’ 
Reverse: 5’-GGACATCTCGAGGTTACCGTGACATGATCACG-3’ 
SPTB-1315 and SPTB-D1781R: BamHI and Xhol restriction sites 
Forward: 5’-GACTGTGGATCCATGAAGAAGAACCAGACACTG-3’ 
Reverse: 5’-GTAATACTCGAGTTAGAATTTATCCGCCGTG-3’ 
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Figure 2.1: The plasmid map of GST-tagged proteins. The schematic diagram of pGEX-6P-3 
showing the location and their associated restriction sites of ANK-1_Zu5, SPTB-1315 and SPTB-
D1781R inserts with their residue position in the native proteins.  
 
For the His-tag expression plasmid, DNA fragments containing cDNA for the human β-spectrin 
protein residue 1583-1905 (SPTB-1315) and the mutated version (SPTB-D1781R) were inserted 
into 6xHis-tag expression plasmid (pRSET-A) and purchased from Thermo Scientific (Figure 2.2a). 
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The cDNA ANK-1 protein residue 911-1068 (ANK-1 Zu5) were amplified with primers listed as 
below to introduce restriction sites for cloning into the pRSET-A plasmid backbone (Figure 2.2b): 
 
ANK-1 Zu5: BamHI and HinDIII restriction sites into pRSET-A plasmid (for residues 911-1068) 
Forward: 5’-CTGATTGGATCCACAGGGTTTCTGGTGAGC-3’ 
Reverse: 5’-GTAACTAAGCTT TTACCGTGACATGATCACG-3’ 
 
 
 
 
 
a) 
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Figure 2.2: The plasmid maps of 6xHis-tagged proteins. The schematic diagram of pRSET-A 
plasmid with SPTB-1315 or SPTB-D1781R inserts as purchased (a), and the cloned ANK-1 Zu5 
insert using BamHI and HinDIII restriction sites (b).  
 
The PCR products were purified with Wizard® SV Gel and PCR Clean-Up System (Promega, 
Madison, WI) and restriction digested with appropriate enzymes according to the 
manufacturer’s instructions (New England Biolabs, Ipswich, MA). The expression constructs 
were also restriction digested. The digested constructs and PCR products were then gel purified 
using QIAquick® Gel Extraction Kit (Qiagen, Venlo, Netherlands). The purified fragments were 
b) 
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ligated into the constructs using T4 DNA ligase (New England Biolabs, Ipswich, MA) in a 1:3 
construct to fragments ratio overnight at 4°C according to the manufacturer’s instructions. 
 
2.6.2 Transformation of competent Escherichia coli (E. coli)  
50-100 ng purified or ligated plasmid DNA was added into 30-50 µl of MAX Efficiency® DH5α™ 
Competent Cells (Thermo Scientific, Waltham, MA) or competent BL21 and incubated on ice for 
at least 30 minutes. It was then heat-shocked in water bath at 420C for 45 seconds and 
immediately cooled on ice for 2-5 minutes. 500-1000µl of lysogeny broth (LB) or Super Optimal 
Broth with Catabolite repression (SOC medium) (Thermo Scientific, Waltham, MA) was then 
added and incubated at 370C with shaking for 60-90 minutes. 200 µl of the culture was spread 
on an LB agar plate containing 100 µg/ml ampicillin. The plates were incubated overnight at 370C 
and the transformed colonies were isolated and amplified. The plasmid DNA from each amplified 
colony was extracted using PureLink® Quick Plasmid Miniprep Kit (Thermo Scientific, Waltham, 
MA), and PCR was conducted as described in Section 2.3.2, using the primers described below. 
Frozen stocks were prepared for long-term storage by adding 50% sterile glycerol with the 
culture in 1 to 1 ratio and stored at -80oC.  
 
pGEX-6P-3 SPTB-1315 and SPTB-D1781R primer sets: 
A) Forward: 5’-ATATAGCATGGCCTTTGCAG-3’; Reverse: 5’-GATGATCTGTTCCCCCTCAG-3’ 
B) Forward: 5’-TGTGATGCTGAAGCGACATT-3’; Reverse: 5’-GGCACCCGTGTAGAAGTAGC-3’ 
C) Forward: 5’-ATCGCCCAGTGGAAGGAC-3’; Reverse: 5’-TCAGAGGTTTTCACCGTCATC-3’ 
pGEX-6P-3 ANK-1 Zu5 primer sets: 
A) Forward: 5’-GCGACCATCCTCCAAAATC-3’; Reverse: 5’-CTCCTGTGCTCCTTCCACAC-3’ 
B) Forward: 5’-GCCAGCAGGATCATAGCACT-3’; Reverse: 5’-GACAAGCTGTGACCGTCTCC-3’ 
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For pRSET-A ANK-1 Zu5, genotyping was carried out using the same primers in Section 2.6.1. 
  
2.6.3 Heterologous protein expression 
A starter culture was first grown overnight from frozen stock in 5 ml of LB with 100µg/ml 
ampicillin (LB-A). The culture was then diluted to 250 ml with LB-A and incubated at 370C with 
shaking until the OD600 reached 0.5-1.0. 1 mM of Isopropyl β-D-1-thiogalactopyranoside (IPTG) 
was added to the culture to induce protein expression for 4 hours. The culture was centrifuged 
and the pellet was stored at -800C until needed. 
For ANK-1 Zu5 protein expression at 160C, the culture was instead cooled on ice in a 40C room 
for an hour before adding 1 mM IPTG. The culture was then incubated at 160C for at least 16 
hours before being harvested as described above. 
 
2.6.4 Protein purification 
For purification of GST-tagged proteins, frozen pellets were first resuspended in 20 ml PBS, 
followed by lysing with a French press. The lysates were then centrifuged at 20,000 g for 20 
minutes at 40C and the supernatant was collected. The supernatant was loaded onto a 5 ml 
GSTrap HP column (GE Healthcare Life Sciences, Arlington Heights, IL) and purified via syringes 
according to the manufacturer’s instructions. The proteins could either be treated with 
PreScission Protease (GE Healthcare Life Sciences, Arlington Heights, IL) before elution or eluted 
with GST-tag attached.  
For His-tagged SPTB-1315 and SPTB-D1781R purification, the frozen pellets were first 
resuspended in 5 ml of lysis buffer (20mM sodium phosphate pH 8.0, 1 mg/ml lysozyme and 
protease inhibitor) and sonicated with 1 minute pulses (1 minute on, 1 minute off) for 5 times 
on ice.  The lysates were then centrifuged at 20,000 g for 20 minutes at 40C and the supernatant 
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was collected. The supernatant was then diluted to 40 ml with 20 mM sodium phosphate pH 8.0 
and loaded onto a High Performance Liquid Chromatography (HPLC) with 1 ml HiTrapTM 
Chelating column loaded with 0.25 M nickel sulphate (GE Healthcare Life Sciences, Arlington 
Heights, IL). The column was first washed with 30 mM imidazole for 20 minutes before eluting 
with 200 mM imidazole.  
For His-tagged ANK-1 Zu5 purification, the frozen pellet were resuspended in 5 ml lysis buffer 
with 8 M urea, followed by sonication and centrifugation as described for His-tagged Sptb1315 
purification. The supernatant was loaded onto HPLC as described above, followed by dialysis 
with Pur-A-Lyzer™ Midi Dialysis Kit with 3.5kDa cutoff (Sigma-Aldrich, St Louis, MO) to remove 
urea (and equilibrated with 1 M NaCl when stated). The proteins were then eluted with stepwise 
with up to 200-500 mM imidazole.   
All fractions were analysed on SDS-PAGE, Coomassie and western blot to determine the 
presence and amount of purified protein.  
 
2.6.5 Protein binding assay 
The protein interaction was carried out on Biacore 2000 (GE Healthcare Life Sciences, Arlington 
Heights, IL) with the help of Dr Ante Jerkovic. Briefly, the purified GST-tagged SPTB-1315 and 
SPTB-D1781R and GST-cleaved ANK-1 Zu5 were first dialysed into Biacore Running Buffer. The 
Sensor Chip CM5 (GE Healthcare Life Sciences, Arlington Heights, IL) were purchased and coated 
with anti-GST antibody (Abcam, Cambridge, UK) according to the manufacturer’s instructions, 
followed by the loading of GST-tagged SPTB-1315 and SPTB-D1781R proteins into two different 
chambers as the ligand for the binding assay. The binding assay was carried out as described by 
Ipsaro, et al. 396, where 0, 0.62, 1.25, 2.5, 5, 10, 20 µg/ml of GST-cleaved ANK-1 Zu5 were injected 
as analyte and the responses were recorded.  
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2.7 Statistical Analysis 
The LOD score method coupled with Bonferroni correction was used to determine the causative 
mutation for ENU-treated mouse strains. All data sets were tested for normality using Shapiro-
Wilk Normality Test (http://sdittami.altervista.org/shapirotest/ShapiroTest.html) 411. The 
statistical significance of the malaria survival was tested using the Log-Rank test. The statistical 
significance of parasite infection was determined via the statmod software package for R 
(http://bioinf.wehi.edu.au/software/compareCurves) using the ‘compareGrowthCurves’ 
function with 10,000 permutation, followed by adjustments for multiple testing. The statistical 
significance for the ratios of IVET assays was determined using the one sample t-test with 
hypothetical mean of 1. For the rest of the results, statistical significance was determined using 
two-tailed Students t-tests, either through direct comparison or on the area under curves, with 
P<0.05 being statistically significant.  
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2.8 Recipes 
MT-PBS (Mouse-tonicity phosphate buffered saline) 
150mM NaCl 
16mM Na2HPO4 
4mM NaH2PO4 
Adjusted to pH 7.4 
 
Annexin V Binding Buffer 
150mM NaCl 
10mM HEPES 
25mM CaCl2 
 
CCM (Complete Culture Media) 
500ml Roswell Park Memorial Institute (RPMI) medium  
1.6% GlutaMAX™ Supplement 
0.2% Albumax®  
4% pooled human serum 
10mM D-Glucose 
25μg/ml gentamycin 
6mM HEPES 
0.2mM hypoxanthine 
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Red Cell Wash/Sorbitol 
13.3% Sorbitol 
10mM sodium phosphate 
160mM NaCl 
Adjusted to pH 7.4 and filter sterilise 
 
 
MTRC (Mouse-tonicity Ringer’s complete solution) 
154mM NaCl 
5.6mM KCl 
1mM MgCl2 
2.2mM CaCl2 
10mM glucose 
20mM HEPES 
0.5% BSA 
4mM EDTA 
Adjusted to pH 7.4 and filter sterilise 
 
Biacore Running Buffer 
0.01 M HEPES pH 7.4  
0.15 M NaCl  
3 mM EDTA  
0.005% v/v Surfactant P20 
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CHAPTER 3 
ENU-INDUCED ANKYRIN-1 MUTATION MRI61689   
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3.1 Introduction 
Malaria is a mosquito-borne disease caused by the protozoan Plasmodium, responsible for many 
deaths every year, mostly children 14. In endemic regions with limited healthcare access, host 
genetics is one of the major determinants of malaria susceptibility and survival 89,94,97. This is 
evident from the distributions of various genetic polymorphisms in humans, such as Duffy 
antigen negativity and sickle cell trait, which coincide with malaria distribution 97,158,160. It is 
thought that these genetic polymorphisms confer protection against malaria, thus providing a 
survival advantage in the face of malaria-induced mortality 186,209.  
In addition, these polymorphisms also provide crucial insights into host-parasite interactions. 
Plasmodium relies on a favourable host environment in order to thrive, many erythrocyte-
related polymorphisms have been discovered that interfere with parasite survival thus 
contributing to malaria resistance. These include polymorphisms that affect the cytoskeleton of 
erythrocytes, such as Southeast Asian Ovalocytosis (SAO), hereditary elliptocytosis (HE) and 
spherocytosis (HS) 182,183,185,188,193. Several hypotheses have been proposed for the mechanisms 
by which they confer malaria protection, including reduced erythrocyte invasion, intra-
erythrocytic growth and cytoadherence 186,191-193,232,256,257,282. However, due to the heterogeneity 
of the manifestation of these disorders in the human population, contradicting evidences for 
resistance mechanisms has often been presented. A study done by Facer 193 showed that only 
patients carrying certain spectrin mutations have impaired parasite invasion of red blood cells 
(RBC), but not others that also exhibited HE symptoms. A similar observation was reported by 
Chishti, et al. 192, where individuals with defective protein 4.1 exhibited intra-erythrocytic growth 
inhibition, but not those with glycophorin C defects, despite the fact that both defects gave rise 
to HE. These differences in malaria resistance mechanisms remained largely unexplored, and 
further studies in this aspect would potentially provide useful insight into host-parasite 
interactions. 
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The RBC cytoskeletal protein ankyrin-1 (ANK-1), is a 210kDa protein responsible for connecting 
the spectrin network with the RBC membrane through interactions with band 3, protein 4.2 and 
the Rhesus complex 393,412,413. Spherocytosis is a genetic disorder where RBCs are abnormally 
small and are known as spherocytes. ANK-1 mutations account for more than 50% of human HS 
cases 201. However, similar to SAO and HE, HS is a heterogeneous disorder where the symptoms 
vary greatly depending on the mutations.  The disorder can range from asymptomatic through 
to severe anaemia requiring splenectomy 414. Despite a possible association with malaria, HS is 
actually common in Northern European and Japanese populations with frequency of about 1 in 
2000 individuals 196-198,415, but much rarer in other populations 194. Nevertheless, several in vitro 
and in vivo studies have repeatedly reported association between HS and malaria resistance, 
and several mechanisms have been suggested. An in vitro study done by Schulman, et al. 191 
using RBCs from HS patients suggested that parasite invasion and growth in these erythrocytes 
was impaired. This is further supported by studies done in mice with ankyrin-1 mutations. Both 
Ank-1(nb/nb) and Ank-1 (MRI23420/+)  have shown inhibited intra-erythrocytic growth and erythrocyte 
invasion possibly due to spectrin and ankyrin deficiency, respectively 189,204. On the other hand, 
another mutation described by Rank, et al. 190, Ank-11674/+, parasite invasion appeared to be 
normal in these erythrocytes. Instead, increased erythrocyte fragility was proposed as a 
contributing factor for increased malaria resistance 190. Taking these observations together, it is 
possible that disruption to erythrocyte cytoskeletons can mediate multiple mechanisms of 
resistance. 
In a large phenotypic N-ethyl-N-nitrosourea (ENU) mutagenesis screen, using either abnormal 
red cells or resistance to malaria as to the screened phenotypes, we identified many novel 
mutations that give rise to RBC abnormalities and consequently malaria resistance in mice. As 
part of the discovery process for HDT candidate gene for malaria, I further characterised these 
genes and examined the role they played during malaria infections. It is reported here an ENU-
induced mutation in the ankyrin-1 gene (Ank-1(MRI61689)) which was found to exhibit a HS-like 
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phenotype, with significantly lower RBC volumes, increased osmotic fragility and decreased 
deformability. Ank-1(MRI61689) also confers resistance towards Plasmodium chabaudi adami 
infection in mice, and Ank-1(MRI61689/+) mice were shown to show both reduced merozoite 
invasion and increased RBC clearance, possibly as a consequence of reduced red blood cell 
deformability. 
This work has previously been published and presented here as a direct excerpt from: Huang, H. 
M., D. C. Bauer, P. M. Lelliott, A. Greth, B. J. McMorran, S. J. Foote and G. Burgio (2016). "A novel 
ENU-induced ankyrin-1 mutation impairs parasite invasion and increases erythrocyte clearance 
during malaria infection in mice." Sci Rep 6: 37197. This work investigated the effect of 
MRI61689 mutation on the manifestation of HS-like phenotypes, as well as highlighting the 
complex roles of ankyrin-1 in mediating malaria resistance.   
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3.2 Results 
3.2.1 The MRI61689 mutation gives rise to a hereditary spherocytosis-like phenotype 
To identify genes associated with malaria susceptibility, ENU-treated male B6.BKS (D)-Leprdb/J 
mice (G0) was crossed with isogenic female mice to produce G1 progeny with random point 
mutations across the genome. Genes affecting RBCs are hypothesised to be associated with 
malaria protection, therefore, a haematological screening was performed on these G1 mice and 
those exhibiting abnormal blood parameters were selected for further studies. The G1 mouse 
carrying the MRI61689 mutation was initially identified from an unrelated ENU suppressor 
screen for the recessive mutation db/db. The G1 MRI61689 exhibited abnormal blood 
parameters on an ADVIA haematological analyser, with reduced mean corpuscular volume (MCV) 
of 48.6fl compared to the background of 53.3±0.5fl. The MCV value from the B6.BKS (D)-Leprdb/J 
background is comparable to C57BL/6 mice. The G1 founder mouse was crossed with B6.BKS 
(D)-Leprdb/J to produce G2 mice where approximately half of the animals exhibited an abnormal 
phenotype (Table 3.1). The affected G2 progeny, which were obligate heterozygotes for the 
ENU-induced mutation, showed reduction in MCV (46.1±0.2fl) compared to unaffected progeny 
(51.4±0.4fl), lower mean corpuscular haemoglobin (MCH) (13.5±0.1pg compared to 14.6±0.1pg 
of wild-type), elevated RBC count (11.1±0.1x109 cells/ml compared to 10.5±0.1x109 cells/ml of 
wild-type) (Table 3.1). No differences were observed for total haemoglobin (HB), mean 
corpuscular haemoglobin concentration (MCHC), white blood cell (WBC) count, platelets count 
(PLT) or reticulocyte percentage (Table 3.1).  
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WBC  
(x10
6
 
/ml) 
RBC  
(x10
9
 
/ml) 
HGB  
(g/L) 
MCV  
(fl) 
MCH  
(pg) 
MCHC 
(g/L) 
PLT  
(x10
6
 
/ml) 
% 
Retics 
Wild type 8.7±0.5 10.5±0.1 153.2
±2.2 
51.4±0.4 14.6±0.1 283.6±
2.8 
1151± 
57 
2.69± 
0.26 
Ank-1
(MRI61689/+) 11.9± 
4.5 
11.1±0.1 151.2
±1.4 
46.1±0.2 13.5±0.1 281.4±
9.3 
1151± 
61 
2.24± 
0.21 
p-values NS P<0.01 NS P<0.001 P<0.001 NS NS NS 
 
However, when two affected mice were intercrossed, a quarter of the pups were found to die 
within 1 week postnatally, suggesting homozygosity for MRI61689 might be incompatible with 
life. Blood smears were taken from these pups and compared with the other affected and 
unaffected mice. The heterozygotes have slightly smaller RBCs but no target cells or spherocytes 
were observed (Figure 3.1a). Conversely, homozygous mice had significantly smaller RBCs with 
anisocytosis, fragmented RBCs, acanthocytes and reticulocytosis (Figure 3.1a). Under SEM, RBCs 
of heterozygous mice seemed to have less distinct discoid shape, but otherwise no distinguishing 
features were observed. (Figure 3.1b). On the other hand, the RBCs of homozygous mice 
appeared very deformed, acanthocytic and appeared to lack the discoid shape (Figure 3.1b). 
When subjected to osmotic stress, RBCs of heterozygous mice showed significantly increased 
fragility compared to wild-type erythrocytes (with 50% haemolysis at approximately 5.6 g/L 
compared to 4.5 g/L of wild-type) (Figure 3.1c). The RBC deformability was assessed using an in 
vitro spleen retention assay by filtering RBCs through a layer of beads with varying sizes. This is 
thought to model splenic filtration in vivo, with retention thought to indicate reduced 
Table 3.1: The complete blood count of Ank-1(MRI61689/+) mice.  
 
The haematological parameters of Ank-1(MRI61689/+) compared to wild-type mice (n=19-25). WBC 
= white blood cell count; RBC = red blood cell count; HGB = haemoglobin; MCV = mean 
corpuscular volume; MCH = mean corpuscular haemoglobin; MCHC = mean corpuscular 
haemoglobin concentration; PLT = platelet concentration; %Retics = percentage of 
reticulocytes. P values were calculated using Student’s t-tests, and data were presented as 
mean ± SEM. 
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deformability. As shown in Figure 3.1d, up to 70% of the RBCs from heterozygous MRI61689 
mice were retained within the bead layer compared to 3.5% of wild-type RBCs, suggesting a 
significantly reduced RBC deformability in the presence of this ankyrin-1 mutation. 
Figure 3.1: The phenotypic characterisation of Ank-1(MRI61689/+) mice. The morphology of Ank-
1(MRI61689/+) and Ank-1(MRI61689/MRI61689) erythrocytes under light microscopy with Giemsa stain 
(a) and scanning electron microscopy (b). The osmotic fragility curve of wild-type and Ank-
1(MRI61689/+) erythrocytes when subjected to osmotic stress (c) (n=5-7 mice per group). The in-
vitro spleen retention rate of wild-type and Ank-1(MRI61689/+) erythrocytes when passing 
through filter beds (d) (n=3 mice per group). P values were calculated using parametric 
Student’s t-test. ** indicates P<0.01, *** indicates P<0.001, and all error bars are standard 
error of mean (SEM). 
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3.2.2 MRI61689 carries a splice site mutation in Ank-1 gene resulting in an alternative 
transcript and exon skipping 
To identify the causative mutation responsible for this abnormal RBC count, the exomes of 2 
heterozygous mice were sequenced. Exome sequencing revealed a number of variants. These 
were prioritised based on filters as shown in Table 3.2. Through further genotyping using Sanger 
sequencing, a mutation in Ank-1 gene was found to correlate with all the affected mice and was 
proven to segregate perfectly with the reduced MCV for over 3 generations of mouse crosses. 
The mutation was found in the 17-18 intron of Ank-1 gene, with T to A transversion 11 base pair 
upstream of exon 18 (IVS17-11T>A) (Figure 3.2a). This is situated in the ankyrin-repeats domain 
involved in band 3 binding. It was proposed that the mutation introduced a new acceptor splice 
site for exon 18, potentially leading to a frameshift mutation.  
  
Chromosom
e 
Gene 
name 
Location Reference 
base 
Variant 
base 
Number 
of mutant 
mice with 
mutation 
LOD score 
(Threshold: 
2.08) 
9 Acp5 22129643 C A (3/8) -0.32 
8 Kcnk1 126025024 C T (4/8) 0 
17 Epas1 86825679 A T (0/8) -2.33 
7 Picalm 90165538 G T (0/8) -2.33 
18 Socs6 88869240 A G (5/8) 0.32 
8 Ank-1 23106019 T A (8/8) 2.33 
Table 3.2: The identification of MRI61689 mutation. 
Six variants were selected from the exome sequencing, each mutation was sequenced in 
Ank-1(MRI61689/+) mice and the number of mutant mice carrying each mutation was determined 
and LOD score was calculated based on Chi-squared distribution, with LOD threshold being 
2.08, adjusted using Bonferroni’s correction (n=8 mice).  
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To assess this hypothesis, transcript analysis was performed. Embryonic liver RNA was extracted, 
cDNA was synthesized and PCR-amplified using primers listed in the experimental procedures. 
Figure 3.2b shows the PCR products of embryonic liver cDNA from non-mutant, Ank-1(MRI61689/+) 
and Ank-1(MRI61689/MRI61689) when amplified using primer set 1, which covers exon 17 to 21. Bands 
of approximately 400bp can be observed in all the genotypes, but Ank-1(MRI61689/MRI61689) also 
exhibited a second smaller product of approximately 300bp length.  It is likely that this second 
band was the product of exon skipping. Sanger sequencing of these PCR products revealed that 
the 300bp product lacked exon 18, confirming that the exon 18 was skipped, and exon 19 was 
directly connected to exon 17 during transcription (Figure 3.2c). This transcript is predicted to 
produce a shortened, in-frame 207kDa ANK-1 protein.  
To examine the effect of MRI61689 mutation in heterozygous mice, a primer set containing the 
predicted acceptor splice site (primer set 2) was designed. Figure 3.2d shows that the mutant 
transcript is only present in Ank-1(MRI61689/+) and Ank-1(MRI61689/MRI61689) mice, as predicted. Further 
Sanger sequencing revealed an insertion of 11bp into the transcript adding an additional donor 
splicing site and causing a frameshift mutation in the exon that would result in a premature stop 
codon at amino acid position 724, as illustrated in Figure 3.2e, thus giving rise to a truncated 
protein of 78.5kDa. Therefore, the homozygous mice exhibit a mutation at 11 bp upstream of 
the exon 18 donor splicing site resulting in two alternative transcripts: the skipping of exon 18 
and an 11bp insertion and creation of an additional donor splicing site leading to frameshift 
mutation that would result in a premature stop codon and a truncated protein.    
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Figure 3.2: The identification of Ank-1(MRI61689) mutation and its effects on transcription. The 
sequencing of Ank-1(MRI61689) mutation, showing a T to A transversion (a). Gel electrophoresis 
of amplified cDNA product from wild-type, Ank-1(MRI61689/+) and Ank-1(MRI61689/MRI61689) 
embryonic livers with primers that spanned the exon 17 to 21 of ankyrin-1 cDNA (primer set 
1) (b). The sequencing results of both bands, showing exon skipping in the abnormal 
transcript of Ank-1(MRI61689/MRI61689) embryonic liver (c). Gel electrophoresis of amplified cDNA 
product from wild-type, Ank-1(MRI61689/+) and Ank-1(MRI61689/MRI61689) embryonic livers with 
primers that contained the predicted 11bp insertion (primer set 2) (d). Sequencing result 
showing an 11bp insertion between exon 17 and 18 cDNA of the Ank-1(MRI61689) transcript (e). 
The predicted effect of the insertion on the translation of ankyrin-1, showing a frameshift 
and a premature chain termination (f).  
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This mutation was likely to reduce the Ank-1 expression levels. Therefore, this hypothesis was 
assessed by examining the gene expression levels of Ank-1 in embryonic liver using qPCR at 
mRNA level and Western blotting at protein level in mature RBCs. As shown in Figure 3.3a, Ank-
1 mRNA levels in both Ank-1(MRI61689/+) and Ank-1(MRI61689/MRI61689) E14 embryonic livers were 
significantly reduced, up to 60% and 80% reduction compared to the wild-type, respectively, 
which supported our hypothesis. However, no significant reduction in the full length ANK-1 
(210kDa) protein levels was observed in both Coomassie staining and Western blotting (Figure 
3.3b-d). No truncated form of ANK-1 (78.5kDa) was observed in Ank-1(MRI61689/+) erythrocytes. 
Furthermore, no reduction was observed for the protein levels of other cytoskeletal proteins, 
including band 3, protein 4.2, alpha- and beta-spectrin (Figure 3.3b and c, Supp. Figure 3.1). This 
suggested that erythrocyte protein levels might be compensated by the WT allele in Ank-
1(MRI61689/+) mice, and the reduction in Ank-1 mRNA levels did not seem to affect the protein levels. 
 
 3.2.3 Ank-1(MRI61689/+) mice are resistant to Plasmodium chabaudi infection 
It was hypothesised that the Ank-1(MRI61689) mutation would confer malaria resistance. The 
malaria susceptibility of Ank-1(MRI61689/+) mice was examined by injecting a lethal dose of 
Plasmodium chabaudi adami DS, a murine strain of malaria that models the Plasmodium 
falciparum erythrocytic stage 416, which invades erythrocytes of all ages. The Ank-1(MRI61689/+) mice 
exhibited significantly lower peak parasitaemia, with only approximately 13% parasitaemia 
compared to 52% parasitaemia of wild-type (Figure 3.4a) but no delay in the appearance of 
parasites was observed. In addition, Ank-1(MRI61689/+) have a significantly increased survival rate, 
where all the Ank-1(MRI61689/+) mice survived the infection (Figure 3.4b) compared to the 16% 
survival of wild-type mice. Since Ank-1(MRI61689) directly affects the red cell (cytoskeletal protein), 
the malaria resistance was likely due to a RBC-autonomous effect.   
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Figure 3.3: The effect of Ank-1(MRI61689) mutation on the Ank-1 expression. Quantitative PCR 
showing the ankyrin-1 mRNA levels in both Ank-1(MRI61689/+) and Ank-1(MRI61689/MRI61689) embryonic liver 
(a). The protein levels of various cytoskeletal proteins examined with Coomassie (b). Representative 
Western blot images for ankyrin-1 (ANK1), Band 3, alpha-spectrin (SPTA), beta-spectrin (SPTB), 
protein 4.2 (P 4.2) and Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) housekeeping gene 
in RBC membrane(c). The quantitative analysis of ankyrin-1 (d) (n=3 replicates per group). P values 
were calculated using Student’s t-test. **P<0.01, ***P<0.001, error bars indicate SEM.  
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Therefore, three mechanisms of P. chabaudi resistance in Ank-1(MRI61689/+) mice were postulated. 
Firstly, the maturation of parasite inside the Ank-1(MRI61689/+) erythrocytes could be impaired 
leading to reduced growth and death of parasites 189. Secondly, the Ank-1(MRI61689/+) erythrocytes 
might be resistant to merozoite invasion, which resulted in reduced parasitaemia and delayed 
course of infection 257. Finally, the infected Ank-1(MRI61689/+) erythrocytes might more prone to 
destruction during the course of infection (increased clearance), thus posing a challenge for the 
parasite to establish a successful infection 205.   
 
3.2.4 Ank-1(MRI61689) does not impair the intra-erythrocytic growth of P. chabaudi 
To elucidate the possible mechanisms of resistance, the effect of the Ank-1(MRI61689/+) mutation 
on parasite intra-erythrocytic growth was investigated using the TUNEL assay at 1-10% 
parasitaemia. TUNEL detects DNA fragmentation, a marker for apoptosis or necrosis. In 
conjunction with a DNA fluorescent dye, DAPI, it is possible to detect dying parasites in the 
erythrocytes (Figure 3.4c) 189,417. The TUNEL-positivity of P. chabaudi in Ank-1(MRI61689/+) 
erythrocytes was measured during the late trophozoite stage of the infections, which was the 
portion of the parasite lifecycle affected by the Ank1 mutation in the Ank-1(MRI23420/+) line. As 
shown in Figure 3.4d, no differences was observed in the percentage of TUNEL-positive parasites 
in both wild-type and Ank-1(MRI61689/+) erythrocytes (24.7 ± 2.3% in Ank-1(MRI61689/+) mice compared 
to 29.5 ± 2.9% in wild-type). This indicated that Ank-1(MRI61689) did not impair parasite intra-
erythrocytic growth. 
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Figure 3.4: The response of Ank-1(MRI61689/+) mice to malaria infection. The parasite load of wild-
type and Ank-1(MRI61689/+) mice when infected with 1x104 P. chabaudi (a) and the associated 
survival curve (b). Parasite intra-erythrocytic growth was assessed through TUNEL assay at 1-10% 
parasitaemia during late trophozoite stage, as visualised from immunofluorescent images 
showing presence of parasites and TUNEL-positive parasites (c). The number of TUNEL-positive 
parasites in both wild-type and Ank-1(MRI61689/+) mice were counted and expressed as a percentage 
(d) (n=3). For parasite invasion and RBC clearance, The IVET assay was done showing the ratio of 
infected Ank-1(MRI61689/+) to wild-type erythrocytes over 36 hours (e) and the relative number Ank-
1(MRI61689/+) and wild-type erythrocyte in both infected and uninfected mice (f) during P. chabaudi 
infection (n=7 mice per group). P values for (a) and (b) were calculated using permutation test 
and Log-Rank test, respectively, p value for (d) - (f) was calculated using Student’s t-test, with 
hypothetical mean of 1 for (e). ** indicates P<0.01, *** indicates P<0.001, ## and ### indicates 
P<0.01 and P<0.001 respectively when compared to wild-type RBC number in infected mice, 
whereas ^^^ indicates P<0.001 when compared to Ank-1(MRI61689/+) RBC number in uninfected 
mice. Error bars indicate SEM. 
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3.2.5 Ank-1(MRI61689/+) erythrocyte is resistant to P. chabaudi invasion, and have 
increased clearance from circulation 
Erythrocyte invasion and clearance were assessed via an in vivo erythrocyte tracking (IVET) assay. 
Labelled blood of wild-type and Ank-1(MRI61689/+) mice were injected into infected wild-type mice 
during merozoite invasion to examine the ability of Plasmodium chabaudi to invade and grow 
within erythrocytes of both genotypes. The result compared the percentage of parasitized cells 
of both genotypes and expressed as a ratio of parasitaemia in Ank-1(MRI61689/+) RBC to wild-type 
RBC populations. As shown in Figure 3.4e, lower parasitaemia ratio (approximately 0.55) was 
observed from 30 minutes after injection with labelled blood, and was consistently lower in Ank-
1(MRI61689/+) blood over 36 hours post injection, which indicates a lower invasion rate into the Ank-
1(MRI61689/+) RBCs. Additionally, the remaining proportion of labelled RBCs was also monitored 
over the course of the assay. A significant reduction of Ank-1(MRI61689/+) erythrocytes in infected 
mice compared to wild-type erythrocytes was observed, with up to a 45% reduction in Ank-
1(MRI61689/+) RBC number compared with wild-type (Figure 3.4f). On the other hand, a smaller 
reduction was observed for Ank-1(MRI61689/+) erythrocytes compared to wild-type in uninfected 
mice, suggesting Ank-1(MRI61689/+) RBCs are more likely to get cleared from circulation during 
malaria infection.  As the percentage of infected erythrocytes was low (5-20%) (Supp. figure 3.3), 
this indicates that the majority of the RBCs getting cleared were uninfected RBCs, possibly as a 
result of bystander effect. This experiment suggested that two possible mechanisms of 
resistance are both operating to produce the lower parasitaemia and increased survival in Ank-
1(MRI61689/+) mice, the reduction of parasite invasion and increased clearance of Ank-1(MRI61689/+) 
RBCs.  
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3.3 Discussion 
3.3.1 Summary of findings 
A novel mutation in Ank-1 gene, MRI61689, is reported here to cause a hereditary spherocytosis-
like phenotype, with reduced MCV, increased osmotic fragility and reduced deformability. 
MRI61689 is an intronic mutation between exon 17 and 18 where two possible splice variants 
could arise, one has an introduced acceptor site resulting a frameshift, whereas the other 
consists of a skipped exon 18. The Ank-1 mRNA levels were reduced, but no reduction in protein 
levels were observed. The predicted truncated form (78.5kDa) was also not observed.  Ank-
1(MRI61689/+) mice also have increased resistance to Plasmodium chabaudi infections, and the 
erythrocyte invasion was impaired but the intra-erythrocytic growth appeared normal. The Ank-
1(MRI61689/+) RBCs were also more likely to be cleared from circulation during infection, an 
observation independent of number of parasitized erythrocytes. 
 
3.3.2 Ank-1(MRI61689) is unique but comparable to other ankyrin-1 mutations in human 
and mice 
In comparison of Ank-1(MRI61689) mice to other previously described Ank-1 mouse models, they 
appeared comparable to Ank-1(MRI23420) mice, but more severe than Ank-11674 and Ank-1nb mice. 
More specifically, most homozygous Ank-1(MRI61689) mice died within a week after birth, similar to 
homozygous Ank-1(MRI23420) mice, while homozygous Ank-11674 and Ank-1nb mice were viable 190,204. 
However, no notable differences were observed in heterozygous Ank-1MRI61689 mice in terms of 
their RBC microcytosis, morphology and susceptibility to osmotic stress compared to 
heterozygous Ank-11674 and Ank-1(MRI23420) mice 189,190. However, similar to Ank-11674/+ mice and 
unlike Ank-1(MRI23420/+) mice, Ank-1(MRI61689/+) mice exhibited similar levels of ankyrin-1 and other 
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RBC cytoskeletal protein to wild-type, which might suggest compensation by the wild-type allele, 
and thus warrants further studies.  
In humans, many ANK-1 mutations that result in frameshift have been described, most of which 
situated in the band 3 binding domain towards the N terminus 394,418. While no Ank-1(MRI61689) 
homologous mutation has been described in humans, a frameshift mutation has been reported 
to be in the exon 17, called Ankyrin Osaka I, which gave rise to symptomatic HS 418. Furthermore, 
exon skipping in human ANK-1 gene has also been documented. Edelman, et al. 419 reported a 
HS patient exhibiting a severe ankyrin-deficient HS due to an introduction of a new splice 
acceptor site for exon 17, known as ankyrinAnkara. Under further examination, this mutation was 
found to give rise to multiple splice forms, including insertions and skipped exons. Most splice 
forms with insertion were expected to cause frameshift, potentially leading to premature 
termination of ankyrin 419. This finding is in agreement with the observation in Ank-
1(MRI61689/MRI61689) mice, where frameshift caused by new splice acceptor site, leading to high 
mortality rate with severe HS-like phenotype in Ank-1(MRI61689/MRI61689) mice. It is likely that the 
surviving Ank-1(MRI61689/MRI61689) mice relied on the exon-skipping splice form to produce in-frame 
functional Ank-1 proteins. However, further studies are required for support this hypothesis.  
 
3.3.3 Complex mechanisms of P. chabaudi resistance mediated by ankyrin-1 mutations 
In terms of the response to malaria infection, Ank-1(MRI61689/+) mice exhibited similar degree of 
malaria resistance as Ank-1(MRI23420/+) and Ank-11674/+ mice, with at least 30-40% reduction in 
parasitaemia and increased survival 189,190, and unlike Ank-1nb/+ mice with only 10% reduction 204. 
Previous studies suggested the reduction in erythrocyte invasion and intra-erythrocytic growth 
to be the major resistance mechanisms 189,204. However, normal parasite invasion was reported 
in Ank-11674/+ mice 190. As a result, the potential mechanisms of Ank-1(MRI61689/+) mice were 
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explored in this study in attempt to elucidate the complex roles ankyrin-1 plays during malaria 
infections. 
First, Ank-1(MRI61689/+) mice exhibit normal parasite intra-erythrocytic growth (Figure 3.4d), in 
contrast to Ank-1(MRI23420/+) mice. TUNEL assay detects the presence of DNA fragmentation which 
occurs during apoptosis and necrosis 420, indicating dying parasites in RBCs 417. McMorran, et al. 
417 reported TUNEL-positive parasites in C57BL/6 wild-type mice at a level consistent with the 
observations in this study. On the other hand, Greth, et al. 189 reported a lower TUNEL-positive 
in their SJL/J wild-type mice, which most likely due to differences in the genetic background of 
experimental mice. Nevertheless, abnormal parasite morphology was not observed under light 
microscopy unlike Ank-1(MRI23420/+) mice, which support the deductions of parasite death from 
the TUNEL assays. No difference in gametocyte numbers was observed (Supp. Figure 3.2), 
indicating gametocytogenesis was not affected. However, the possible growth retardation that 
might occur in other parasite stages cannot be excluded, which were not tested in this study. 
In terms of parasite invasion, Ank-1(MRI61689/+) RBCs were found to be more resistant to merozoite 
invasion as shown in the IVET assay (Figure 3.4e). The Ank-1(MRI61689/+) erythrocytes were less 
infected compared to the wild-type 30 minutes after injection during merozoite invasion, and 
stayed consistently lower compared to wild-type throughout the erythrocytic cycle. This 
reduction in invasion has also been observed in Ank-1(MRI23420/+) mice 189. In contrast, Rank, et al. 
190 reported no difference in parasite invasion for Ank-11674/+ mice, indicating a different effect 
mediated by Ank-11674 mutation compared to Ank-1(MRI23420) and Ank-1(MRI61689) mutations. 
From these comparisons with other ankyrin mouse models, it is evident that RBC cytoskeleton 
plays an important yet complex role during malaria infections. However, the exact mechanism 
for each of these different phenotypes for each ankyrin haplotype remains elusive, different 
ankyrin mutations can exert different effects on the parasites depending on the location of the 
mutations, giving rise to multiple resistance mechanisms. This hypothesis is also consistent with 
89 
 
the heterogeneous HS symptoms associated with ankyrin mutations, which highlights the 
complicated interactions between RBC cytoskeletons and malaria parasites.  
 
3.3.4 Increased clearance of uninfected RBCs as a novel resistance mechanisms in Ank-
1(MRI61689/+) mice 
On the other hand, one important observation from the IVET assay is the rapid clearance of Ank-
1(MRI61689/+) erythrocytes from the circulation within 36 hours post-injection, up to 40% of the 
initial RBC number (Figure 3.4f). However, at this timepoint the parasitaemia of the host mice 
was only 5-20% (Supp. Figure 3.3), therefore the rate of RBC clearance cannot be explained by 
the clearance of parasitized RBCs, instead, it is likely that the majority of the RBCs being cleared 
were uninfected. In comparison, no loss was observed for wild-type erythrocytes in both 
infected and uninfected mice. Since, in these experiments both wild-type and Ank-1(MRI61689/+) 
blood were subjected to the same host environment simultaneously, it implies that the 
clearance of Ank-1(MRI61689/+) erythrocytes is cell autonomous, rather than due to other effects of 
the host animal during infection. This is further supported by the observation that increased 
Ank-1(MRI61689/+) erythrocyte clearance in uninfected mice, indicating that Ank-1(MRI61689/+) 
erythrocytes were predisposed for clearance. This is the first observation of increased, 
uninfected RBC clearance associated with an ankyrin mutation. Bystander clearance is typically 
observed in inflammation, such as during sepsis 421, and is thought to cause severe malaria 
anaemia during malaria infection in humans through the destruction of normal uninfected RBCs 
422,423. It is possible that Ank-1(MRI61689) causes a more exaggerated bystander effect during malaria 
infection, leading to a further reduction of Ank-1(MRI61689/+) erythrocyte numbers.   
Reduced RBC deformability was proposed to be one of the mechanisms of bystander clearance 
during malaria anaemia through phagocytosis and splenic filtration 424,425. From the in vitro 
spleen retention assay (Figure 3.1d), Ank-1(MRI61689/+) erythrocytes exhibited reduced 
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deformability, making them more likely to be retained in the filter layer, which is likely to 
promote their destruction in in vivo settings. Therefore, that Ank-1MRI61689 mutation was 
proposed to cause alteration to the erythrocyte, which renders them more likely to be cleared 
from the circulation.  
 
3.4 Conclusion 
In summary, the ENU-induced Ank-1MRI61689 mutation was reported to cause an HS-like 
phenotype in mice, and confers significant resistance to P. chabaudi infection. Ank-1(MRI61689/+) 
erythrocytes were proposed to be significantly resistant to parasite invasion but appeared to 
support normal trophozoite development, although it is possible that this mutation might affect 
growth of other parasite stages. This ankyrin mutation was associated with an increased RBC 
clearance during malaria infection, which is a novel observation from this study. This study 
emphasizes the importance of RBC cytoskeletal proteins in mediating multiple complex 
mechanisms of resistance towards malaria, which provide further insights to the complex 
interaction between the host and parasites.  
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3.5 Supplementary Figures 
 
  
Supplementary Figure 3.1: The full western blot membrane when probed with anti-beta-
spectrin antibody. The disparity of band intensity as shown in Figure 3c is due to uneven 
surface of the membrane rather than post-processing issue. 
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Supplementary Figure 3.2: The percentage of gametocytes of wild-type and of  
Ank-1(MRI61689/+) mice during malaria infection. Parasite gametocyte numbers were counted 
under light microscopy at 15-30% parasitaemia, and the proportion of gametocytes to total 
infected RBCs were calculated (n=6). P values was calculated using Student’s t-test. Error bars 
indicate SEM. 
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Supplementary Figure 3.3: The parasite load of the mice during IVET assays. The parasite 
load of the host mice during IVET assay (n=7). Error bars indicate SEM. 
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CHAPTER 4 
ENU-INDUCED ANKYRIN-1 MUTATIONS  
MRI96570 AND MRI95845  
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4.1 Introduction 
Historically, malarial parasites have been co-evolving with humans for thousands of years and 
have played a major role in shaping human genetics in malaria endemic regions 94,426. Indeed, 
many genetic polymorphisms were selected for as they provide significant survival advantages 
during malaria infections 94,427, resulting in high frequencies of protective genetic mutations in 
malaria endemic regions. The majority of them affect the red blood cell, and hence the blood 
stage of malaria infections 174,427,428.  
Interestingly, these genetic mutations or alleles often exhibit varying degrees of malaria 
protection even if they affect the same gene, which is influenced by the location and the severity 
of mutations 429,430. This phenomenon, known as “allelic heterogeneity”, is characterised by 
multiple different phenotypes arising from mutations in a single gene. It has been described for 
certain genes affecting malaria susceptibility, which is reflected by their geographical 
distribution within endemic regions 431. One of the most prominent examples of this is the β-
globin gene, which is well known for its two malaria protective alleles – the HbS and HbC in 
African populations 100,339. HbC is restricted to West Africa, whereas HbS is widespread 
throughout Africa, which is thought to be linked to the effectiveness of each allele to confer 
malaria resistance, and their associated morbidity 432,433. Studies on these alleles would not only 
allow a better understanding of host-parasite interactions, but also give us insights into the 
dynamics of population genetics in malaria endemic regions 431. 
However, allelic heterogeneity could also complicate the characterisation of the malaria 
protective roles of certain genes, often resulting in conflicting evidence from various studies. 
One example of such polymorphisms is CD36 deficiency, which was originally thought to be 
protective against malaria, as evidenced by the positive selection in East Asian and African 
populations 322,434,435. While some studies reported increased malaria protection 436, others 
reported no significant associations 324 or even increased susceptibility 322,323. It is possible that 
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these contradictive findings are due to confounding factors associated with allelic heterogeneity 
in CD36 deficiency 429. This also further emphasises the importance of taking allelic 
heterogeneity into consideration to enable a better design in future studies involving host 
genetics in malaria, as well as various infectious diseases. 
In contrast, the allelic heterogeneity of genes affecting RBC cytoskeleton in terms of malaria 
susceptibility is poorly understood. Many of the resulting genetic disorders are heterogeneous, 
such as hereditary spherocytosis (HS), which is characterised by the formation of “spherocytes”, 
RBCs that exhibit reduced volume due to disruptions in erythrocyte cytoskeletons. HS is caused 
by mutations in ankyrin, spectrins, band 3 and protein 4.2, with ankyrin mutations contributing 
to more than 50% of HS cases 195,201,437-439. HS also exhibits clinical heterogeneity, where the 
severity depends greatly on the location and the nature of mutations 394. However, the 
prevalence of HS in malaria endemic regions is not well studied, where only specific cases were 
reported 200,440-442. Nevertheless, in vivo and in vitro studies have repeatedly suggested an 
association of HS with increased malaria resistance, and several mechanisms have been 
proposed, although not all of them were consistent 189-191,204. Based on these observations, it 
was hypothesised that the inconsistencies in resistance mechanisms might be due to the allelic 
heterogeneity of genes associated with HS.  
To explore this hypothesis, mouse models carrying two novel N-ethyl-N-nitrosourea (ENU)-
induced ankyrin mutations were examined. These two mouse lines, Ank-1(MRI96570/+) and Ank-
1(MRI95845/MRI95845), displayed haematological and clinical features consistent with HS, and a 
marked resistance to infection by the murine malarial parasite, P. chabaudi. Analysis of the 
underlying mechanism of resistance to infection revealed both common and distinct features 
between the strains.  RBCs from both lines were similarly resistant to merozoite invasion. 
However, the Ank-1(MRI95845/MRI95845) erythrocytes were also more rapidly cleared from circulation 
during an infection, whereas an impairment in intra-erythrocytic parasite maturation was 
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observed in the infected Ank-1(MRI96570/+) erythrocytes. This study highlights the first report of 
allelic heterogeneity of Ank-1 gene in the context of malaria resistance in mouse models.  
 
 
4.2 Results 
4.2.1 MRI96570 and MRI95845 carry mutations in Ank-1 gene 
ENU-treated SJL/J male mice were crossed with wild-type female to produce G1 progeny with 
random point mutations, which were then subjected to haematological screening to identify 
genes affecting RBC properties, as potential candidates that might confer malaria protection. G1 
mice MRI96570 and MRI95845 were identified from the ENU-dominant screen with mean 
cellular volume (MCV) three standard deviations below the normal level of the respective 
parental line - 48.5fl for MRI96570, and 50.6fl for MRI95845, compared to the background of 
55.1±1.2fl. Both G1 mice were crossed with wild-type to produce G2 offspring to assess the 
heritability of the phenotype, where approximately half of the progeny showed reduction in 
MCV (20 out of 36 MRI96570 mice with 47.2±0.22fl, and 24 out of 45 MRI95845 mice with 
47.6±0.24fl), suggesting a dominant mode of inheritance. Two affected MRI96570 and 
MRI95845 G2 progeny, which also showed a reduction of MCV, were sent for exome sequencing 
to identify the causative genetic mutations. Unique variants shared between the affected mice 
were filtered and selected for mice carrying MRI96570 mutation (Table 4.1a) or MRI95845 
mutation (Table 4.1b). Each candidate mutation was genotyped by Sanger sequencing and it was 
found that a mutation in ankyrin-1 (Ank-1) was present in all the affected mice (Table 4.1a and 
b), and co-segregated completely with the reduced MCV phenotype for over three generations 
of crosses. The MRI96570 mutation is a T to A transversion in exon 34 of Ank-1 gene (Figure 
4.1a), resulting in a premature stop codon at amino acid position 1398, as opposed to the full-
length protein of 1907 amino acids. The MRI95845 mutation is a T to A transversion in exon 5 
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(Figure 4.1b), which is predicted to cause a substitution of tyrosine for asparagine at amino acid 
residue 149. MRI96570 mutation is situated in the spectrin binding domain, whereas MRI95845 
mutation is located in the 4th ankyrin repeat domain (Figure 4.1c). MRI96570 and MRI95845 will 
be referred as Ank-1(MRI96570) and Ank-1(MRI95845) respectively, for the rest of the chapter. 
 
 
  
Variants from exome sequencing were filtered to exclude strain-specific variants and variants 
found in other ENU-induced mice. Variants that were shared between the two mice carrying 
MRI96570 mutation or MRI95845 mutation are shown in (a) and (b), respectively. For each 
mutation, the candidate genes were Sanger sequenced in effected mice to determine the 
correlation between the genetic mutations and the phenotype by calculating the LOD score 
based on Chi-squared distribution. LOD Threshold = 1.9 for MRI96570, 2.0 for MRI95845 (n= 
10 mice).  
Table 4.1: The candidate genes for MRI96570 and MRI95845 mutations. 
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Figure 4.1: The location of Ank-1(MRI96570) and Ank-1(MRI95845) mutation. Sanger sequencing of 
mice carrying Ank-1(MRI96570) revealed a T to A transversion in exon 34 of Ank-1 gene, which is 
predicted to induce a premature stop codon (a). Mice carrying Ank-1(MRI95845) mutation were 
found to have a T to A transversion in exon 5 of Ank-1 gene, which is predicted to cause a 
missense mutation from tyrosine to asparagine at residue 149 (b). The schematic diagram 
showing the location of Ank-1(MRI96570) and Ank-1(MRI95845) mutations in the ankyrin-1 protein (c). 
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4.2.2 Ank-1(MRI96570) and Ank-1(MRI95845) cause HS-like phenotypes  
4.2.2.1 Mice carrying Ank-1(MRI96570) and Ank-1(MRI95845) mutation exhibit microcytosis and 
anisocytosis  
Affected Ank-1(MRI96570) and Ank-1(MRI95845) G2 progeny showed a significant reduction in MCV and 
mean cellular haemoglobin (MCH), elevated RBC count and red cell distribution width (RDW) 
(Table 4.2). When two Ank-1(MRI96570/+) or Ank-1(MRI95845/+) G2 progeny were intercrossed, Ank-
1(MRI96570/MRI96570) mice were born with severe jaundice and died within several days from birth 
(Figure 4.2a), suggesting homozygosity for Ank-1(MRI96570) mutation caused lethal anaemia. On 
the other hand, Ank-1(MRI95845/MRI95845) appeared healthy with normal lifespan, but exhibited 
exaggerated RBC abnormalities compared to Ank-1(MRI95845/+) mice, showing further reduction of 
MCV (43.0±0.1 fl), significantly increased reticulocytosis (5.68±0.43% compared to 2.23±0.26% 
of wild-type) and lower total haemoglobin level (142.6±1.7 g/L compared to 150.5±0.8 g/L of 
wild-type) (Table 4.2). However, no significant differences were observed for white blood cell 
count, platelet count and haemoglobin concentration in each RBC, suggesting that production 
of leukocytes, platelets and haemoglobin are not affected by both mutations. These findings are 
consistent with the hallmarks of HS patients. 
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4.2.2.2 Ank-1(MRI96570) and Ank-1(MRI95845) cause increased RBC osmotic fragility and reduced RBC 
deformability  
Mice carrying these Ank-1 mutations were expected to have increased osmotic fragility, as 
observed in HS patients. As such, the susceptibility of erythrocytes towards osmotic stress was 
assessed by subjecting the RBCs to various concentration of hypotonic sodium chloride solutions. 
Both Ank-1(MRI96570/+) and Ank-1(MRI95845/+) RBCs showed significantly increased fragility, where 50% 
haemolysis was observed at approximately 5.6 and 5.4 g/L (equivalent to 104mM and 100mM) 
sodium chloride, respectively, compared to approximately 4.6g/L (84mM) sodium chloride of 
wild-type (Figure 4.2b). The Ank-1(MRI95845/MRI95845) RBCs showed further susceptibility towards 
osmotic stress, with 50% haemolysis at approximately 6.5 g/L (121mM) sodium chloride 
concentration.  
  Wild type Ank-1
(MRI96570/+)
 Ank-1
(MRI95845/+)
 Ank-1
(MRI95845/MRI95845)
 
WBC (x10
6
 /ml) 11.3±0.3 11.2±0.4 11.9±0.8 12.1±0.8 
RBC (x10
9
 /ml) 10.1±0.1 11.0±0.1*** 10.7±0.1*** 10.9±0.1*** 
HGB (g/L) 150.5±0.8 150.7±1.1 148.8±1.9 142.6±1.7* 
MCV (fl) 52.3±0.2 46.9±0.2*** 46.6±0.2*** 43.0±0.1*** ^ 
MCH (pg) 14.9±0.1 13.7±0.1*** 13.9±0.1*** 13.1±0.2*** ^ 
MCHC (g/L) 285.3±1.2 290.3±1.8 298.3±2.4 294.7±4.0 
RDW (%) 14.5±0.1 15.3±0.1*** 16.1±0.3*** 18.4±0.2*** ^ 
PLT (x10
6
 /ml) 1036±31 1051±34 992±51 1026±53 
Retics (%) 2.23±0.26 3.34±0.42 3.33±0.46 5.68±0.43*** 
The blood parameters were obtained from a haematological analyser ADVIA 120. WBC = white 
blood cell count; RBC = red blood cell count; HGB = total haemoglobin; MCV = mean corpuscular 
volume; MCH = mean corpuscular haemoglobin; MCHC = mean corpuscular haemoglobin 
concentration; RDW = red cell distribution width; PLT = platelet counts; Retics = percentage of 
reticulocytes, n=23-50. P values were calculated using Student’s t-test, with Bonferroni 
adjusted significance threshold = 0.001852, * P< 0.001, ** P< 1x10
-5 
compared to wild-type 
mice; whereas ^ P<0.001 compared to Ank-1
(MRI95845/+)
 mice.  
 
Table 4.2: The complete blood count of Ank-1(MRI96570/+), Ank-1(MRI95845/+) and Ank-1(MRI95845/MRI95845) 
mice. 
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The mutant RBCs were also predicted to have shorter half-life, which is also one of the symptoms 
of HS. Therefore, RBC half-life was determined by biotinylating mouse RBCs and tracking the 
remaining biotinylated RBCs over time. As shown in Figure 4.2c, erythrocytes from Ank-
1(MRI95845/MRI95845) RBCs have significantly shorter half-life of approximately 9.5 days as opposed 
to 16 days of wild-type erythrocytes, but no significant difference was observed for erythrocytes 
from heterozygous mice.  
Another feature of HS is the reduced RBC deformability, which was examined using two different 
analytical techniques: ektacytometry and an in vitro spleen retention assay. Ektacytometry 
measures the flexibility of RBCs when subjected to shear pressure, and expresses as an 
elongation index, which indicates the deformability of RBCs. The Ank-1(MRI96570/+) RBCs showed 
reduced elongation index compared to wild-type, whereas Ank-1(MRI95845/MRI95845) RBCs showed 
further reduction in elongation index, indicating significant reduction in RBC deformability 
(Figure 4.2d). In addition, the in vitro spleen retention assay was performed by passing the 
erythrocytes through layer of microbeads of varying sizes, modelling in vivo splenic filtration. 
RBC deformability was assessed by the ability of RBCs to pass through the bead layer. Figure 
4.2e showed three independent measurements of RBC deformability via splenic retention assay, 
comparing between wild-type, Ank-1(MRI96570/+), Ank-1(MRI95845/+) and Ank-1(MRI95845/MRI95845) RBCs. 
An approximately 70% increased retention for Ank-1(MRI96570/+) RBCs was observed compared to 
wild-type, whereas erythrocytes of Ank-1(MRI95845/+) and Ank-1(MRI95845/MRI95845) mice showed 86% 
and 90% increased RBC retention compared to wild-type, respectively. However, no significant 
difference was observed between Ank-1(MRI96570/+) and Ank-1(MRI95845/MRI95845) erythrocytes. 
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Figure 4.2: The phenotypes of Ank-1(MRI96570/+), Ank-1(MRI95845/+) and Ank-1(MRI95845/MRI95845) mice. 
The Ank-1(MRI96570/MRI96570) pups (indicated by arrows) showed severe jaundice and died within 1 
week after birth (a). The osmotic fragility of Ank-1(MRI96570/+), Ank-1(MRI95845/+) and Ank-
1(MRI95845/MRI95845) erythrocytes in hypotonic solution from 0-10g/L sodium (n=5 mice) (b). The 
RBC half-life of Ank-1(MRI96570/+), Ank-1(MRI95845/+) and Ank-1(MRI95845/MRI95845) mice (n=5 mice) (c). 
The elasticity of Ank-1(MRI96570/+) and Ank-1(MRI95845/MRI95845) RBCs under shear pressure as 
measured by ektacytometer (n=3 mice) (d). The proportion of retained Ank-1(MRI96570/+), Ank-
1(MRI95845/+) and Ank-1(MRI95845/MRI95845) RBCs when passing through a layer of beads during the in 
vitro spleen retention assay (n=3 mice) (e). P values were calculated using Student’s t-tests. * 
P<0.05, ** P<0.01, *** P<0.001. All error bars indicate standard error of mean (SEM). 
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4.2.2.3 Ank-1(MRI96570) and Ank-1(MRI95845) caused RBC morphological changes 
The morphological changes of erythrocytes as the result of these mutations were examined 
under a light microscope, as HS patients often exhibit abnormal RBC morphology. As shown in 
Figure 4.3a, both Ank-1(MRI96570/+) and Ank-1(MRI95845/+) mice exhibited slight reduction in RBC size, 
but otherwise no obvious shape differences. Ank-1(MRI95845/MRI95845) mice had smaller RBCs and 
displayed anisocytosis, where RBCs were of unequal sizes.  On the other hand, blood smears 
obtained from jaundiced Ank-1(MRI96570/MRI96570) pups showed reticulocytosis, fragmented RBCs 
and severe anisocytosis. Under scanning electron microscopy (SEM) (Figure 4.3b), the 
erythrocytes of both Ank-1(MRI96570/+) and Ank-1(MRI95845/+) mice were slightly smaller and less 
distinct discocyte-shaped, whereas Ank-1(MRI95845/MRI95845) erythrocytes appeared more 
acanthocytic.  
 
4.2.2.4 Ank-1(MRI96570/+) and Ank-1(MRI95845/MRI95845) erythrocytes exhibit increased susceptibility to 
haemolysis and higher phosphatidylserine externalisation. 
The susceptibility of RBCs Ank-1(MRI95845/+) and Ank-1(MRI95845/MRI95845) erythrocytes to haemolysis 
was also examined, which is one of the symptoms of HS 443. Erythrocytes were incubated ex vivo 
at room temperature, and monitored haemolysis rate. Ank-1(MRI95845/MRI95845) RBCs underwent 
rapid haemolysis after 12 hours, with approximately 31% haemolysis compared to 9% of wild-
type erythrocytes (Figure 4.4a). Ank-1(MRI96570/+) erythrocytes, on the other hand, only exhibited 
increased haemolysis after 48 hours of incubation (32% haemolysis compared to 7% of wild-
type). These Ank-1(MRI96570/+) and Ank-1(MRI95845/MRI95845) erythrocytes also exhibited higher Annexin 
V on flow cytometer regardless of incubation temperature (Figure 4.4b-d), indicating higher 
phosphatidylserine (PS) externalisation as the result of membrane instability. These results 
suggested that Ank-1(MRI95845/MRI95845) erythrocytes, and to the lesser extent, Ank-1(MRI96570/+) 
erythrocytes, were more susceptible to degradation, and possibly have a more unstable RBC 
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membrane. The findings so far demonstrated that these Ank-1 mice exhibit haematological and 
clinical features consistent with HS. 
  
Figure 4.3: The RBC morphology of mice carrying Ank-1(MRI96570) or Ank-1(MRI95845) mutation. 
Giemsa-stained blood smears as examined under light microscope at 100x magnification (a).  
Scanning electron microscopic images showing the RBC shape of Ank-1(MRI96570/+), Ank-
1(MRI95845/+)
 
and Ank-1(MRI95845/MRI95845) mice (b). 
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Figure 4.4: The susceptibility of Ank-1(MRI96570/+) and Ank-1(MRI95845/MRI95845) erythrocytes to 
haemolysis and eryptosis. The percentage of haemolysis of wild-type, Ank-1(MRI96570/+) and Ank-
1(MRI95845/MRI95845) erythrocytes when incubated ex vivo at room temperature (a) (n=3 mice).  The 
exposure of phosphatidylserine (PS) as a marker for eryptosis was measured using FITC-
conjugated Annexin V on flow cytometry (b). The proportion of RBCs population positive for 
Annexin V binding was recorded over 4 days of incubation at room temperature (c) or 4
o
C (d)(n=3 
mice). All experiments were conducted with n=3-5 mice per group and p values were calculated 
using Student’s t-tests. * P<0.05, ** P<0.01, *** P<0.001. Error bars indicate SEM. 
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4.2.3 Ank-1(MRI95845/MRI95845) erythrocytes have disrupted cytoskeletal structure and 
reduced expression of RBC cytoskeletal proteins 
 
4.2.3.1 Reduced Ank-1 mRNA levels in embryonic livers of mice carrying Ank-1(MRI96570) and Ank-
1(MRI95845) mutation 
The effect of these mutations on the Ank-1 expression levels were also investigated. The Ank-1 
mRNA levels were examined via quantitative PCR on E14 embryonic livers, as it is the major 
erythropoietic organ during embryo development, and normalised against the wild-type levels. 
As shown in Figure 4.5a, significant reduction of Ank-1 mRNA levels was observed in Ank-
1(MRI96570/+), Ank-1(MRI95845/+) and Ank-1(MRI95845/MRI95845) embryonic livers (ranging from 0.61 to 0.67 
of wild-type levels), whereas Ank-1(MRI96570/MRI96570) embryonic liver showed the most reduction 
(mean of 0.38 of wild-type levels). 
 
4.2.3.2 Expression levels of various RBC cytoskeletal proteins in mice carrying Ank-1(MRI96570) and 
Ank-1(MRI95845) mutation 
The ANK-1 and other erythrocyte cytoskeletal protein levels were also examined. Coomassie 
staining and Western blotting of the RBC membrane fractions did not show a significant 
difference in ANK-1 levels between wild-type, Ank-1(MRI96570/+) and Ank-1(MRI95845/MRI95845) 
erythrocytes (Figure 4.5b-d). The predicted truncated ANK-1(MRI96570/+) form (160kDa) was also 
not evidenced. The levels of other cytoskeletal proteins were also examined to account for 
possible disruptions to interactions with other binding partners of ankyrin-1. However, no 
difference was observed for Band 3, α- and β-spectrin, whereas significantly lower protein 4.2 
level was observed in Ank-1(MRI95845/MRI95845) erythrocytes (Figure 4.5d).  
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Further characterisation of Ank-1(MRI95845/MRI95845) erythrocyte cytoskeletal proteins was 
performed using liquid chromatography/mass spectrometry (LC/MS) on the RBC membrane. 
They were first separated on SDS-PAGE, followed by alkylation and trypsin-digestion, before 
being analysed on LC/MS. Of the protein hits obtained from the mass spectrometry, RBC 
cytoskeleton-related proteins were selected and examined. Figure 4.5e shows the relative 
abundance of various RBC cytoskeletal proteins normalised to the total protein content. 
Significant reduction in ankyrin-1, protein 4.2 and stomatin levels were observed in Ank-
1(MRI95845/MRI95845) erythrocyte membranes.  
 
4.2.3.3 Ank-1(MRI95845/MRI95845) erythrocytes exhibit increased band 3 mobility and solubility 
It is likely that Ank-1(MRI95845/MRI95845) caused disruption to the RBC cytoskeletons, as evidenced 
from the reduced amount of various RBC cytoskeletal proteins from previous experiments. In 
order to support our hypothesis, the band 3 mobility across the RBC membrane was examined 
as an indicator of disrupted RBC cytoskeleton 444,445. Erythrocytic band 3 was fluorescently 
labelled with eosin-5’-maleimide and performed Fluorescence Recovery after Photobleaching 
(FRAP) on erythrocytes, which involved photobleaching with high-powered laser followed by a 
recovery period where the fluorescence intensity was recorded. Ank-1(MRI95845/MRI95845) RBCs were 
found to have significantly higher fluorescence recovery compared to wild-type and Ank-
1(MRI96570/+) RBCs (Figure 4.6a), which suggests a higher band 3 mobility in Ank-1(MRI95845/MRI95845) 
erythrocytes. It was proposed that this was due to an increased amount of band 3 that was not 
associated with the RBC cytoskeleton, which was assessed by measuring the solubility of band 3 
in the presence of detergent. It has been shown that un-bound band 3 is more soluble compared 
to those interacting with the RBC cytoskeleton 446. Therefore, it was predicted that Ank-
1(MRI95845/MRI95845) erythrocytes would have higher amounts of soluble band 3 when treated with 
detergent, which can be visualised on Western blot, and the relative amount of soluble band 3 
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 Figure 4.5: The expression of Ank-1 and other RBC cytoskeletal proteins in mice carrying Ank-
1(MRI96570) or Ank-1(MRI95845) mutation. Quantitative PCR was carried out on E14 embryonic livers 
to examine Ank-1 expression levels (n=3 mice) (a).  The abundance of ANK-1 and other RBC 
cytoskeletal protein levels of Ank-1(MRI96570/+), Ank-1(MRI95845/+) and Ank-1(MRI95845/MRI95845) mice as 
examined via Coomassie (b) and Western blot (c) on membranes of mature RBCs. The relative 
abundance of various cytoskeletal protein levels calculated from Western blots (n=3 mice) (d). 
The proteomics results of Ank-1(MRI95845/MRI95845) erythrocyte membrane compared to wild-type 
as measured using LC/MS (n=3 mice) (e). SPTA = α-spectrin, SPTB = β-spectrin, P 4.2 = Protein 
4.2. P values were calculated using Student’s t-tests. * P<0.05, ** P<0.01. Error bars indicate 
SEM. 
ANK-1 
Band 3 
α-spectrin 
β-spectrin 
Protein 4.1 
Protein 4.2 
Actin 
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 was expressed as a percentage of the total band 3 amount. Indeed, significantly higher 
proportions of soluble band 3 was observed in Ank-1(MRI95845/MRI95845) erythrocytes compared to 
wild-type and Ank-1(MRI96570/+) erythrocytes in three independent replicates of the experiment 
(Figure 4.6b-c). These results suggested that Ank-1(MRI95845/MRI95845) erythrocytes have increased 
amount of un-associated band 3 in the membrane compared to Ank-1(MRI96570/+) erythrocytes, 
indicating a disrupted RBC cytoskeleton.  
Figure 4.6: The mobility and solubility of band 3 of Ank-1(MRI96570/+) and Ank-1(MRI95845/MRI95845) 
erythrocytes. The band 3 mobility on RBC membrane was measured using Fluorescence 
recovery after Photobleaching (FRAP), showing the recovery rate of fluorescence as a result 
of Band 3 migration to the bleach spot (n=9-21) (a). The solubility of band 3 of Ank-1(MRI96570/+) 
and Ank-1(MRI95845/MRI95845) erythrocytes as determined by comparing the proportion of triton-
X100-soluble band 3 to the total band 3 amount in RBC membrane on Western blot (b) (SF= 
triton-X100-soluble fraction; IF = triton-X100-insoluble fraction), with quantitation as shown 
in (c) (n=3 mice per group). P-values for (a) were calculated using Student’s t-test on the area 
under curve, whereas paired Student’s t-test was used in (b) for three separate replicates of 
the experiment. ** P< 0.01, *** P<0.001. Error bars indicate SEM. 
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4.2.4 Ank-1(MRI96570) and Ank-1(MRI95845) give rise to resistance towards P. chabaudi 
infection 
It was proposed that mice carrying these mutations have reduced susceptibility to malaria 
infection, which was examined by injecting with a lethal dose of P. chabaudi, and the percentage 
of parasitised RBCs (parasitaemia) was recorded. As shown in Figure 4.7a, Ank-1(MRI96570/+) and 
Ank-1(MRI95845/+) mice showed significant reduction in peak parasitaemia of approximately 15-20%, 
while Ank-1(MRI95845/MRI95845) mice showed approximately 30% reduction in peak parasitaemia 
compared to wild-type. Ank-1(MRI95845/MRI95845) mice also showed a two-day delay in parasitaemia, 
peaking on day 12 post-infection rather than day 10 as with wild-type. Ank-1(MRI95845/MRI95845) mice 
also exhibited significantly higher survival rate compared to wild-type during P. chabaudi 
infection, but no significant difference was observed for Ank-1(MRI96570/+) and Ank-1(MRI95845/+) mice 
compared to wild-type (Figure 4.7b). Overall, these results suggested that both Ank-1(MRI96570/+) 
and Ank-1(MRI95845/+) mice showed moderate resistance, whereas Ank-1(MRI95845/MRI95845) mice 
exhibited significant resistance towards P. chabaudi infection in relative to the wild-type mice. 
From these results, further investigation on the possible mechanisms of resistance mediated by 
Ank-1(MRI96570) and Ank-1(MRI95845) mutations was performed. Three important determinants of 
parasite growth and survival within the host were examined. Firstly, the ability of parasite to 
survive within these erythrocytes was studied, since ankyrin-1 mutations have previously been 
implicated to impair parasite intra-erythrocytic maturation 189. Secondly, the erythrocyte 
invasion was assessed as the mutations disrupt erythrocyte cytoskeletal structure, which is 
important for facilitating efficient erythrocyte invasion 192. Thirdly, the mutations might result in 
an improved detection of parasitised RBCs, thus enhancing their removal from circulation during 
malaria infection. Since Ank-1(MRI96570/+) and Ank-1(MRI95845/MRI95845) mice exhibited differences in 
malaria resistance, it was hypothesised that they mediate malaria resistance through different 
pathways. 
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Figure 4.7: The parasitaemia and survival curves of Ank-1(MRI96570/+), Ank-1(MRI95845/+) and Ank-
1(MRI95845/MRI95845) mice when challenged with P. chabaudi. The parasite load (a) and survival 
rate (b) of Ank-1(MRI96570/+) , Ank-1(MRI95845/+) and Ank-1(MRI95845/MRI95845) mice from day 7 to day 15 
post-infection when challenged with 1x104 parasite intraperitoneally as determined by light 
microscopy. (n=9-13 mice each genotype). P values for (a) and (b) were calculated using 
permutation test and Log-Rank test, respectively.* P<0.05, *** P<0.001. Error bars indicate 
SEM. 
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4.2.5 Ank-1(MRI96570/+) and Ank-1(MRI95845/MRI95845) erythrocytes are resistant to merozoite 
invasion 
First, the ability of parasite to invade erythrocytes was assessed via an in vivo erythrocyte 
tracking (IVET) assay. Labelled RBCs from either wild-type, Ank-1(MRI96570/+) or Ank-
1(MRI95845/MRI95845) mice were injected into infected wild-type mice of 1-10% parasitaemia during 
late schizogony stage and the parasitaemia of each genotype was monitored over 36-40 hours 
to indicate relative invasion rates. The initial invasion period was expected at 30 minutes to 3 
hour timepoints, and the results were expressed as a ratio of parasitised RBCs of either, Ank-
1(MRI96570/+) to wild-type (Figure 4.8a), Ank-1(MRI95845/MRI95845) to wild-type (Figure 4.8b), or Ank-
1(MRI96570/+) to Ank-1(MRI95845/MRI95845) (Figure 4.8c). From Figure 4.8a and 4.8b, Ank-1(MRI96570/+) and 
Ank-1(MRI95845/MRI95845) erythrocytes were less parasitised compared to wild-type (0.6-0.7 for Ank-
1(MRI96570/+) and 0.55-0.8 for Ank-1(MRI95845/MRI95845)) from 3 hours up to 36 hours post-injection, 
indicating both Ank-1(MRI96570/+) and Ank-1(MRI95845/MRI95845) erythrocytes were more resistant to 
parasite invasion than wild-type. However, no significant differences in parasitaemia ratio were 
observed at 30 minute timepoint. Furthermore, when the invasion rate of both Ank-1(MRI96570/+) 
and Ank-1(MRI95845/MRI95845) erythrocytes were compared in infected wild-type mice (Figure 4.8c), 
no significant difference in parasitaemia ratio was observed, suggesting a similar invasion rate 
between the two mutant erythrocytes. 
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4.2.6 Ank-1(MRI96570/+) erythrocytes impair parasite maturation 
Second, the parasite intra-erythrocytic maturation was determined through a TUNEL assay, 
which allows the detection of fragmented DNA in RBCs, as an indication of dying parasites 
(Figure 4.8d) 417. Samples were collected from infected mice at 1-10% parasitaemia at both 
young ring stage and late trophozoite stage, and the proportion of TUNEL-positive infected RBCs 
were calculated. As seen from Figure 4.8e, more TUNEL-positive parasites were observed within 
Ank-1(MRI96570/+) erythrocytes, in both ring (30.1±3.4% compared to 15.2±3.1% of wild-type) and 
trophozoite stage (30.8±3.8% compared to 11.7±1.0% of wild-type), whereas no differences 
were observed for Ank-1(MRI95845/+) and Ank-1(MRI95845/MRI95845) erythrocytes. This result suggested 
that the growth of parasites within Ank-1(MRI96570/+) erythrocytes was impaired, but was normal 
in Ank-1(MRI95845/+) and Ank-1(MRI95845/MRI95845) erythrocytes. This also indicate that Ank-1(MRI96570) 
disrupts parasite maturation, whereas Ank-1(MRI95845) seems to support normal parasite growth, 
although growth inhibition at other stages were not studied.  
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Figure 4.8: The parasite invasion and intra-erythrocytic growth as indicated via IVET and 
TUNEL assay. The relative invasion efficiency into Ank-1(MRI96570/+) and Ank-1(MRI95845/MRI95845) 
erythrocytes was examined through IVET assay, where parasitaemia ratio was calculated 
from parasite load of either Ank-1(MRI96570/+) to wild-type (a), Ank-1(MRI95845/MRI95845) to wild-type 
(b), or Ank-1(MRI96570/+) to Ank-1(MRI95845/MRI95845) erythrocytes (c) (n=5-7). The parasite growth 
inhibition was determined via TUNEL assay on infected RBCs (DAPI-positive) as an indicator 
of apoptotic and necrotic parasites (d). At least 100 infected RBCs was counted and the 
proportions of TUNEL-positive infected RBCs were calculated for Ank-1(MRI96570/+), Ank-
1(MRI95845/+) and Ank-1(MRI95845/MRI95845) mice at 1-5% parasitaemia at ring stage (6-8 hours) and 
late trophozoite (18-20 hours) stage (n=4) (e). P values were calculated using Student’s t-
tests. *P<0.05, **P<0.01, ***P<0.001. Error bars indicates SEM. 
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4.2.7 Ank-1(MRI95845/MRI95845) erythrocytes are more likely to get cleared during malaria 
infections 
The proportions of labelled erythrocytes were also monitored during the IVET assays to compare 
the relative loss of the two labelled RBC populations as the indicator of RBC clearance during 
malaria infection.  No significant reduction in Ank-1(MRI96570/+) erythrocyte numbers was observed 
during IVET assay compared to wild-type (Figure 4.9a). On the other hand, the number of 
labelled Ank-1(MRI95845/MRI95845) erythrocytes decreased significantly compared to wild-type and 
Ank-1(MRI96570/+) erythrocytes (Figure 4.9b and c), with approximately 20% and 50% reduction, 
respectively. However, the parasitaemia measurements during the IVET assays were 
approximately 2% to 16-30% (Supp. Figure 1a and b), which did not correlate with the reduction 
of labelled Ank-1(MRI95845/MRI95845) erythrocytes. This suggested an increased bystander clearance 
rather than clearance of infected Ank-1(MRI95845/MRI95845) RBCs. To further investigate this 
phenomenon, the RBCs of infected mice from each genotype were biotinylated and the RBC 
half-life was examined without blood transfusion. As shown in Figure 4.9d, the Ank-1(MRI96570/+) 
mice exhibited no significant reduction in RBC numbers, whereas Ank-1(MRI95845/MRI95845) mice 
were found to have significantly shorter half-life of approximately 6 days, which did not correlate 
with the parasitaemia curve (Supp. Figure 1c). This observation of shorter RBC half-life in 
infected Ank-1(MRI95845/MRI95845) mice is consistent with the increased Ank-1(MRI95845/MRI95845) 
erythrocyte clearance as shown in IVET assays. The Ank-1(MRI95845/MRI95845) mice were also found 
to have increased reticulocytes count early infection compared to wild-type and Ank-1(MRI96570/+) 
mice (Figure 4.9e). Overall, these results indicated that Ank-1(MRI95845/MRI95845) erythrocytes have 
increased clearance and turnover rate and Ank-1(MRI95845/MRI95845) mice have increased 
erythropoiesis during malaria infection, both of which were not evidenced in Ank-1(MRI96570/+) 
mice. 
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Figure 4.9: The clearance of wild-type, Ank-1(MRI96570/+) Ank-1(MRI95845/MRI95845) erythrocytes and 
reticulocytosis during malaria infection. The remaining percentage of labelled RBCs was 
monitored during the course of IVET assays, comparing between wild-type and Ank-1(MRI96570/+) 
erythrocytes (a), wild-type and Ank-1(MRI95845/MRI95845) erythrocytes (b), and Ank-1(MRI96570/+) and 
Ank-1(MRI95845/MRI95845) erythrocytes (c) (n=5-7). The half-life of wild-type, Ank-1(MRI96570/+) Ank-
1(MRI95845/MRI95845) erythrocytes during malaria infection as determined by biotinylation of RBCs 
when parasites were detectable (n=6-7) (d). The reticulocytosis of wild-type, Ank-1(MRI96570/+) Ank-
1(MRI95845/MRI95845) mice during malaria infection as calculated by the proportion of non-
biotinylated CD71-positive population (n=6-7) (e). P values were calculated using Student’s t-
test on the area under curve for each genotype and treatment. ** P<0.01, *** P<0.001. Error 
bars indicate SEM. 
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4.2.8 Increased Ank-1(MRI95845/MRI95845) erythrocytes clearance during malaria infection 
is mainly mediated via splenic filtration  
Two mechanisms were hypothesised for the increased clearance of Ank-1(MRI95845/MRI95845) 
erythrocytes. First, the Ank-1(MRI95845/MRI95845) erythrocytes might be more likely to be detected 
and cleared by the spleen, and second, the Ank-1(MRI95845/MRI95845) erythrocyte clearance might be 
mediated through the immune system. To determine the role of the spleen in erythrocyte 
clearance, splenectomised mice were first infected with P. chabaudi and infused with labelled 
wild-type and Ank-1(MRI95845/MRI95845) erythrocytes, the proportions of which were monitored over 
time. As shown in Figure 4.10a, Ank-1(MRI95845/MRI95845) erythrocyte numbers are approximately 
two-fold higher (P<0.01) in splenectomised mice compared to non-splenectomised mice. This 
suggests that the spleen is a major contributor towards Ank-1(MRI95845/MRI95845) erythrocyte 
clearance, although the clearance was not completely abrogated in the absence of the spleen. 
 
4.2.9 Toll-like receptor 4 (TLR4)-mediated pathways play a minor role in Ank-
1(MRI95845/MRI95845) erythrocytes clearance 
As a result, the role of the immune system in the clearance of Ank-1(MRI95845/MRI95845) erythrocytes 
was explored. It is thought that innate immune system requires several days to be activated to 
eliminate parasitised RBCs 447,448. Therefore, the activation of the innate immune system was 
minimised by infecting mice with high dose of P. chabaudi (2x107) and performed an IVET assay 
two days post-infection. From Figure 4.10b, Ank-1(MRI95845/MRI95845) erythrocytes were significantly 
less parasitised compared to wild-type erythrocytes, in agreement with previous IVET assays. In 
terms of Ank-1(MRI95845/MRI95845) erythrocyte numbers, no significant clearance was observed for 
up to 15 hours post-injection, indicating a possible delay in Ank-1(MRI95845/MRI95845) erythrocyte 
clearance (Figure 4.10c). 
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Figure 4.10: The role of splenic filtration and TLR4-mediated clearance in the destruction of 
Ank-1(MRI95845/MRI95845) erythrocytes. The remaining proportion of labelled wild-type and Ank-
1(MRI95845/MRI95845)  erythrocytes in infected splenectomised and control mice over 3 days starting 
at 1% parasitaemia (n=6) (a). The parasitaemia ratio (b) and the proportion (c) of labelled Ank-
1(MRI95845/MRI95845)  to wild-type erythrocytes in mice infected with high dose (2x107) of parasites 
during IVET assay (n=8). The remaining proportion of labelled wild-type and Ank-
1(MRI95845/MRI95845) erythrocytes in uninfected LPS-treated and control mice over 62 hours (n=6) 
(d). The proportion of labelled wild-type and Ank-1(MRI95845/MRI95845)  erythrocytes in uninfected 
control C57BL/6, MyD88-/- and TLR4-/- mice during IVET assay (n=5-6) (e). P values were 
calculated using Student’s t-test with hypothetical mean of 1 for (b), and on the area under 
curve for the rest of the figures. ** P<0.01, *** P<0.001. Error bars indicate SEM. 
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The effect of an activated innate immune system on Ank-1(MRI95845/MRI95845) erythrocyte clearance 
was further studied using lipopolysaccharides (LPS) as the activating agent, which has been 
shown to activate Toll-like receptor 4 (TLR4) pathway to mediate innate immune responses 449. 
Uninfected mice were first injected with labelled blood, followed by LPS injection into the 
intraperitoneal cavity the following day. Mice treated with LPS showed increased Ank-
1(MRI95845/MRI95845) erythrocyte clearance compared to control mice, with an additional 20% 
reduction in Ank-1(MRI95845/MRI95845) erythrocyte numbers at 60 hours post-injection (Figure 4.10d), 
whereas no reduction in numbers was observed for wild-type erythrocytes in both control and 
LPS-treated mice. These findings suggest a possible LPS-mediated pathway involving TLR4 or 
other secondary pro-inflammatory pathways, resulting in the activation of the innate immune 
system for the clearance of Ank-1(MRI95845/MRI95845) erythrocytes, although it might also due to 
other effects LPS has on other aspects of immune system.  
As such, this theory was further investigated by monitoring the Ank-1(MRI95845/MRI95845) erythrocyte 
numbers in Myeloid Differentiation Primary Response 88 (MyD88) and TLR4 knockout mice, 
both of which have previously shown activation by LPS 449. Figure 4.10e compares the wild-type 
and Ank-1(MRI95845/MRI95845) erythrocyte numbers in C57BL/6 control, with MyD88-/- and TLR4-/- 
mice. In agreement with previous findings, the Ank-1(MRI95845/MRI95845) erythrocyte number 
reduced significantly compared to wild-type erythrocytes. Both MyD88-/- and TLR4-/- mice 
showed approximately 15% reduction in Ank-1(MRI95845/MRI95845) erythrocyte clearance, which is 
statistically significant. These results suggest that TLR4-MyD88 pathway might not be the major 
contributor for increased Ank-1(MRI95845/MRI95845) erythrocyte clearance. 
 
  
122 
 
4.3 Discussion 
4.3.1 Summary of findings 
In this study, two novel ENU-induced ankyrin-1 mutations in mice were investigated: MRI96570 
which carries a nonsense mutation, and MRI95845 which carries a missense mutation. Both 
mutations resulted in HS-like phenotypes, with a reduction in RBC MCV and MCH, elevated RBC 
count and increased RBC osmotic fragility. Mice carrying either mutation showed significant 
resistance towards malaria infections. Although both mutations impair parasite invasion, they 
also affect other processes related to the survival of the parasites. Increased parasite growth 
inhibition was observed in Ank-1(MRI96570/+) erythrocytes, whereas Ank-1(MRI95845/MRI95845) 
erythrocytes were more likely to be removed from circulation predominantly via splenic 
filtration. 
 
4.3.2 Ank-1(MRI96570) and Ank-1(MRI95845) mutations displayed allelic heterogeneity on 
host mice phenotypes and during malaria infections 
Although both Ank-1 mutations give rise to HS-like phenotype in mice, the severity was notably 
different. Homozygosity for MRI96570 mutation is lethal, while MRI95845 homozygotes 
appeared healthy, while both Ank-1(MRI96570/+) mice and Ank-1(MRI95845/+) mice exhibited HS-
phenotypes with similar severity. Unlike the heterozygotes, Ank-1(MRI95845/MRI95845) RBCs are more 
susceptible to haemolysis (Figure 4.4) and a disrupted RBC cytoskeletal structure (Figure 4.6).  
These findings are consistent with the clinical heterogeneity of HS in human populations, where 
various ANK-1 mutations give rise to symptomatic HS 394, and homozygosity for null mutations 
are usually lethal 450.  
While both mutations conferred malaria protection (Figure 4.7) and appeared to impair parasite 
invasion (Figure 4.8), they also showed some remarkable differences in mediating this resistance. 
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Parasites in Ank-1(MRI96570/+) erythrocytes were more likely to be TUNEL-positive, indicating 
impaired intra-erythrocytic maturation, which was not observed in Ank-1(MRI95845/+) and Ank-
1(MRI95845/MRI95845) erythrocytes (Figure 4.8b). While it is possible that MRI95845 mutation might 
affect parasite growth in other stages, MRI95845 appeared to support normal parasite 
maturation at least in ring and trophozoite stages.  
Conversely, Ank-1(MRI95845/MRI95845) erythrocytes were more likely to be removed from circulation 
and possibly increased turnover rate (Figure 4.9c-e), a phenomenon that was not observed in 
Ank-1(MRI96570/+) erythrocytes. This increased removal was most likely due to bystander RBC 
clearance during infection, since it did not correlate with the parasite load (Supp. Figure 4.1), 
and only detectable during malaria infection or upon immune system stimulation (Figure 4.10d). 
The majority of Ank-1(MRI95845/MRI95845) erythrocyte clearance was partly mediated by the spleen 
(Figure 4.10a) and possibly the LPS-TLR4 mediated pathway, to a lesser extent (Figure 4.10d). 
However, immune activation via other pathways might also contribute to the clearance, which 
could be explored in further studies. Nevertheless, it is evident from these findings that Ank-1 
gene exhibits allelic heterogeneity in mediating malaria resistance.  
 
4.3.3 Similarities of allelic heterogeneity in Ank-1 and other malaria susceptibility 
genes 
As evidenced from this study, the protective effect of the Ank-1 gene against malaria is 
dependent on the nature and the location of mutations within the gene. Similarly, this allelic 
heterogeneity is also observed in other malaria susceptibility genes in human populations. For 
instance, although many G6PD deficiency-causing alleles have been implicated with malaria 
protection 451,452, the protective effects are often debated, with many studies reporting 
increased, or no protection, for individuals with certain alleles of G6PD deficiency 121,123,453-456. 
This is thought to be due to the phenotypic complexity of G6PD deficiency associated with 
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malaria susceptibility 430. Indeed, various G6PD alleles have been shown to cause a reduction of 
G6PD activity with differing severity, and was proposed to correlate with the malaria protection 
they conferred 453. Similarly, Ank-1 mutations described in this study, as well as other previous 
mouse studies 189,190,204, exhibit variability in malaria resistance, most likely as the result of allelic 
heterogeneity. 
The heterogeneity in malaria resistance mechanisms of the Ank-1 gene as observed in this study 
is comparable to the two prevalent alleles of the β-globin gene – the HbS and HbC, which result 
from amino acid substitution at position 6 from glutamate to valine, or lysine, respectively. They 
exhibit some similarities in mediating malaria resistance, including impaired parasite growth 
209,211, reduced cytoadherence 210,212,288 and increased erythrocyte clearance 205. However, HbS 
erythrocytes were found to be more resistant to all forms of malaria, whereas HbC erythrocytes 
appeared to be protective against cerebral malaria 432. This difference in malaria protection was 
proposed to correlate with distribution of HbS and HbC in Africa 433, further emphasising the 
importance of allelic heterogeneity in understanding host-parasite interactions. 
 
4.3.4 Allelic heterogeneity of Ank-1 and its association with malaria 
In contrast, due to lack of large scale studies on the HS prevalence in malaria endemic regions, 
ankyrin has not been associated with malaria protection.  Although HS prevalence is more well-
characterised in Northern European and Japanese populations, with a prevalence of about 1 in 
2000 196,198,415, one study proposed an increased HS incidence in Algeria of about 1 in 1000 457, 
raising the possibility of positive selection of HS by malarial parasites. However, as the result of 
extreme allelic heterogeneity of HS-causing genes, many alleles do not reach sufficient 
frequencies 458 or achieve consistent symptoms 459 to be easily associated with malaria 
protection. In addition, technical difficulties 200, confounding factors from large genetic variation 
in African populations 460, as well as poor diagnostics and health systems 460, pose significant 
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challenges for dissecting the connection between HS and malaria. With development of more 
advanced technologies and better characterisation of the genetic structure of African 
populations, further studies into the association of HS and malaria could potentially yield 
beneficial insights into the co-evolutionary relationships between humans and Plasmodium.  
Nonetheless, previous in vivo studies have indicated that Ank-1 mutations affect merozoite 
invasion and maturation 189,204, both of which were also demonstrated in this study. However, 
this study also describes the first direct in vivo observation of different mutations in the Ank-1 
gene mediating two distinct, independent mechanisms of malaria resistance, where one impairs 
parasite maturation and the other increases RBC clearance. Ankyrin is one of the key proteins 
involved in RBC remodelling by parasites 236,272,280, and maintaining the structure of RBC 
cytoskeleton 394,461. It is possible that this allelic heterogeneity is due to the effect each mutation 
has on the integrity of RBC cytoskeletal structure, as evidenced by the significantly increased 
band 3 solubility and mobility caused by Ank-1(MRI95845), but not Ank-1(MRI96570) mutation (Figure 
4.6). This suggests that mutations at different locations of the ankyrin protein might have 
different effects on the RBCs, consequently impacts the ability of parasites to invade and grow. 
This hypothesis also agrees with the findings from other Ank-1 mice from previous studies, as 
well as Ank-1(MRI61689/+) mice from previous chapter, where each mutation exhibited differences 
in terms of mechanisms of malaria resistance. However the interaction between RBC 
cytoskeletons and malarial parasites was not directly tested in this study, which is one major 
limitation of this study. Nevertheless, this could be the basis for further studies, which might 
explain the differences in the underlying malaria resistance between ankyrin-1 mutations. 
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4.4 Conclusion 
In conclusion, this chapter reported a novel observation where the Ank-1 gene exhibits 
phenotypic heterogeneity in mediating malaria resistance mechanisms either via impairing 
intra-erythrocytic parasite growth, or promoting RBC clearance. Further studies should extend 
the understanding of the effects of various Ank-1 mutations on the development of intra-
erythrocytic parasites, as well as the association of HS with malaria in human populations. This 
could provide new insights into the intricate relationships between RBC cytoskeletal structure 
and parasite interactions. Furthermore, understanding the mechanisms of malaria resistance 
caused by ankyrin-1 gene enables us to further assess the suitability of ankyrin-1 gene as a HDT 
target, which is ultimately the goal of this project. 
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4.5 Supplementary Figures 
 
  
Supplementary Figure 4.1: The parasitaemia of the host mice during IVET assays and half-
life assay. The parasitaemia curve of the host mice during IVET assays, when comparing wild-
type with Ank-1(MRI95845/MRI95845) erythrocytes (a), and Ank-1(MRI96570/+) with Ank-
1(MRI95845/MRI95845) erythrocytes (b) (n=5-7). The parasitaemia curve of wild-type, Ank-
1(MRI96570/+) and Ank-1(MRI95845/MRI95845) mice during RBC half-life assay (n=6-7) (c). 
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CHAPTER 5 
ANKYRIN-1 AS A POTENTIAL HDT CANDIDATE FOR 
MALARIA  
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5.1 Introduction 
The erythrocytic cytoskeleton is comprised of various interconnecting proteins, such as band 3, 
ankyrin-1, α- and β-spectrin, protein 4.2 and protein 4.1R, forming a mesh-like network 
throughout the RBC, which gives rise to the distinct shape and reversible deformability of RBCs 
to travel through narrow capillaries 462,463. During malaria infection, the RBC cytoskeleton plays 
an important role during the development of blood-stage parasites, which includes facilitating 
the invasion of merozoites 236,464 and the presentation of parasite-derived proteins on RBC 
surface 272,465. As such, many genetic mutations affecting RBC cytoskeletal proteins 184,186,260 have 
been associated with disruptions to these processes, thereby conferring malaria protection.  
RBC cytoskeleton consists of two major protein complexes, the ankyrin complex and the actin 
junctional complex 466. Ankyrin complex contains several key proteins, such as band 3, ankyrin-
1, protein 4.2, β-spectrin and the Rhesus complex 466,467. In particular, ankyrin-1 is involved in 
the “anchoring” of spectrin tetramers onto the RBC membrane through interactions with other 
membrane proteins 468. Ankyrin-1 contains several important functional domains: an N-terminal 
domain comprised of ankyrin repeats, a 33-residue motif that interacts with band 3 and protein 
4.2; a central spectrin-binding domain; and a C-terminal regulatory domain, which is thought to 
affect the expression of various isoforms of ankyrin-1 469-471. Of particular interest in this chapter 
is the spectrin-binding domain, which is predicted to confer malaria resistance when disrupted. 
Detailed studies examining ankyrin-spectrin interactions by others determined the ankyrin-
spectrin interactions involved a so-called Zu5 subdomain within the spectrin-binding domain of 
ankyrin-1 that binds specifically to the spectrin repeat 14 and 15 of β-spectrin 396,472,473, as 
illustrated in Figure 5.1. Studies by Ipsaro and Mondragon 398 have further isolated the specific 
amino acid residues crucial in mediating ankyrin-spectrin binding in vitro. Through the use of 
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recombinant protein fragments containing the interacting domains of the two proteins, they 
observed a significantly reduced inter-protein binding interaction when the aspartic acid residue 
at position 1781 of β-spectrin was substituted with arginine (D1781R) 398. 
Mutations in the RBC cytoskeleton proteins are associated with increased malaria resistance, as 
evidenced from previous in vitro 191,192 and in vivo 189,190,204 studies, as well as findings from 
previous chapters. From the findings by Ipsaro and Mondragon 398 and previous data, it is 
possible that interrupting the ankyrin-spectrin interaction though drugs could induce host 
resistance towards malaria. Therefore, in order for assess this possibility, a mouse line was 
created with the D1781R mutation and examined the effects on the erythrocyte and the 
response to malarial infection, to genetically validate the resulting interruption of ankyrin-
Figure 5.1: Schematic diagram of the interaction between human ankyrin-1 and β-spectrin. 
The human ankyrin-1 consists of 3 domains, the N-terminal band 3-binding domain with 
many ankyrin repeats, the central spectrin-binding domain with the Zu5 subdomain and the 
regulatory domain. The human β-spectrin consists of the N-terminal actin-binding domain, 
followed by 16 repeats of spectrin and the tetramerisation domain. The binding sites 
between ankyrin-1 and β-spectrin was localised at the Zu5 subdomain of ankyrin-1, and the 
spectrin repeat 14 and 15 of β-spectrin, as indicated by the two-headed arrow. 
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spectrin interaction. It was hypothesised that mice carrying D1781R would exhibit features 
consistent with an abnormal RBC cytoskeleton and consequently malaria resistance. The result 
would also indicate the feasibility of targeting ankyrin-spectrin interaction as part of the host-
directed therapy (HDT) for malaria. As such, the development of a high-throughput screening 
(HTS) assay was initiated to enable the identification of small molecules that may disrupt the 
ankyrin-spectrin interaction, replicating the effect of the D1781R mutation biochemically. 
In the context of clinical studies, disruptions to the RBC cytoskeleton are associated with several 
genetic disorders, such as hereditary spherocytosis (HS) and elliptocytosis (HE). In particular, HS 
is thought to be a result of the weakening of vertical interactions 474, with ankyrin-1 defect being 
the most common 201. Despite many in vivo studies implicating the association of HS with malaria 
resistance 189,190,204, this relationship is not well-defined in clinical settings. Furthermore, as 
evidenced from the previous chapter, mice with HS-like phenotypes exhibit heterogeneity in 
mediating malaria resistance. Therefore, it was hypothesised that human HS patients might also 
exhibit differences in their malaria susceptibility, as a result of allelic heterogeneity in the HS-
causing genes. Further studies on the various HS-causing alleles in humans could provide 
beneficial insights to the roles of specific alleles in conferring malaria protection, which could 
lead to the discovery of more potential HDT candidates for malaria.  
The aim of this chapter is to evaluate the suitability of targeting ankyrin-spectrin interaction as 
a HDT target, by further investigating the possibility of the D1781R mutation in giving rise to 
malaria resistance. A mouse strain, TAR3.5, was generated which carries the D1781R mutation 
in its β-spectrin gene through the CRISPR/Cas9 system. Mice carrying the D1781R mutation was 
observed to exhibit HS-like phenotype and increased resistance to malaria infections, in 
agreement with our hypothesis. As a result, pilot studies into characterising the binding kinetics 
of ankyrin and spectrin were conducted to be used for HTS for HDT drug development. The 
ability of P. falciparum to invade and growth within the RBCs HS patients in vitro was assessed, 
as a further validation of malaria resistance mechanisms observed in mouse models from 
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previous chapters. The process of carrying out whole genome sequencing is currently underway 
to identify new HS-causing alleles, which would allow us to associate these alleles with the 
malaria protection they conferred, as well as determine their potential as HDT candidates. This 
chapter highlights the potential of targeting RBC cytoskeletal proteins to develop a HDT for 
malaria, as well as providing more direct evidence for the protective role of HS during malaria 
infections. 
 
 
5.2 Results 
5.2.1 D1781R mutation causes HS-like phenotypes in mice 
D1781R is situated in the 14th spectrin repeat (Figure 5.2a), which is involved in ankyrin binding 
396. The D1781R mutation was introduced into SJL/J mice via the CRISPR/Cas9 system through 
homologous recombination in the presence of a guide RNA containing the sequence of interest 
and a single-stranded oligonucleotides containing the D1781R mutation, generating the TAR3.5 
mouse strain. Ten days old founder mice were genotyped by Sanger sequencing to reveal a 
dinucleotide point mutation in exon 34 of Sptb gene, with a substitution of GA with CG 
nucleotides indicating successful editing (Figure 5.2b). TAR3.5 mice heterozygous for D1781R 
mutation will be referred to as Sptb(D1781R/+), whereas homozygotes will be referred to as 
Sptb(D1781R/D1781R). Both Sptb(D1781R/+) and Sptb(D1781R/D1781R) mice appeared healthy with no signs of 
morbidity and exhibited a normal lifespan, indicating that the mutation had a minor detrimental 
effect on the mice.  
If the mutation disrupts ankyrin-spectrin binding, as predicted by Ipsaro and Mondragon 398, it 
was hypothesised to give rise to a HS-like phenotype. As a result, haematological analysis was 
performed on Sptb(D1781R/+) mice. The Sptb(D1781R/+) mice exhibited a significant reduction in MCV 
(49.7±0.4 fl compared to 53.3±0.6 fl of wild-type) and MCH (14.4±0.2 pg compared to 15.1±0.1 
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pg of wild-type) (Figure 5.3a-b), suggesting a reduced RBC volume and haemoglobin amount. 
RBC osmotic fragility was also assessed as part of the diagnosis for HS. As shown in Figure 5.3c, 
the RBCs of Sptb(D1781R/+) mice showed no significant difference compared to wild-type RBCs, 
however, the RBCs of Sptb(D1781R/D1781R) mice exhibited a significant increase in osmotic fragility 
compared to wild-type RBCs, with 50% lysis at approximately 5.6 g/L sodium chloride 
concentration, as opposed to 4.4 g/L of wild-type RBCs. These findings indicate that D1781R 
mutation can give rise to HS-like phenotype in mice.  
Figure 5.2: The location of D1781R mutation. The predicted effect of D1781R mutation on 
the SPTB protein, showing an aspartate to arginine substitution at residue 1781 in the 14th 
repeat of spectrin domain (a). The Sanger sequencing of mice carrying the D1781R mutation 
in the heterozygous state, showing a dinucleotide mutation from GA to CG (b).  
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The disruptive effect of the D1781R mutation was hypothesised to affect the structural integrity 
of the RBC cytoskeleton. Therefore, the mobility of membrane band 3 was examined as an 
indication of binding affinity of band 3 with the RBC cytoskeleton, via Fluorescence recovery 
after photobleaching (FRAP) analysis with fluorescently labelled band 3, and recorded the 
recovery of fluorescence intensity after photobleaching with high-powered laser. The RBCs from 
Sptb(D1781R/D1781R) mice were specifically examined, as they reflected the full disruptive effect of 
the mutations. As shown in Figure 5.3d, they exhibited a significantly increased fluorescence 
recovery, indicating increased band 3 mobility, which supported our hypothesis. It is likely that 
this disruption would lead to decreased RBC deformability 475. Therefore, two methods were 
used to investigate the RBC deformability: Ektacytometry and in vitro retention assay though 
the use of metal beads to model splenic filtration (described by Deplaine, et al. 400), in which RBC 
retention indicates reduction in RBC deformability. Firstly, when subjected to shear stress in the 
ektacytometer, erythrocytes of Sptb(D1781R/+) mice exhibited a similar elongation index as wild-
type erythrocytes (Figure 5.3e), suggesting no difference in RBC deformability in Sptb(D1781R/+) 
mice, however, Sptb(D1781R/D1781R) mice were not analysed due to time constraints. For the in vitro 
retention assay, Sptb(D1781R/+) erythrocytes showed significantly increased retention in the bead 
layer, whereas the Sptb(D1781R/D1781R) erythrocytes showed a further increased retention (Figure 
5.3f). These findings suggest a reduction in RBC deformability in Sptb(D1781R/+) and Sptb(D1781R/D1781R) 
mice.  
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Figure 5.3: The phenotypic characterisation of D1781R mice. The RBC mean cellular volume 
(MCV) (a) and the mean cellular haemoglobin (b) of wild-type and Sptb(D1781R/+) mice. The RBC 
osmotic fragility of wild-type, Sptb(D1781R/+) and Sptb(D1781R/D1781R) mice (c) (n=4). Membrane band 3 
mobility of wild-type and Sptb(D1781R/D1781R) erythrocytes as measured via FRAP assay (n=15-17) (d). 
The RBC deformability was measured by ektacytometry (n=3) (e) and in vitro spleen retention 
assay (n=4) (f). All p values were calculated using parametric Student’s t-test. Specifically, p-value 
for (d) was calculated on the area under curves. * P<0.05, ** P<0.01, *** P<0.001. Error bars 
indicate SEM. 
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5.2.2 D1781R mutation confer malaria resistance in mice, and inhibit merozoite 
invasion 
To test if the D1781R mutation confers malaria resistance, both Sptb(D1781R/+) and Sptb(D1781R/D1781R) 
mice were challenged with P. chabaudi adami DS and recorded the parasite load and survival 
rate over time. Approximately 60% of the Sptb(D1781R/D1781R) mice survived the challenge, whereas 
none of the wild-type littermates survived (p<0.01). Comparing between these two genotypes, 
there was also a significant reduction in peak parasitaemia (28% compared with 57% of wild-
type; p<0.01) and a three-day delay before this was reached in the homozygotes (Figures 5.4a 
and 5.4b). On the other hand, the Sptb(D1781R/+) mice exhibited a less pronounced increase in 
survival and reduction in parasitaemia compared to wild-type, although these differences are 
not statistically significant (P=0.09).  
The mechanisms for the resistance to malaria infection observed in the Sptb(D1781R/D1781R) mice 
were investigated. An IVET assay was performed to assess the ability of parasites to invade 
mutant erythrocytes and the RBC clearance rate during malaria infection. The parasitaemia of 
both genotypes of RBCs were compared and expressed as a ratio to indicate the relative 
susceptibility towards merozoite invasion. The ratio of infected mutant (Sptb(D1781R/D1781R)) versus 
wild type erythrocytes infected with P. chabaudi parasites was significantly less than one, from 
one hour until 32 hours after the labelled red cells were injected into an infected wild-type 
recipient mouse with 2-9% initial parasitaemia (Figure 5.4c). This suggested that mutant RBC 
were more resistant than their wild type counterparts to merozoite invasion. The proportions 
of labelled wild-type and Sptb(D1781R/D1781R) RBCs remained similar during the examined period of 
infection (Figure 5.4d), suggesting no significant difference clearance of Sptb(D1781R/D1781R) 
erythrocytes. To further verify this observation, the RBC half-life was monitored in infected wild-
type and Sptb(D1781R/D1781R) mice. The RBCs of Sptb(D1781R/D1781R) mice exhibited modest but a 
statistically significant reduction in RBC half-life of about 10% compared to wild-type mice 
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(Figure 5.4e), thus unlikely to be a major contributor to the malaria resistance, although the 
exact mechanisms remained to be explored. Overall, these results suggested that impaired 
merozoite invasion is likely to be the major underlying resistance mechanisms of Sptb(D1781R/D1781R) 
mice. 
Figure 5.4: The effect of D1781R mutation during malaria infections. The survival rate (a) 
and the parasite load (b) of wild-type, Sptb(D1781R/+) and Sptb(D1781R/D1781R) mice when 
challenged with 1x104 P. chabaudi. The parasitaemia ratio of Sptb(D1781R/D1781R) to wild-type 
erythrocytes as measured by IVET assay (c), and the percentage of remaining labelled 
erythrocytes (d) over 36 hours post-injection (n=5). The RBC half-life of Sptb(D1781R/D1781R) mice 
during malaria infection, in conjunction with the parasitaemia curve (e) (n=5). P values for (a) 
were calculated using Log-Rank test; for (b), (d) and (e), p values were calculated on the area 
under curves using Student’s t-test; while for (c), p values were obtained using Student’s t-
test with hypothetical mean of 1. * P<0.05, **P<0.01, ***P<0.001. Error bars indicate SEM. 
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5.2.3 Expression and purification of recombinant ankyrin and spectrin protein 
fragments 
Following the validation of malaria protection conferred by D1781R mutation, the development 
of an assay for the HTS was initiated to identify potential drug molecules to interrupt ankyrin-
spectrin interactions, as a possible HDT drug for malaria treatment. A heterologous expression 
of recombinant protein fragments containing the binding site of ankyrin (ANK-1 Zu5; residues 
911 to 1068) and β-spectrin (SPTB-1315; residues 1583 to 1905), and the β-spectrin fragment 
with the D1781R mutation (SPTB-D1781R) was performed in E. coli. These fragments were first 
expressed in a GST-tag expression plasmid (pGEX-6P-3), and purified on a GST affinity column 
(Supp. Figure 5.1a-b). 
However, the ANK-1 Zu5 protein exhibited low solubility and stability, where more than 50% of 
the ANK-1 Zu5 protein were found in the insoluble fraction after protein expression, and some 
soluble protein precipitated after purification. The preliminary binding assay was carried out on 
the Biacore 2000, which showed a reduced binding of SPTB-D1781R fragment with the ANK-1 
fragment, compared to the SPTB-1315 fragment (Supp. Figure 5.1c), which is possibly consistent 
with the previous study 398.  
As a result, GST tags were replaced with 6X histidine (His) tags (Figure 5.5a) to improve the 
solubility of these protein fragments by reducing steric interference during protein folding. The 
protein fragments were purified on high performance liquid chromatography (HPLC) on a 
nickel affinity column (HiTrap Chelating HP). For SPTB-1315 and SPTB-D1781R protein 
fragments, the chromatograms of the purification, as well as the analysis of each fraction via 
Coomassie staining and Western blotting with anti-6XHis antibody were illustrated in Figure 
5.5b. This result indicates the successful purification of His-tagged spectrin fragments, as 
evidenced from the presence of expected size on SDS-PAGE and presence of 6xHis tags on a 
Western blot. Similarly for ANK-1 Zu5 purification, the fractions from purification as indicated 
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by the arrows were analysed using Coomassie staining and Western blotting (Figure 5.5c). The 
presence of His-tagged ANK-1 Zu5 protein fragments were verified based on the expected size 
on SDS-PAGE, as well as the presence of His-tags when probed with anti-6xHis antibody on 
Western blot. However, due to time constraints, further protein purifications and binding 
assays were not conducted. 
Figure 5.5: The purification of 6xHis-tagged recombinant GST-tagged ANK-1 and SPTB binding 
fragments. The schematic diagram and predicted protein sizes of 6xHis-tagged ankyrin Zu5 
domain (ANK-1 Zu5), beta spectrin repeat 13 to 15 (SPTB-1315) and beta spectrin repeat 13 to 
15 carrying D1781R mutation (SPTB-D1781R) (a). The HPLC chromatograms of SPTB-1315 and 
D1781R purification (b); and ANK-1 Zu5 purification (c), where each coloured arrow indicates 
fraction analysed via Coomassie staining or Western blotting using Anti-6xHis antibody. FT= 
flow through during purification, * indicates the presence of SPTB proteins fragments, ^ 
indicates the presence of ANK protein fragments. 
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5.2.4 Erythrocytes from HS patients are resistant to parasite invasion 
Based on the findings above, it is likely that mutations that disrupt RBC cytoskeleton which give 
rise to genetic disorders such as HS could be targeted for HDT development against malaria. As 
such, it is of our interest to identify more HS-causing alleles as potential HDT candidates, as well 
as verifying our proposed malaria resistance mechanisms as seen in ENU-mice from previous 
chapters. With the collaboration of Dr David Rabbolini from the Royal North Shore Hospital, 
blood samples were obtained from human patients which had been diagnosed with 
symptomatic HS and monitored periodically. Under light microscopy, the RBCs of HS patients 
appeared echinocytic, anisocytic and some exhibited loss of central pallor (Figure 5.6a). The 
RBCs of HS patients also appeared more likely to undergo haemolysis compared to control RBCs. 
To assess their susceptibility towards P. falciparum, an in vitro parasite invasion and growth 
assay was conducted on the RBCs of four HS patients (A-D). Some purified trophozoites stage 
parasites was first inoculated with either control or HS erythrocytes to give an approximately 1% 
starting parasitaemia and measured the parasite load and developmental stages in these RBCs. 
As shown in Figure 5.6b, RBCs from all four HS patients exhibited a significant reduction in 
parasitaemia at 12 hours post-inoculation, suggesting a significant reduction in the invasion rate 
of P. falciparum into these RBCs. However, these spherocytes exhibit constant parasitaemia and 
similar proportion of parasite stages compared to control RBCs throughout the cycle, possibly 
indicating normal parasite maturation within these RBCs from HS patients, although further 
investigation is required.  
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Figure 5.6: The RBC morphology and P. falciparum susceptibility of HS patients. The RBC 
morphology of the HS patient compared to the healthy control in in vitro P. falciparum culture 
(a). The parasitaemia and the stages of P. falciparum (3D7 strain) in control and HS (A-D) 
erythrocytes up to 47 hours, starting with approximately 1% mature trophozoites, each with 4 
technical replicates (b). P values were calculated using Student’s t-tests. *** P<0.001. Error 
bars indicate SEM.  
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5.3 Discussion 
5.3.1 Summary of findings 
In this chapter, a CRISPR/Cas9 generated mouse strain with a D1781R substitution in the β-
spectrin gene was reported to exhibit HS-like phenotype and resistance to malaria, thus 
providing a genetic validation for the disruptive effect of D1781R. The development of HTS assay 
for disrupting ankyrin-spectrin interaction was also initiated to look for potential HDT drug 
candidates. Finally, an in vitro P. falciparum invasion and growth assay was performed on RBCs 
of HS patients to verify our previous observations of reduced invasion and growth of malarial 
parasites in mouse models. 
 
5.3.2 The genetic validation of D1781R disruptive effect for HDT development  
With better characterisation of various protein-protein interactions (PPI) and technological 
advances, drug inhibition for PPI is one of the emerging areas of research in the past decade 476. 
Many studies have been conducted with the aim of identifying PPI inhibitors for various cancers 
or inflammatory diseases (reviewed by Arkin, et al. 477). Notably, the BCL-family, which is 
involved in apoptosis, has been one of the targets for PPI inhibition to treat cancers 478,479, with 
several potential inhibitors having progressed into clinical trials 480-482, highlighting the realities 
of using PPI as drug targets. However, many challenges still remain, such as the lack of defined 
binding sites in many PPI and the low inherent hit rate from HTS 483. Nevertheless, with the 
discovery of critical binding residues of ankyrin-spectrin interactions 398, it is possible to target 
this PPI for malaria HDT development, providing that it could be verified in vivo. 
The genetic validation of the D1781R disruptive effect described in this study enabled further 
investigations into developing a HTS for discovering potential drugs that interrupt ankyrin-
spectrin binding. One important observation is that these mice did not exhibit any signs of 
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morbidity and survived well into adulthood, indicating minimal toxicity associated with the 
D1781R mutation. In the context of malaria infections, the D1781R mutation appeared to confer 
significant malaria protection to the host mice without detrimental effects, unlike many 
protective genetic polymorphisms in humans, which are often accompanied with fitness cost. 
These observations also further suggested that interruption of ankyrin-spectrin interaction is 
unlikely to result in morbidity, which presents an attractive target for HDT development. 
As such, the characterisation of the binding kinetics of ankyrin-spectrin interaction was carried 
out for HTS development. However, the poor solubility and stability of ANK-1 Zu5 protein 
fragment posed a significant technical challenge to the study, possibly due to misfolding during 
protein expression. Therefore, further optimisation of the expression or purification is required, 
either by slowing protein expression or using additives to improve the protein stability after 
purification. Nevertheless, our preliminary result on the ankyrin-spectrin binding appeared 
consistent with the observation by Ipsaro and Mondragon 398 (Supp. Figure 5.1c), which could 
be further investigated in future studies. 
 
5.3.3 Identification of more potential HDT candidates via studies on HS patients 
The genetic validation of the D1781R mutation also presented the prospect of discovering other 
alleles as suitable HDT targets. Disruptions to the ankyrin-spectrin interaction is likely to 
manifest as HS in human populations, since it is part of vertical interactions of RBC cytoskeleton. 
Therefore, with collaboration with local hospitals, HS patients were recruited and their 
susceptibility to malarial parasites and causative mutations were characterised. As reported in 
this study, the RBCs of all four HS patients examined in this study exhibited significant resistance 
towards merozoite invasion (Figure 5.6b), indicating each patient allele could be a potential HDT 
candidate. Although the causative mutations still remained to be identified, it is possible that 
these alleles would affect various areas of RBC cytoskeleton, not just restricted to ankyrin-
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spectrin interactions, due to the heterogeneous nature of HS. This would reveal other RBC 
cytoskeletal interactions as potential drug targets, such as protein 4.2-band 3 interactions, which 
would increase the likelihood of successful malaria HDT developments.  
Furthermore, despite the strong association of HS and malaria as implicated in many in vivo 
studies, evidence from in vitro and epidemiological association studies on the relationship of HS 
with malaria have been lacking, with only a few studies being reported 191,457. Observations from 
this study would consolidate with the existing evidence on the malaria protective effect in 
humans, allowing further examination on the possible resistance mechanisms conferred by HS. 
Coupled with the genetic information of these HS patients, it is possible to infer the effect of 
each HS-causing allele on the parasite survival, as the result of HS heterogeneity in conferring 
malaria resistance. Further studies would provide a better understanding of crucial cytoskeletal 
components that are essential for parasite development. 
 
5.4 Conclusion 
In conclusion, this study demonstrated the genetic verification of the importance of β-spectrin 
D1781 residue in vivo, which could potentially be mimicked using drugs for malaria HDT 
development. In addition, the potential protective roles of HS against malaria in humans were 
explored in vitro, which would provide additional insights to host-parasite interaction, and 
possibly identify more suitable HDT targets for malaria. With sufficient timeframe, this study 
could potentially yield valuable evidence on the possibility of translating in vivo studies into 
clinical settings.  
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5.5 Supplementary Figures 
  
Supplementary Figure 5.1: The purification and interaction of recombinant GST-tagged 
ANK-1 and SPTB binding fragments. The schematic diagram and predicted protein sizes of 
GST-tagged ankyrin Zu5 domain (ANK-1 Zu5), beta spectrin repeat 13 to 15 (SPTB-1315) and 
beta spectrin repeat 13 to 15 carrying D1781R mutation (SPTB-D1781R) (a). The purification 
process of ANK-1 Zu5 and SPTB fragments using GST-Trap column (b), where S/N = 
supernatant, FT = flow through, and the expected size of ANK-1 and SPTB fragments are 
indicated by the red arrows. The preliminary result of ANK-1 and SPTB binding as determined 
via Biacore 2000, using a chip coated with biotinylated SPTB fragments and variable 
concentration of cleaved ANK fragments (d) (n=1). 
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CHAPTER 6 
GENERAL DISCUSSION AND CONCLUSION  
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Plasmodium infections have been a major driver of the evolution of human genetics for 
thousands of years, as evidenced by the large number of genetic polymorphisms associated with 
malaria protection in populations of malaria endemic regions 427,484. These genetic 
polymorphisms reveal host-parasite interactions that are crucial for parasite survival, allowing 
the identification of potential drug targets for malaria treatments, as well as providing potential 
solutions to the emergence of multidrug-resistant malarial parasites. One such approach is to 
target host proteins or pathways essential to parasite survival to mediate the killing of parasites, 
mimicking the protective effect of human genetic polymorphisms, known as host-directed 
therapy (HDT). It is hypothesised that since HDT targets are not under the influence of parasite 
genetics, the parasites unlikely to overcome these host protection though mutations. As a result, 
it is proposed that HDT would be more resilient to parasite resistance, potentially providing a 
useful adjuvant to be used with the current combination chemotherapy for malaria. HDT could 
also prevent the establishment of infections, allowing it to be a prophylactic therapy for malaria. 
However, one of the biggest drawbacks for HDT is potential toxicity as a result of inhibition of 
host proteins. Therefore, it is important to have a full understanding of the biology of the 
potential HDT targets to ensure the safety of administering HDT drugs for malaria treatment. 
This project was conducted with the goals of identifying novel mutations in host genes through 
an ENU mutagenesis screen in mice that provide protection against a malarial infection, 
understanding the mechanisms of malaria protection, and determining the suitability of these 
genes as drug targets for HDT development. RBC cytoskeletal proteins were identified in this 
screen to be potential HDT targets for further investigation. In particular, this study revolved 
around one RBC cytoskeletal protein, ankyrin-1 (Ank-1), which was previously identified to give 
rise to a HS-like phenotype and confer malaria resistance in mice 189. This study aimed to extend 
the understanding of the underlying malaria resistance mechanisms in mice carrying ankyrin-1 
mutations, as well as exploring the possibility of targeting ankyrin-1 for malaria HDT 
development. 
149 
 
Although Ank-1 has been repeatedly implicated to confer malaria resistance, the underlying 
mechanisms were not always clear. Previous studies have suggested that ankyrin-1 mutations 
mediate malaria resistance by reducing erythrocyte invasion and impairing intra-erythrocytic 
parasite maturation 189,204, however, some studies reported the absence of such effects 190. With 
further investigation on another ankyrin-1 mutation, Ank-1(MRI61689), a novel malaria resistance 
mechanism via increased RBC bystander clearance was discovered, where uninfected RBC are 
more likely to be removed from the circulation, resulting in an overall increased RBC turnover 
rate, thus possibly impairing the establishment of malaria infections. It is interesting to note that 
it appeared to support normal intra-erythrocytic parasite maturation, in contrast with previous 
studies on Ank-1(MRI23420/+) and Ank-1(nb/nb) mice 189,204. However, rather than portraying these as 
contradicting evidences, it was proposed that these differences were due to the ability of 
ankyrin-1 to mediate multiple resistance mechanisms, ranging from impairing merozoite 
invasion, inhibiting intra-erythrocytic maturation and mediating the senescence of RBCs, adding 
a level of complexity in characterising the protective roles of ankyrin-1. It was hypothesised that 
the various ankyrin-1 mutations can exert different effects on the parasites depending on the 
location of the mutations, although the exact mechanism of each mutant allele remains to be 
investigated. 
To further support our hypothesis, two different ankyrin-1 mutations were examined, Ank-
1(MRI96570) and Ank-1(MRI95845), and compared them in terms of their effect on RBCs and their 
protective mechanisms against malaria. Results shows that ankyrin-1 can mediates two 
distinctly different malaria resistance mechanisms depending on the mutations. While both 
mutations impaired merozoite invasion, Ank-1(MRI96570) inhibited the maturation of parasites, 
whereas Ank-1(MRI95845) caused a rapid RBC clearance during malaria infections. Although further 
examinations of each resistance mechanism were not performed, this difference in resistance 
mechanisms is likely due to the various effects each ankyrin-1 mutation had on the RBC 
cytoskeleton. Ank-1(MRI95845/MRI95845) erythrocytes, possibly similar to Ank-1(MRI61689/+) erythrocytes, 
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could be inherently more susceptible to clearance. This is evidenced by significantly reduced 
deformability, increased susceptibility towards haemolysis and band 3 mobility, which is thought 
to be due to the disrupted RBC cytoskeleton resulting in the dissociation of band 3 from the 
cytoskeletal protein complexes 349. Alternatively, it could be the result of expression of pro-
phagocytic signals on the surface of these RBCs, such as increased PS exposure or band 3 
aggregation, which requires further investigation. On the other hand, the underlying 
mechanisms of parasite growth arrest mediated by Ank-1(MRI96570) was less clear, but it could be 
due to the disruption to the RBC remodelling process during parasite growth, since intra-
erythrocytic parasites require interactions with the RBC cytoskeleton for the expression of 
parasite-derived proteins on the RBC surface 272. When comparing these mutations with the Ank-
1(MRI61689) and those in previous studies 189,204, it is implied that all Ank-1 mutations are associated 
with impaired merozoite invasion, while the additional resistance mechanisms are dependent 
on the location and nature of Ank-1 mutations, although the exact relationship between 
genotype and phenotype remains elusive. As a result, the future work for this aspect of the study 
lies in obtaining direct evidence on the effects of diverse causative ankyrin-1 mutations on the 
RBC cytoskeletal structure, as well as examining the sequestration of RBC in various organs, 
through super resolution microscopy and intra-vital imaging techniques, to further support our 
current findings. Nevertheless, this is the first direct description of the allelic heterogeneity in 
the ankyrin-1 gene. This also suggests that RBC cytoskeleton is important for multiple aspects of 
the erythrocytic stage of malarial parasites, potentially poses a significant challenge for the 
parasites to overcome, thus presents a promising target for malaria HDT development. 
In addition, both ankyrin-1 mutations showed differences in the severity of HS-like phenotypes 
in mice, consistent with the observations in human population studies 394. Since HS is a 
heterogeneous disorder, the manifestation of HS symptoms is dependent on the nature of the 
causative mutations 394. Indeed, most symptomatic HS due to ankyrin-1 mutations in humans 
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are caused by nonsense, insertion and deletion mutations, inferring that some missense 
mutations might be asymptomatic, and hence, have not been identified. 
While the association of ankyrin-1 mutations with HS symptoms is well-established in human 
populations, it is not yet described in terms of malaria resistance. This is most likely due to the 
lack of detailed association studies between HS and malaria, which is further compounded by 
co-occurrence of other malaria susceptibility genes, poor healthcare systems and the limited 
technical capabilities of current technologies 200,460. Nevertheless, it is reasonable to expect the 
allelic heterogeneity of ankyrin-1 mutations to have a malaria protective role in human 
populations, similar to the observations in mouse models. This hypothesis is further supported 
by the similar phenomenon observed in other malaria susceptibility genes, such as the β-globin 
gene, and disorders including G6PD deficiency 430,432. Perhaps the most striking example of this 
is the β-globin gene, where the HbS and HbC alleles exhibit different geographical distributions 
throughout Africa based on their genotype-dependent malarial protective effects 432,433; while 
heterozygosity for HbS provides significant malaria protection, it is only homozygosity which is 
significantly protective for HbC. This also provides insights to the evolutionary history between 
human and Plasmodium. Although it was predicted that ankyrin-1 alleles that give rise to 
symptomatic HS would also confer malaria resistance, it is unknown if the alleles that cause mild 
or asymptomatic HS would also exhibit malaria protection. Therefore, it is of interest to 
characterise these asymptomatic HS alleles, which could lead to identification of potential HDT 
targets with significant malaria protection while exhibiting minimal side-effects. 
Although there is still much to learn on the association of HS and malaria, it is evident that 
disruptions to the RBC cytoskeletal structure leads to malaria protection, as observed in other 
RBC disorders such as SAO and HE 188,260. With better understanding of the interactions between 
the RBC cytoskeleton and parasites, it is possible to mimic the disruptive effects of HS to confer 
malaria resistance, which raised the possibility of using ankyrin-1 and its related binding partners 
as HDT candidates for malaria. One such protein is β-spectrin (Sptb), which interacts with 
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ankyrin-1 via the 14th and 15th spectrin motifs 396. Similar to ankyrin-1, β-spectrin mutations were 
also associated with increased malaria resistance in both human and mice 191,194,257, thus 
presenting a likely target for HDT development as well. Furthermore, the recent identification 
of binding residues of ankyrin-1 with β-spectrin 398 allowed us to explore the prospect of 
interrupting the ankyrin-spectrin interaction using small molecules to confer malaria protection 
in host RBCs. 
The genetic validation of ankyrin-spectrin interaction described in this study provided a 
promising indication for the feasibility of using such interaction for HDT development. Although 
further verification on the exact disruptive effect is needed, we expect to identify drug 
candidates which could interrupt ankyrin-spectrin interaction in vitro. With further optimisation, 
such drugs would also interrupt ankyrin-spectrin interactions in vivo, which would disrupt the 
RBC cytoskeleton structure and consequently impair parasite survival, similar to observations 
on Sptb(D1781R) mice, although the exact effect of such drugs on parasites requires further 
characterisation. Furthermore, the interruption of ankyrin-spectrin interactions was expected 
to have minor toxicity on the host, as evidenced from the lack of apparent morbidity of 
Sptb(D1781R) mice, however, other potential toxic effects of these drugs cannot be excluded, which 
is an important factor to consider for therapeutic targets. It is speculated that these drugs could 
be used in conjunction with the current chemotherapies for malaria, as a preventative to drug-
resistant parasites. However, it is unknown whether such drugs would be ideal as malaria 
prophylactics, since the roles of ankyrin-1 during the establishment of liver stage infections were 
not explored. 
The study on Sptb(D1781R) mice also led us to investigate other areas of the RBC cytoskeletal 
structure as attractive targets for HDT development. Therefore, the malaria susceptibility of HS 
patients was assessed in an attempt to identify protective alleles as potential HDT candidates. 
Results so far indicated that all of them displayed reduced merozoite invasion, but the causative 
mutations remain to be identified. Despite this, it is expected that all of them would exhibit 
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different causative alleles due to the heterogeneous nature of HS, which might reveal interesting 
roles of other parts of the RBC cytoskeleton in malaria infections, such as band 3-protein 4.2-
ankyrin interactions, as well as their suitability as HDT candidates. 
Altogether, this thesis demonstrated the importance of the RBC cytoskeleton in the survival of 
blood stage malaria parasites. The RBC cytoskeleton exhibits complex interactions during 
various parasite processes. This is evidenced by the specific disruptive effects, which are 
observed to be dependent on the nature and location of mutations, giving rise to multiple 
mechanisms of malaria resistance. This study also highlighted the possibility of developing HDT 
revolving around the interactions between RBC cytoskeletal proteins, which might fill certain 
niches that current antimalarials could not, by providing a theoretically resistance-proof 
treatment for malaria. Coupled with the naturally rapid turnover rate of RBCs and the specificity 
of such drugs to RBC cytoskeletons, such HDTs might contribute significantly to the current 
malaria treatments.  
In the context of human populations, this thesis first consolidates the heterogeneous nature of 
HS, as seen with the varying severity of HS-like phenotypes of ankyrin-1 mice. This is consistent 
with what is observed in human populations, emphasising the robustness of using mouse 
models to mimic human RBC disorders. This study also uncovered the possible allelic 
heterogeneity of HS in mediating malaria resistance. While such phenomenon still remains to 
be discovered in human populations, it is reasonable to expect that different HS-causing 
mutations would result in various degrees of malaria protection, perhaps similar to G6PD 
deficiency, where each geographical region exhibits a predominant allele responsible for malaria 
protection, enabling further investigations into the evolutionary relationship of human and 
Plasmodium.  
In order to achieve these goals, further studies should revolve around characterising the exact 
effects of ankyrin-1 mutations on the RBC cytoskeletal structure, which potentially provide 
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direct evidence for the disruptive effects of ankyrin-1 mutations on the RBC cytoskeleton. 
Through the use of super-resolution microscopy, the RBC cytoskeletal network lattice of mice 
carrying ankyrin-1 mutations could be resolved, potentially providing explanations for the 
underlying heterogeneous phenotype of ankyrin-1 mutations. This would also indicate whether 
the disrupted RBC cytoskeleton is crucial in mediating malaria resistance, addressing one of the 
important knowledge gaps in this study. In addition, further examination of the binding kinetics 
of ankyrin-spectrin interaction should be conducted as the first step towards HDT development 
for malaria, since it is required for the downstream HTS assay to identify potential drug 
candidates. Further genomic sequencing and in vitro studies on the erythrocytes of HS patients 
should also be performed in order to identify other potential HDT candidates within the RBC 
cytoskeleton. 
Nevertheless, this thesis extended our understanding of the relationship between the RBC 
cytoskeleton and malarial parasites, as well as opening up new opportunities for further studies. 
With the correct tools and more advanced technologies, future research could broaden our 
knowledge on host-parasite interactions and population genetics, perhaps even discover new 
therapeutic approaches for malaria.  
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